

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



B1

(43) International Publication Date
27 December 2001 (27.12.2001)

PCT


(10) International Publication Number
WO 01/97786 A2

- (51) International Patent Classification: A61K 31/00 (74) Agent: POPPE, Regina; 124 Grenzacherstrasse, CH-4070 Basle (CH).
- (21) International Application Number: PCT/EP01/06506
- (22) International Filing Date: 8 June 2001 (08.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00113219.0 21 June 2000 (21.06.2000) EP
- (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH];
124, Grenzacherstrasse, CH-4070 Basle (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors: ALANINE, Alexander; 11a, rue de Bale, F-68440 Schlierbach (FR). FLOHR, Alexander; 142 St. Galler-Ring, CH-4054 Basle (CH). MILLER, Aubry, Kern; 72A Alvarado St., San Francisco, CA 94110 (US). NORCROSS, Roger, David; Alte Saline 20, CH-4310 Rheinfelden (CH). RIEMER, Claus; Optizstrasse 5, 79110 Freiburg (DE).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97786 A2


(54) Title: BENZOTHAIAZOLE DERIVATIVES



(57) Abstract: The present invention relates to compounds of the general formula (I) and to their pharmaceutically acceptable salts for the treatment of diseases related to the adenosine receptor.

Benzothiazole derivatives

The present invention relates to the use of compounds of the general formula



wherein

R^1 is hydrogen, lower alkyl, lower alkoxy, benzyloxy, cycloalkyloxy, halogen, hydroxy or trifluoromethyloxy;

R^2, R^3 are independently from each other hydrogen, halogen, lower alkyl or lower alkyloxy;

R^4 is hydrogen, lower alkyl, lower alkenyl, halogen, $-C(O)OH$, $-C(O)$ -lower alkyl, $-C(O)$ -halogen-lower alkyl, $-CH(OH)$ -halogen-lower alkyl, $-C(O)O$ -lower alkyl, $-NHC(O)$ -lower alkyl, $-(CH_2)_n-OH$,
 or is phenyl, which is optionally attached to the benzo group via the linker $-(O)_m-(CH_2)_n-$ and is optionally substituted by $N(R^5)(R^6)$, halogen, alkoxy or nitro, or is 2,3-dihydro-1H-indolyl, azepan-1-yl, [1,4]oxazepan-4-yl, or is a five or six membered aromatic or non aromatic heterocycle, which may be attached to the benzo group via the linker $-(O)_m-(CH_2)_n$ or $-N=C(CH_3)-$ and is optionally substituted by one or two group(s) R^7 , wherein R^7 is defined below;

R is
 (a) phenyl, optionally substituted by lower alkyl, halogen-lower alkyl, lower alkoxy, cyano, nitro, $-C(O)H$, $-C(O)OH$ or by the following groups
 $-(CH_2)_n-C(O)-N(R^5)-(CH_2)_o$ -lower alkoxy,
 $-(CH_2)_nO$ -halogen-lower alkyl,
 $-(CH_2)_nO-(CH_2)_{n+1}-O$ -lower alkyl,
 $-S(O)_2-N(R^5)-(CH_2)_n-O$ -lower alkyl,
 $-(CH_2)_n-OR^5$,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -lower alkoxy,

- 5 $-(CH_2)_nN[(CH_2)_o\text{-lower alkoxy}]_2$,
 $-(CH_2)_nN(R^5)(R^6)$,
 $-(CH_2)_nN[S(O)_2CH_3]_2$,
 $-(CH_2)_nN[R^5][S(O)_2CH_3]$,
 $-(CH_2)_nN(R^5)-(CH_2)_oNR^5R^6$,
 $-(CH_2)_nN(R^5)\text{-lower alkenyl}$,
 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-cycloalkyl}$,
 $-(CH_2)_nN(R^5)\text{-C(O)O-lower alkyl}$,
 $-(CH_2)_n\text{-S-(CH}_2)_n\text{-N(R}^5)(R^6)$,
 10 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-S-lower alkyl}$,
 $\text{-S(O)}_2\text{-N(R}^5)(R^6)$,
 $-(CH_2)_nN(R^5)\text{-S(O)}_2CH_3$,
 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-phenyl}$,
 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-OH}$,
 15 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-CH(OH)-CF}_3$,
 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-CF}_3$,
 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-O-CH(OH)-C}_6\text{H}_3(\text{OCH}_3)_2$,
 $-(CH_2)_nN(R^5)\text{-(CH}_2)_o\text{-O-C(O)-C}_6\text{H}_3(\text{OCH}_3)_2$,
 $\text{-N(R}^5)\text{-C(O)-morpholin}$,
 20 $\text{-N(R}^5)\text{-C(O)-N(R}^5)\text{-phenyl, substituted by alkoxy}$,
 $\text{-S(O)}_2\text{-morpholin}$,

or is phenyl, which is optionally substituted by

- $-(CR^5R^6)_n$ -five to seven membered aromatic or non aromatic heterocycle, and
 wherein the heterocycle may further substituted by hydroxy, $\text{-N(R}^5)(R^6)$, lower
 25 alkoxy or lower alkyl, or by
 $-(CH_2)_nN(R^5)(CH_2)_o$ -five or six membered aromatic or non aromatic heterocycle
 and wherein the heterocycle may further substituted by hydroxy, $\text{-N(R}^5)(R^6)$ or
 lower alkyl, or

is

- 30 b) $-(CH_2)_n$ -five or six membered aromatic or non aromatic heterocycle, with the
 exception of the the piperazinyl group in case if $n=0$, which rings may be optionally
 substituted by one or two substituents, selected from the group consisting of
 2-oxo-pyrrolidin, piperidinyl, phenyl, $-(CH_2)_nOH$, halogen, CF_3 , $=O$, lower alkyl,
 cycloalkyl, $-(CH_2)_n\text{-O-lower alkyl}$, $-(CH_2)_nNH_2$, $-(CH_2)_nCN$, $\text{-C(O)O-lower alkyl}$,
 35 $\text{-CH}_2\text{-O-S(O)}_2CH_3$, -C(O)-lower alkyl , $\text{-C(O)-(CH}_2)_n\text{-lower alkoxy}$,

- 3 -

$-\text{CH}_2-\text{N}(\text{R}^6)\text{C}_6\text{H}_4\text{F}$, $-\text{CH}_2-\text{N}(\text{R}^6)\text{C}(\text{O})\text{O}$ -lower alkyl,
 $-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^5)-(\text{CH}_2)_n-\text{O}$ -lower alkyl, -or by tetrahydrofuran, substituted by
 4-Cl-phenyl, or by piperazin-1-yl, morpholinyl, thiomorpholinyl,
 thiomorpholin-1-oxo, pyrrolidin-1-yl or by piperidin-1-yl or is
 5 benzopiperidin-1-yl or benzothien-2-yl, or

is

c) $-(\text{CH}_2)_{n+1}$ -phenyl,
 $-\text{N}(\text{R}^5)(\text{CH}_2)_n$ -phenyl, optionally substituted by lower alkoxy,
 $-\text{O}(\text{CH}_2)_n$ -phenyl, or
 10 $-\text{N}(\text{R}^5)\text{C}(\text{O})$ -phenyl, or

is

d) $-\text{N}(\text{R}^5)(\text{CH}_2)_n$ -5-or 6 membered aromatic or non aromatic heterocycle,
 optionally substituted by lower alkyl, $-(\text{CH}_2)_n$ -5-or 6 membered aromatic or non
 aromatic heterocycle

15 or is

e) $-(\text{CH}_2)_n-\text{N}(\text{R}^5)(\text{R}^6)$, lower alkyl, $-\text{O}-(\text{CH}_2)_n$ -lower alkoxy, $-(\text{CH}_2)_n$ -lower alkoxy,
 lower alkoxy, cycloalkyl, $-\text{N}(\text{R}^5)(\text{CH}_2)_n\text{O}$ -lower alkyl, $-\text{N}(\text{R}^5)(\text{CH}_2)_n\text{OH}$,
 $-\text{N}(\text{R}^5)(\text{CH}_2)_n\text{N}(\text{R}^5)(\text{R}^6)$,
 $-\text{C}(\text{O})\text{O}$ -lower alkyl, $-(\text{CH}_2)_n\text{OH}$, $-(\text{HC}=\text{CH})_n\text{C}(\text{O})\text{O}$ -lower alkyl,
 20 octahydro-quinoline, 3,4-dihydro-1H-isoquinoline,
 2,3-benzo-1,4-dioxo-8-aza-spiro[4,5]decane or 1,4-dioxo-8-aza-spiro[4,5]decane;

X is O, S or two hydrogen atoms;

R^5, R^6 are independently from each other hydrogen or lower alkyl,

R^7 is lower alkyl, lower alkoxy, $-\text{C}(\text{O})$ -lower alkyl, $-\text{C}(\text{O})\text{O}$ -benzyl, $-\text{C}(\text{O})\text{O}$ -lower alkyl,
 25 $-(\text{CH}_2)_n\text{NR}^5\text{R}^6$, pyridinyl, optionally substituted by lower alkyl, or is
 $-\text{CH}_2\text{N}(\text{R}^5)-\text{C}(\text{O})\text{O}$ -lower alkyl, $-\text{NH}-\text{C}(\text{phenyl})_3$, pyrrolidinyl, piperidinyl,
 morpholinyl, piperazinyl, optionally substituted by lower alkyl;

n is 0, 1, 2, 3 or 4;

m is 0 or 1;

30 o is 0, 1, 2, 3 or 4;

and to their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to the adenosine receptor.

Some minor subgroups of compounds of the present formula I are known compounds and have been described, for example in EP 427 963, US 5,099,021, EP 295 656
5 or DE 19 531 49. These compounds possess microbicide activity or may be used for lowering the blood glucose level. Furthermore, WO 00/18767 describes 2-piperazino alkylamino benzoazole, having an affinity to the dopamine subtype specific ligands and are therefore useful in the treatment of diseases, related to this receptor. The compounds of WO 00/18767 are not encompassed from the scope of the present invention.

10 It has surprisingly been found that the compounds of general formula I are adenosine receptor ligands.

Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
15 nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzyme A; and to RNA. Together adenosine and these related compounds are important in the regulation of many aspects of cellular metabolism and in the modulation
20 of different central nervous system activities.

The receptors for adenosine have been classified as A₁, A_{2A}, A_{2B} and A₃ receptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent on the receptor associated G protein. Each of the adenosine receptor subtypes has been
25 classically characterised by the adenylate cyclase effector system, which utilises cAMP as a second messenger. The A₁ and A₃ receptors, coupled with G_i proteins inhibit adenylate cyclase, leading to a decrease in cellular cAMP levels, while A_{2A} and A_{2B} receptors couple to G_s proteins and activate adenylate cyclase, leading to an increase in cellular cAMP levels. It is known that the A₁ receptor system include the activation of phospholipase C and
30 modulation of both potassium and calcium ion channels. The A₃ subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates calcium ion channels.

The A₁ receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90-95% sequence identity among the
35 mammalian species. The A_{2A} receptor (409-412 amino acids) was cloned from canine, rat,

human, guinea pig and mouse. The A_{2B} receptor (332 amino acids) was cloned from human and mouse with 45% homology of human A_{2B} with human A₁ and A_{2A} receptors. The A₃ receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep.

The A₁ and A_{2A} receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the oxygen demand (A₁) or increase the oxygen supply (A_{2A}) and so reinstate the balance of energy supply: demand within the tissue. The actions of both subtypes is to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure activity.

Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A₃ receptor resulted in increased inositol triphosphate and intracellular calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A₃ receptor plays a role in mediating asthmatic attacks and other allergic responses.

Adenosine is also a neuromodulator, possessing global importance in the modulation of molecular mechanisms underlying many aspects of physiological brain function by mediating central inhibitory effects. An increase in neurotransmitter release follows traumas such as hypoxia, ischaemia and seizures. These neurotransmitters are ultimately responsible for neural degeneration and neural death, which causes brain damage or death of the individual. The adenosine A₁ agonists which mimic the central inhibitory effects of adenosine may therefore be useful as neuroprotective agents. Adenosine has been proposed as an endogenous anticonvulsant agent, inhibiting glutamate release from excitatory neurons and inhibiting neuronal firing. Adenosine agonists therefore may be used as antiepileptic agents. Adenosine antagonists stimulate the activity of the CNS and have proven to be effective as cognition enhancers. Selective A_{2A}- antagonists have therapeutic potential in the treatment of various forms of dementia, for example in Alzheimer's disease and are useful as neuroprotective agents. Adenosine A_{2A}- receptor antagonists inhibit the release of dopamine from central synaptic terminals and stimulate locomotor activity and consequently improve Parkinsonian symptoms. The central activities of adenosine are also implicated in the molecular mechanism underlying sedation, hypnosis, schizophrenia, anxiety, pain, respiration, depression and substance abuse. Drugs acting at adenosine receptors therefore have therapeutic potential as sedatives, muscle relaxants, antipsychotics, anxiolytics, analgesics, respiratory stimulants and antidepressants, and they may be used in the treatment of ADHD (attention deficit hyper-activity disorder).

An important role for adenosine in the cardiovascular system is as a cardioprotective agent. Levels of endogenous adenosine increase in response to ischaemia and hypoxia, and protect cardiac tissue during and after trauma (preconditioning). Adenosine agonists thus have potential as cardioprotective agents.

5 Adenosine modulates many aspects of renal function, including renin release, glomerular filtration rate and renal blood flow. Compounds, which antagonise the renal affects of adenosine, have potential as renal protective agents. Furthermore, adenosine A₃ and/or A_{2B} antagonists may be useful in the treatment of asthma and other allergic responsesor and in the treament of diabetes mellitus and obesity.

10 Numerous documents describe the current knowledge on adenosine receptors, for example the following publications:

Bioorganic & Medicinal Chemistry, 6, (1998), 619-641,

Bioorganic & Medicinal Chemistry, 6, (1998), 707-719,

J. Med. Chem., (1998), 41, 2835-2845,

15 J. Med. Chem., (1998), 41, 3186-3201,

J. Med. Chem., (1998), 41, 2126-2133,

J. Med. Chem., (1999), 42, 706-721,


J. Med. Chem., (1996), 39, 1164-1171,

Arch. Pharm. Med. Chem., 332, 39-41, (1999).

20 Objects of the present invention is the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases, related to the adenosine A₂ receptor, novel compounds of formula I-A per se, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or
25 prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and
30 cardioprotective agents. The most preferred indications in accordance with the present invention are those, which base on the A_{2A} receptor antagonistic activity and which include

disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease as well as ADHD and diabetes mellitus.

The present invention relates also to novel compounds of the general formula



wherein

R^1 is hydrogen, lower alkyl, lower alkoxy, benzyloxy, cycloalkyloxy, halogen, hydroxy or trifluoromethyloxy;

R^2, R^3 are independently from each other hydrogen, halogen, lower alkyl or lower alkyloxy;

10 R^4 is hydrogen, lower alkyl, lower alkenyl, halogen, $-C(O)$ -lower alkyl, $-C(O)$ -halogen-lower alkyl, $-CH(OH)$ -halogen-lower alkyl, $-C(O)O$ -lower alkyl, $-NHC(O)$ -lower alkyl, $-(CH_2)_n-OH$,
or is phenyl, which is optionally attached to the benzo group via the linker $-(O)_m-(CH_2)_n$ and is optionally substituted by $N(R^5)(R^6)$, halogen or nitro,
15 or is 2,3-dihydro-1H-indolyl, azepan-1-yl, [1,4]oxazepan-4-yl, or is
a five or six membered aromatic or non aromatic heterocycle, which may be
attached to the benzo group via the linker $-(O)_m-(CH_2)_n$ or $-N=C(CH_3)-$
and is optionally substituted by one or two group(s) R^7 , wherein R^7 is defined below;

R^7 is

20 (a) phenyl, optionally substituted by halogen-lower alkyl, $-C(O)H$ or by the
following groups
 $-(CH_2)_n-C(O)-N(R^5)-(CH_2)_n$ lower alkoxy,
 $-(CH_2)_nO$ -halogen-lower alkyl,
 $-(CH_2)_nO-(CH_2)_{n+1}O$ -lower alkyl,
25 $-S(O)_2-N(R^5)-(CH_2)_nO$ -lower alkyl,
 $-(CH_2)_nOR^5$,
 $-(CH_2)_nN(R^5)-(CH_2)_n$ -lower alkoxy,
 $-(CH_2)_nN[(CH_2)_n$ -lower alkoxy] $_2$,
 $-(CH_2)_nN[S(O)_2CH_3]_2$,
30 $-(CH_2)_nN[R^5][S(O)_2CH_3]$,

- (CH₂)_nN(R⁵)-lower alkenyl,
- (CH₂)_nN(R⁵)-(CH₂)_o-cycloalkyl,
- (CH₂)_nN(R⁵)-C(O)O-lower alkyl,
- (CH₂)_n-S-(CH₂)_n-N(R⁵)(R⁶),
- 5 -(CH₂)_nN(R⁵)-(CH₂)_o-S-lower alkyl,
- (CH₂)_nN(R⁵)-S(O)₂CH₃
- (CH₂)_nN(R⁵)-(CH₂)_o-phenyl,
- (CH₂)_nN(R⁵)-(CH₂)_oOH,
- (CH₂)_nN(R⁵)-(CH₂)_oCH(OH)-CF₃,
- 10 -(CH₂)_nN(R⁵)-(CH₂)_o-CF₃,
- (CH₂)_nN(R⁵)-(CH₂)_o-O-CH(OH)-C₆H₃(OCH₃)₂,
- (CH₂)_nN(R⁵)-(CH₂)_o-O-C(O)-C₆H₃(OCH₃)₂,
- N(R⁵)-C(O)-morpholin,
- N(R⁵)-C(O)-N(R⁵)-phenyl, substituted by alkoxy,
- 15 -S(O)₂-morpholin,

or is phenyl, which is optionally substituted by

- (CR⁵R⁶)_n-five to seven membered aromatic or non aromatic heterocycle, and
- wherein the heterocycle may further substituted by hydroxy, -N(R⁵)(R⁶) or lower
- alkyl, or by -(CH₂)_nN(R⁵)(CH₂)_o-five or six membered aromatic or non aromatic
- 20 heterocycle and wherein the heterocycle may further substituted by hydroxy,
- N(R⁵)(R⁶) or lower alkyl,
- or is -N(R⁵)-phenyl, which is optionally substituted by lower alkoxy, or

is

- b) -(CH₂)_n-five or six membered aromatic or non aromatic heterocycle, with the
- 25 exception of the the piperazinyl group in case if n=0, which rings may be optionally
- substituted by
- 2-oxo-pyrrolidin, piperidinyl, phenyl, -(CH₂)_nOH, halogen, CF₃, =O, lower alkyl,
- cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_nNH₂, -(CH₂)_nCN, -C(O)O-lower alkyl,
- CH₂-O-S(O)₂CH₃, -C(O)-lower alkyl, -C(O)-(CH₂)_n-lower alkoxy,
- 30 -CH₂-N(R⁶)C₆H₄F, -CH₂-N(R⁶)C(O)O-lower alkyl,
- N(R⁶)-C(O)-N(R⁵)-(CH₂)_n-O-lower alkyl, -or by tetrahydrofuran, substituted by
- 4-Cl-phenyl, or by piperazin-1-yl, morpholinyl, thiomorpholinyl,
- thiomorpholin-1-oxo, pyrrolidin-1-yl or by piperidin-1-yl or is
- benzopiperidin-1-yl or benzothien-2-yl, or

is

c) $-N(R^5)(CH_2)_{n+1}$ -phenyl, optionally substituted by lower alkoxy,
 $-O(CH_2)_n$ -phenyl, or
 $-N(R^5)C(O)$ -phenyl, or

5 is

d) $-N(R^5)(CH_2)_n$ -5- or 6 membered aromatic or non aromatic heterocycle,
 optionally substituted by lower alkyl, $-(CH_2)_n$ -5- or 6 membered aromatic or non
 aromatic heterocycle

or is

10 e) $-O(CH_2)_n$ -lower alkoxy, lower alkyl-lower alkoxy, $-N(R^5)(CH_2)_nN(R^5)(R^6)$,
 $-(CH_2)_nOH$, $-(HC=CH)_nC(O)O$ -lower alkyl, octahydro-quinoline,
 3,4-dihydro-1H-isoquinoline, 2,3-benzo-1,4-dioxo-8-aza-spiro[4,5]decane or
 1,4-dioxo-8-aza-spiro[4,5]decane.

X is O, S or two hydrogen atoms;

15 R^5, R^6 are independently from each other hydrogen or lower alkyl,

R^7 is lower alkyl, lower alkoxy, $-C(O)$ -lower alkyl, $-C(O)O$ -benzyl, $-C(O)O$ -lower alkyl,
 $-(CH_2)_nNR^5R^6$, pyridinyl, optionally substituted by lower alkyl, or is
 $-CH_2N(R^5)-C(O)O$ -lower alkyl, $-NH-C(phenyl)_3$, pyrrolidinyl, piperidinyl,
 morpholinyl, piperazinyl, optionally substituted by lower alkyl;

20 n is 0, 1, 2, 3 or 4;

m is 0 or 1;

o is 0, 1, 2, 3 or 4;

and to their pharmaceutically acceptable salts for the manufacture of medicaments for the
 treatment of diseases related to the adenosine receptor.

25 As used herein, the term "lower alkyl" denotes a saturated straight- or branched-
 chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl,
 isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are
 groups with 1 - 4 carbon atoms.

30 As used herein, the term "lower alkenyl" denotes a unsaturated straight- or branched-
 chain alkyl group containing from 2 to 6 carbon atoms, for example, ethylen, propylen,

isopropylen, n-butylen, i-butylen, 2-butylen, t-butylen and the like. Preferred lower alkyl groups are groups with 2 - 4 carbon atoms.

The term "cycloalkyl" denotes a saturated carbocyclic group, containing 3 - 6 carbon atoms.

5 The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined above, and which is attached via an oxygen atom.

The term "five or six membered aromatic or non aromatic heterocycle" denotes the following group: aromatic heterocyclic groups are, for example pyrrol-1-yl, tetrazolyl, 10 imidazol-1 or 2-yl, pyrazol-1-yl, pyridin-1, 2, 3 or 4-yl, pyrazinyl, pyrimidinyl, pyridazinyl, isothiazolyl, isoxazolyl, thiazolyl, thienyl or furyl; Non aromatic heterocyclic groups are, for example, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiomorpholin-1,1-dioxo or thiomorpholin-1-oxo.

The term "pharmaceutically acceptable acid addition salts" embraces salts with 15 inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

Preferred compounds of formula I are those, wherein R^1 is methoxy, X is oxygen and R^2/R^3 are hydrogen.

20 Exemplary preferred are compounds of formula I for the above mentioned use, wherein R is an unsubstituted or substituted five or six membered aromatic heterocycle, for example the following compounds:

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
25 5-methyl-furan-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-4-yl-benzothiazol-2-yl)-amide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-3-yl-benzothiazol-2-yl)-amide,
30 amide,
5-methyl-thiophene-2-carboxylic acid [4-methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl]-amide,
5-methyl-thiophene-2-carboxylic acid [7-(3-amino-phenyl)-4-methoxy-benzothiazol-2-

- yl]-amide,
 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,
 N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide,
 5 N-[4-methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide,
 N-{4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-2-methyl-isonicotinamide and
 N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide.
- 10 276
- Further preferred compounds of formula I for the above mentioned use are compounds, wherein R is an unsubstituted or substituted five or six membered non aromatic heterocycle, for example the following compounds:
- morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 15 thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 1-oxo-11 4-thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 morpholine-4-carboxylic acid {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-amide,
 20 morpholine-4-carboxylic acid [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-amide,
 morpholine-4-carboxylic acid {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-amide,
 morpholine-4-carboxylic acid [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-amide,
 25 2-yl]-amide,
 morpholine-4-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-amide,
 4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester,
 30 1-acetyl-piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 4-oxo-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide and
 1-oxo-11⁴-thiomorpholine-4-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide.
 35 2-yl)-amide.

Preferred are further compounds, wherein R is methoxy, for example the following compounds:

- rac-[7-(2-bromo-1-hydroxy-ethyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester,
- 5 {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-carbamic acid methyl ester,
- [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester,
- [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester and
- 10 {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-carbamic acid methyl ester.

Preferred compounds of formula I for the above mentioned use are those, wherein R is

- phenyl, optionally substituted by halogen, CF₃, -CH₂OH, -CH₂NHCH₂CH₂OCH₃,
 15 -CH₂NHCH₂CH₂OH, -CH₂NHCH₂-pyridinyl, -CH₂NH₂, -CH₂NHCH₂CH₂SCH₃,
 -CH₂N(CH₃)CH₂CH₂SCH₃, -CH₂N(CH₃)CH₂CH₂OCH₃,
 -CH₂N(CH₂CH₃)CH₂CH₂OCH₃, -CH₂NHCH₃, -CH₂SCH₂CH₂N(CH₃)₂, -CH₂OCH₃,
 -CH₂OCH₂CH₂OCH₃ or -CH₂N(CH₃)C(O)OCH₃, for example the following compounds:
 4-hydroxymethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 20 4-fluoro-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 2-(4-fluoro-benzoylamino)-4-methoxy-benzothiazole-7-carboxylic acid methyl ester,
 4-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-[(2-hydroxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
 25 benzamide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-4-yl-methyl]-amino]-methyl]-benzamide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-3-yl-methyl]-amino]-methyl]-benzamide,
 30 4-aminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-methylsulfanyl-ethylamino)-methyl]-benzamide,
 4-[[2-methoxy-ethyl]-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 35 N-[7-(2-amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide,
 4-fluoro-N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-

- benzamide,
4-fluoro-N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-benzamide,
4-fluoro-N-{4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-
benzamide,
5 4-{{{(2-methoxy-ethyl)-methyl-amino)-methyl}-N-[4-methoxy-7-[2-(6-methyl-pyridin-3-
yl)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide,
4-{{{(2-Methoxy-ethyl)-methyl-amino)-methyl}-N-(4-methoxy-7-thiophen-2-yl-
benzothiazol-2-yl)-benzamide,
4-{{{(2-methoxy-ethyl)-methyl-amino)-methyl}-N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-
10 4-yl)-benzothiazol-2-yl]-benzamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-trifluoromethyl-benzamide,
4-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
4-chloro-3-{{(ethyl-(2-methoxy-ethyl)-amino)-methyl}-N-(4-methoxy-7-morpholin-4-yl-
15 benzothiazol-2-yl)-benzamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-benzamide,
4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-
benzamide,
4-chloro-3-{{{(2-methoxy-ethyl)-methyl-amino)-methyl}-N-(4-methoxy-7-morpholin-4-
20 yl-benzothiazol-2-yl)-benzamide,
4-chloro-3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-
benzothiazol-2-yl)-benzamide,
3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
yl)-benzamide,
25 3-{{{(2-methoxy-ethyl)-methyl-amino)-methyl}-N-(4-methoxy-7-morpholin-4-yl-
benzothiazol-2-yl)-benzamide,
4-[(2-ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
benzamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide,
30 4-(2-dimethylamino-ethylsulfanylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-
2-yl)-benzamide,
4-{{{(2-ethoxy-ethyl)-ethyl-amino)-methyl}-N-(4-methoxy-7-morpholin-4-yl-
benzothiazol-2-yl)-benzamide,
4-{{{(2-ethoxy-ethyl)-methyl-amino)-methyl}-N-(4-methoxy-7-morpholin-4-yl-
35 benzothiazol-2-yl)-benzamide,
4-(2-methoxy-ethoxymethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
benzamide,

4-methoxymethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide, N-(4-methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl)-benzamide and [4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-benzyl]-methyl-carbamic acid methyl ester.

- 5 Further preferred compounds of formula I for the above mentioned use are those, wherein R is phenyl, substituted by a optionally substituted $-(CH_2)_n$ -five to seven membered aromatic or non aromatic heterocycle, for example the following compounds:
- 4-imidazol-1-yl-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-(4-Hydroxy-piperidin-1-yl-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
 10 benzamide,
 4-[1,4]diazepan-1-yl-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-(3(S)-dimethylamino-pyrrolidin-1-yl-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-4-
 15 pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-4-pyrrolidin-1-yl-methyl-benzamide,
 N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide,
 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-
 20 benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(2-methyl-imidazol-1-yl-methyl)-benzamide and
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(4-methyl-piperazin-1-yl-methyl)-
 25 benzamide.

Especially preferred are compounds, wherein R^4 is an optionally substituted five to seven membered aromatic or non aromatic heterocycle, which is for example morpholine or piperazine.

- Preferred compounds of formula IA are those, wherein R^1 is methoxy, X is oxygen
 30 and R^2/R^3 are hydrogen.

Exemplary preferred are compounds of formula IA, wherein R' is an unsubstituted or substituted five or six membered aromatic heterocycle, for example the following compounds:

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,

- 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 5-methyl-furan-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide,
 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-4-yl-benzothiazol-2-yl)-
 5 amide,
 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-3-yl-benzothiazol-2-yl)-
 amide,
 5-methyl-thiophene-2-carboxylic acid [4-methoxy-7-(2-methyl-pyridin-4-yl)-
 benzothiazol-2-yl]-amide,
 10 5-methyl-thiophene-2-carboxylic acid [7-(3-amino-phenyl)-4-methoxy-benzothiazol-2-
 yl]-amide,
 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,
 N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-
 isonicotinamide,
 15 N-[4-methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-
 isonicotinamide,
 N-[4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl]-2-methyl-
 isonicotinamide and
 N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide.

20

Further preferred compounds of formula IA are compounds, wherein R is an unsubstituted or substituted five or six membered non aromatic heterocycle, for example the following compounds:

- morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 25 thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
 1-oxo-11 4-thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-
 amide,
 morpholine-4-carboxylic acid {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-
 benzothiazol-2-yl}-amide,
 30 morpholine-4-carboxylic acid [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-
 yl]-amide,
 morpholine-4-carboxylic acid {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-
 benzothiazol-2-yl}-amide,
 morpholine-4-carboxylic acid [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-
 35 2-yl]-amide,

- morpholine-4-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-amide,
 4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperidine-1-carboxylic acid tert-butyl ester,
 5 1-acetyl-piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 4-oxo-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide and
 1-oxo-1λ⁴-thiomorpholine-4-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-
 10 2-yl)-amide.
 Preferred are further compounds, wherein R is methoxy, for example the following compounds:
 rac-[7-(2-bromo-1-hydroxy-ethyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester,
 15 {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-carbamic acid methyl ester,
 [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester,
 [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester and
 20 {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-carbamic acid methyl ester.

- Preferred compounds of formula IA are those, wherein R' is phenyl, optionally substituted by -CH₂OH, -CH₂NHCH₂CH₂OCH₃,
 -CH₂NHCH₂CH₂OH, -CH₂NHCH₂-pyridinyl, -CH₂NH₂, -CH₂NHCH₂CH₂SCH₃,
 25 -CH₂N(CH₃)CH₂CH₂SCH₃, -CH₂N(CH₃)CH₂CH₂OCH₃,
 -CH₂N(CH₂CH₃)CH₂CH₂OCH₃, -CH₂NHCH₃, -CH₂SCH₂CH₂N(CH₃)₂, -CH₂OCH₃,
 -CH₂OCH₂CH₂OCH₃ or -CH₂N(CH₃)C(O)OCH₃, for example the following compounds:
 4-hydroxymethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
 30 benzamide,
 4-[(2-hydroxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-4-ylmethyl]-amino]-methyl]-benzamide,
 35 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-3-ylmethyl]-amino]-methyl]-benzamide,

- 4-aminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-methylsulfanyl-ethylamino)-methyl]-
 benzamide,
 4-[[2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 5 benzothiazol-2-yl)-benzamide,
 N-[7-(2-amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide,
 4-fluoro-N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-
 benzamide,
 4-[[2-methoxy-ethyl)-methyl-amino]-methyl]-N-{4-methoxy-7-[2-(6-methyl-pyridin-3-
 10 yl)-thiazol-4-yl]-benzothiazol-2-yl)-benzamide,
 4-[[2-Methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-thiophen-2-yl-
 benzothiazol-2-yl)-benzamide,
 4-[[2-methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-(2-pyridin-2-yl)-thiazol-
 4-yl)-benzothiazol-2-yl)-benzamide,
 15 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-trifluoromethyl-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 4-chloro-3-[[ethyl-(2-methoxy-ethyl)-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-benzamide,
 20 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-
 benzamide,
 4-chloro-3-[[2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-
 yl-benzothiazol-2-yl)-benzamide,
 4-chloro-3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 25 benzothiazol-2-yl)-benzamide,
 3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 yl)-benzamide,
 3-[[2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 30 4-[(2-ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide,
 4-(2-dimethylamino-ethylsulfanylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-
 2-yl)-benzamide,
 35 4-[[2-ethoxy-ethyl)-ethyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 4-[[2-ethoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-

- benzothiazol-2-yl)-benzamide,
 4-(2-methoxy-ethoxymethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 benzamide,
 4-methoxymethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 5 N-(4-methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl)-benzamide and
 [4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-benzyl]-methyl-carbamic
 acid methyl ester.


Further preferred compounds of formula IA are those, wherein R' is phenyl,
 substituted by a optionally substituted $-(CR^5R^6)_n$ -five to seven membered aromatic or non
 10 aromatic heterocycle, for example the following compounds:

- 4-imidazol-1-ylmethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-(4-Hydroxy-piperidin-1-yl-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
 benzamide,
 4-[1,4]diazepan-1-yl-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 15 4-(3(S)-dimethylamino-pyrrolidin-1-yl-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-
 yl)-benzamide,
 N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-4-
 pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-4-pyrrolidin-1-yl-methyl-benzamide,
 20 N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-
 methyl-benzamide,
 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-
 benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-benzamide,
 25 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(2-methyl-imidazol-1-yl-methyl)-
 benzamide and
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(4-methyl-piperazin-1-yl-methyl)-
 benzamide.


Especially preferred are compounds of formula IA, wherein R⁴ is an optionally
 30 substituted five to seven membered aromatic or non aromatic heterocycle, which is for
 example morpholine or piperazine.

The present compounds of formulas I and I-A and their pharmaceutically acceptable salts
 can be prepared by methods known in the art, for example, by processes described below,
 which process comprises

a) reacting a compound of formula




with a compound of formula



5 and an amine of the formula R^5R^6NH or an appropriate cyclic amine


to a compound of formula




or to compounds of formula I-1, wherein the group $-NR^5R^6$ is replaced by a cyclic amine,

wherein $R^1 - R^6$ and X have the significances given above, or

10 b) reacting a compound of formula



with a compound of formula




to a compound of formula I-A, wherein $R^1 - R^4$, R' and X have the significances given


15 above, or

c) reacting a compound of formula


- 20 -



with a compound of formula




to a compound of formula



5


wherein R^1 - R^5 have the significances given above, or

d) hydrogenating a compound of formula I-3 with $H_2/Pd/C$ to give a compound of formula




10 wherein R^1 - R^5 have the significances given above, or

e) reacting a compound of formula I-3 with N-bromosuccinimide/ H_2O to give a compound of formula




wherein R^1 - R^5 have the significances given above, or

f) oxidizing a compound of formula I-4 to a compound of formula




wherein R^1 - R^5 have the significances given above, or

5 g) reacting a compound of formula I-5 with a compound of formula




to a compound of formula




wherein R^1 - R^5 and R^7 have the significances given above, or

10 h) reacting a compound of formula I-5 with a compound of formula




to a compound of formula

- 22 -




wherein $R^1 - R^6$ have the significances given above, or


i) reacting a compound of formula I-5 with a compound of formula



5 to a compound of formula



cleaving off the boc-group to a compound of formula



wherein $R^1 - R^5$ have the significances given above, or

10 j) modifying one or more substituents $R^1 - R^6$ within the definitions given above,

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

All reaction steps described above are carried out in conventional manner and are described in more detail in the working examples.

- 5 In accordance with process variant a) a compound of formula II, for example 2-amino-7-phenyl-4-methoxy-benzothiazol in pyridine is dissolved in tetrahydrofuran and is then treated with phosgene in toluene. The reaction mixture is concentrated to half the volume under reduced pressure and the appropriate amine, for example an amine of formula R^5R^6NH or a cyclic amine, such as morpholine or thiomorpholine, are added. The
10 obtained product is isolated by flash chromatography.


Reaction variant b) describes the process for preparation of a compound of formula I, wherein a compound of formula II is reacting with a compound of formula IV. The reaction is carried out for about 10 minutes in conventional manner. The obtained compound is then isolated by flash chromatography.

- 15 The salt formation is effected at room temperatures in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids came into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrate, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.

- 20 In Examples 1 – 187 and in the following schemes 1 and 2 the preparation of compounds of formula I is described in more detail.

The starting materials are known compounds or may be prepared according to methods known in the art.


Scheme 1



wherein the numbers 1 – 6 have the following meaning:

- 1 MeO(CO)Cl, base
 - 2 ICl
 - 3 $R^4\text{-B(OR}^5)_2$ or $R^4\text{-Sn(CH}_3)_3$, Pd-catalyst
 - 4 KOH
 - 5 $C(X)Cl_2$, R^5R^6NH , or R^5NCX
 - 6 $RC(X)Cl$, base
- 10 The definition of substituents is described above.

Scheme 2




wherein the numbers 1 – 6 have the following meaning

- 1 $R^4-B(OR^5)_2$ or $R^4-Sn(CH_3)_3$, Pd-catalyst
- 2 H_2 , Pd-C
- 3 $Ph(CO)NCS$
- 4 NaOMe
- 5 Br_2
- 6 $RC(X)Cl$, base

and the definition of the substituents $R^1 - R^4$, R^5 , X and R is given above.


Scheme 3



- 10 The definitions of R^1 to R^5 are given above and NBS is N-bromosuccinimide.


- 26 -

Scheme 4



The definitions of R^1 to R^5 and R^7 are given above.


Scheme 5



5

The definitions of R^1 to R^6 are given above.

Scheme 6



The definitions of R^1 to R^5 are given above.

The reactions described in schemes 1 to 6 are carried out in conventional manner.

The compounds of formulas I and I-A and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are adenosine receptor ligands and possess a high affinity towards the adenosine A_{2A} receptor.

The compounds were investigated in accordance with the test given hereinafter.

Human adenosine A_{2A} receptor

The human adenosine A_{2A} receptor was recombinantly expressed in chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested, washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50 mM) buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂ and 10 mM MgCl₂ (pH 7.4) (buffer A). The [³H]-SCH-58261 (Dionisotti et al., 1997, Br J Pharmacol 121, 353; 1nM) binding assay was carried out in 96-well plates in the presence of 2.5 µg of membrane protein, 0.5 mg of Ysi-poly-l-lysine SPA beads and 0.1 U adenosine deaminase in a final volume of 200 µl of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2 µM). Compounds were tested at 10 concentrations from 10 µM-0.3 nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for 1hour at room temperature before centrifugation and then bound ligand determined using a Packard Topcount scintillation counter. IC₅₀ values were calculated using a non-linear curve fitting program and Ki values calculated using the Cheng-Prusoff equation.

In accordance with the invention, it has been shown that compounds of formula I have a high affinity toward the A_{2A} receptor. The most preferred compounds show an affinity to the hA_{2A} binding in the scope of a pKi value between 8.5 to 9.3.

Examples of such compounds are the followings:

Example No.	pKi value
3	8.8
10	9.0
17	9.3
23	8.9

36	9.1
59	9.0
61	8.9
62	9.1
91	8.8
92	8.9
96	8.8
100	9.3
107	8.8
108	8.9
121	9.0
125	9.0
157	8.9
159	8.9
201	8.6
221	8.7
238	8.7
240	8.5
253	8.6
258	8.9
271	8.6
275	8.7

277	8.7
278	8.5
279	8.8
280	8.7
282	8.6
283	9.0
286	8.8
287	8.5
289	8.9
290	8.6
292	8.8
298	8.7
301	8.5
304	8.5
308	9.1
309	8.5
314	8.5
315	8.6
317	8.6
326	8.5
327	8.5
342	8.5

369	9.2
-----	-----

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

In accordance with the invention compounds of formula I as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the adenosine receptor antagonistic activity, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore,

compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents and for the production of corresponding medicaments.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Example 1

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

To a solution of 2-amino-4-methoxy-7-phenyl-benzothiazole (100 mg, 0.4 mmol) in pyridine (2 ml) was added benzoyl chloride (55 mg, 0.4 mmol) and the mixture stirred overnight at 20 °C. To this mixture 2N HCl to pH 1 (20 ml) was added then the mixture was extracted twice with EtOAc (20 ml), washed with saturated NaHCO₃ solution, dried with Na₂SO₄ and the solvent evaporated. The crude product was then chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/MeOH (98:2), the product fractions were pooled and the solvent evaporated, to afford the title compound as a white solid (97 mg, 69 % yield), MS: m/e=360 (M⁺).

Following the general method of example 1 the compounds of examples 2 to 49 were prepared

Example 2

Furan-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using furan-2-carboxylic acid chloride the title compound was prepared as a beige solid (41 % yield), MS: m/e= 251.3 (M+H⁺).

Example 3

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using 5-methyl-thiophene-carboxylic acid chloride the title compound was prepared as a beige solid (36 % yield), MS: $m/e = 381.3$ ($M+H^+$).

Example 4

Furan-2-carboxylic acid (4,6-difluoro-benzothiazol-2-yl)-amide

- 5 Using 2-amino-4,6-difluoro-benzothiazole and furan-2-carboxylic acid chloride the title compound was prepared as a grey solid (81 % yield), MS: $m/e = 280$ (M^+).

Example 5

5-Methyl-thiophene-2-carboxylic acid (4,6-difluoro-benzothiazol-2-yl)-amide

- 10 Using 2-amino-4,6-difluoro-benzothiazole and 5-methyl-thiophene-carboxylic acid chloride the title compound was prepared as a yellow solid (74 % yield), MS: $m/e = 310$ (M^+).

Example 6

N-(4,6-Difluoro-benzothiazol-2-yl)-benzamide

- 15 Using 2-amino-4,6-difluoro-benzothiazole and benzoyl chloride the title compound was prepared as a beige solid (82 % yield), MS: $m/e = 290$ (M^+).

Example 7

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-acetamide

Using acetyl chloride the title compound was prepared as a light brown solid (69 % yield), MS: $m/e = 299.2$ ($M+H^+$).

20

Example 8

4-Cyano-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-cyano-benzoyl chloride the title compound was prepared as yellow solid (84 % yield), MS: $m/e = 385.1$ (M^+).

Example 9

- 25 5-Methyl-thiophene-2-carboxylic acid (4-methoxy-benzothiazol-2-yl)-amide

Using 2-amino-4-methoxy-benzothiazole and 5-methyl-thiophene-2-carboxylic acid chloride in pyridine the title compound was obtained as a beige solid (95 % yield), MS: $m/e=304.1$ (M^+).

Example 10

5 5-Methyl-furan-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using 2-amino-4-methoxy-7-phenyl-benzothiazole and freshly prepared 5-methyl-furan-2-carboxylic acid chloride the title compound was obtained crude, which was chromatographed over SiO_2 (Merck 230-400 mesh) eluting with nHexane/EtOAc (4:1), to afford the pure title compound as a pale yellow solid (67 % yield), MS: $m/e=364.0$ (M^+).

10

Example 11

Furan-2-carboxylic acid (4-methoxy-benzothiazol-2-yl)-amide

Using 2-amino-4-methoxy-benzothiazole and furan-2-carboxylic acid chloride in pyridine the title compound was obtained as a tan solid (100 % yield), MS: $m/e=274.1$ (M^+).

Example 12

15 N-(4-Methoxy-benzothiazol-2-yl)-benzamide

Using 2-amino-4-methoxy-benzothiazole and benzoyl chloride in pyridine the title compound was obtained as a white solid (72 % yield), MS: $m/e=284.1$ (M^+).

Example 13

Benzo[b]thiophene-2-carboxylic acid benzothiazol-2-ylamide

20 Using 2-amino-benzothiazole and benzo[b]thiophene-2-carboxylic acid chloride in pyridine the title compound was obtained as a light yellow solid (86 % yield), MS: $m/e=311.1$ ($M+H^+$).

Example 14

3-Methyl-thiophene-2-carboxylic acid benzothiazol-2-ylamide

25 Using 2-amino-benzothiazole and 3-methyl-thiophene-2-carboxylic acid chloride in pyridine the title compound was obtained as a yellow solid (69 % yield), MS: $m/e=275.1$ ($M+H^+$).

Example 15

5-Methyl-thiophene-2-carboxylic acid benzothiazol-2-ylamide

Using 2-amino-benzothiazole and 5-methyl-thiophene-2-carboxylic acid chloride in pyridine the title compound was obtained as a yellow solid (87 % yield), MS: $m/e=275.1$ (M+H⁺).

Example 16

N-Benzothiazol-2-yl-6-chloro-nicotinamide

Using 2-amino-benzothiazole and 2-chloropyridine-5-carboxylic acid chloride in pyridine the title compound was obtained as a white solid (97 % yield), MS: $m/e=290.1$ (M+H⁺).

10

Example 17

4-Hydroxymethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

To a solution of 4-formyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide (194 mg, 0.5 mmol), in THF (40 ml) was added sodium borohydride (19 mg, 0.5 mmol) and the mixture stirred for 2 h at r.t. Water was added (30 ml) followed by 1N HCl (4 ml) and the mixture agitated. The aqueous phase was then extracted twice with EtOAc (30 ml), the combined organic phases were then washed with saturated NaCl solution, dried with Na₂SO₄ filtered and evaporated. The crude residue was suspended in ether and ultrasonicated for 10 min., the solid precipitate was filtered off, washed with ether then dried under vacuum (0.05 mmHg, 50 °C) to afford the title compound as a light yellow solid (150 mg, 77 % yield), MS: $m/e=390.0$ (M⁺).

20

Example 18

4-Formyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-formyl benzoic acid the title compound was obtained as a light yellow solid (73 % yield), MS: $m/e=388.1$ (M+H⁺).

25

Example 19

2-Methoxy-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

To a solution of 2-amino-4-methoxy-7-phenyl-benzothiazole (200 mg, 0.67 mmol) in THF (10 ml) was added DMAP (10 mg, 0.08 mmol), triethylamine (163 µl, 1.17 mmol) and 2-methoxybenzoyl chloride (136 µl, 1 mmol) in THF (2 ml). The mixture was then heated to

- 35 -

reflux for 2 h, after cooling, it was partitioned between 1:1 AcOEt/THF (70 ml) and 5% NaHCO₃ solution (40 ml). The organic phase was washed with saturated NaCl solution (50 ml), dried with Na₂SO₄, filtered and the solvent removed under reduced pressure. The residue was suspended in ether (10 ml), filtered, washed with ether then dried under vacuum (0.05 mmHg, 60 °C), to afford the title compound as a white solid (260 mg, 85 % yield), MS: m/e= 390.0 (M⁺).

Example 20

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-2-methyl-benzamide

Using 2-methyl-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid, (88 % yield), MS: m/e=374.1 (M⁺).

Example 21

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-methyl-benzamide

Using 3-methyl-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a light yellow solid, (80 % yield), MS: m/e=374.0 (M⁺).

Example 22

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-methyl-benzamide

Using 4-methyl-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid, (79 % yield), MS: m/e=374.1 (M⁺).

Example 23

4-Fluoro-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-fluoro-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid (68 % yield), MS: m/e=378.0 (M⁺).

Example 24

3-Methoxy-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 3-methoxy-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a light yellow foam (75 % yield), MS: m/e=390.0 (M⁺).

Example 25

5 4-Methoxy-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-methoxy-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white foam (79 % yield), MS: m/e=390.1 (M⁺).

Example 26

10 N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-2-phenyl-acetamide

Using phenylacetyl-chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid (29 % yield), MS: m/e=374.1 (M⁺).

Example 27

15 3-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using 3-methyl-thiophene-2-carboxylic acid chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid (64 % yield), MS: m/e=380.0 (M⁺).

20

Example 28

2,5-Dimethyl-furan-3-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using 2,5-dimethyl-furan-3-carboxylic acid chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid (73 % yield), MS: m/e=378.1 (M⁺).

25

Example 29

3-Cyano-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 3-cyano-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid (80 % yield), MS: m/e=385.0 (M⁺).

Example 30

5 N-(4-Methoxy-7-phenoxy-benzothiazol-2-yl)-benzamide

Using 4-Methoxy-7-phenoxy-benzothiazol-2-ylamine and benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a white solid (72 % yield), MS: m/e=376.1 (M⁺).

10

Example 31

4-Dimethylamino-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-dimethylamino-benzoyl chloride in pyridine the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/(2N NH₃ in MeOH) (19:1), to afford the pure title compound as a beige solid (70 % yield), MS: m/e=403.0 (M⁺).

Example 32

4-Fluoro-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-N-methyl-benzamide

Using (4-methoxy-7-phenyl-benzothiazol-2-yl)-methyl-amine and 4-fluoro-benzoyl chloride in pyridine the title compound was obtained crude, which was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/EtOAc (1:1), to afford the pure title compound as a beige solid (88 % yield), MS: m/e=393.2 (M+H⁺).

Example 33

2-(4-Fluoro-benzoylamino)-4-methoxy-benzothiazole-7-carboxylic acid methyl ester

Using 2-amino-4-methoxy-benzothiazole-7-carboxylic acid methyl ester and 4-fluoro-benzoyl chloride the title compound was obtained as a white solid (91 % yield), MS: m/e=361.1 (M+H⁺).

Example 34

N-(7-tert-Butyl-4-methoxy-benzothiazol-2-yl)-4-fluoro-benzamide

25

Using 7-tert-butyl-4-methoxy-benzothiazol-2-ylamine and 4-fluoro-benzoyl chloride the title compound was obtained as a white solid (75 % yield), MS: $m/e=258.1$ ($M+H^+$).

Example 35

N-(7-Acetylamino-4-methoxy-benzothiazol-2-yl)-4-fluoro-benzamide

- 5 Using 7-acetylamino-4-methoxy-benzothiazol-2-ylamine and 4-fluoro-benzoyl chloride the title compound was obtained as a tan solid (25 % yield), MS: $m/e=359.1$ ($M+H^+$).

Example 36

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide

- Using pyridine-4-carboxylic acid chloride hydrochloride salt in pyridine the title
10 compound was obtained crude. After cooling a solid precipitated from the reaction mixture which was further triturated with ether (10 ml) then collected on a glass sinter and further washed with ether (10 ml). The filter cake was then washed sequentially with 10% Na_2CO_3 (20 ml), water (20 ml) followed by ether (20 ml) and the resulting product dried under vacuum (0.05 mmHg, 60 °C) to afford the pure title compound as a yellow solid
15 (188 mg, 67 % yield), MS: $m/e=361.0$ (M^+).

Example 37

4-Fluoro-N-(4-methoxy-7-phenoxy-benzothiazol-2-yl)-benzamide

- Using 4-methoxy-7-phenoxy-benzothiazol-2-ylamine and 4-fluoro-benzoyl chloride the title compound was obtained crude, which was chromatographed over SiO_2 (Merck 230-
20 400 mesh) eluting with $CH_2Cl_2/EtOAc$ (1:1), to afford the pure title compound as a white solid (75 % yield), MS: $m/e=394.1$ (M^+).

Example 38

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenoxy-benzothiazol-2-yl)-amide

- Using 4-methoxy-7-phenoxy-benzothiazol-2-ylamine and 5-methyl-thiophene-2-
25 carboxylic acid chloride the title compound was obtained crude, which was chromatographed over SiO_2 (Merck 230-400 mesh) eluting with $CH_2Cl_2/EtOAc$ (1:1), to afford the pure title compound as a pale yellow solid (76 % yield), MS: $m/e=396.0$ (M^+).

Example 39

4-Fluoro-N-(4-methoxy-7-morpholin-4-ylmethyl-benzothiazol-2-yl)-benzamide

Using 4-methoxy-7-morpholin-4-ylmethyl-benzothiazol-2-ylamine and 4-fluoro-benzoyl chloride in pyridine the title compound was obtained as a yellow solid (44 % yield), MS: $m/e=402.4$ ($M+H^+$).

Example 40

5 5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-morpholin-4-ylmethyl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-ylmethyl-benzothiazol-2-ylamine and 5-methyl-thiophene-2-carboxylic acid chloride in pyridine the title compound was obtained as a yellow solid (53 % yield), MS: $m/e=404.4$ ($M+H^+$).

10

Example 41

4-Fluoro-N-[4-methoxy-7-(1H-tetrazol-5-yl)-benzothiazol-2-yl]-benzamide

Using 4-methoxy-7-(1H-tetrazol-5-yl)-benzothiazol-2-ylamine and 4-fluoro-benzoyl chloride in pyridine the title compound was obtained as a tan solid (70 % yield), MS: $m/e=371.2$ ($M+H^+$).

15

Example 42

N-Benzothiazol-2-yl-benzamide

Using 2-amino-benzothiazole and benzoyl chloride in pyridine the title compound was obtained as a white solid (87 % yield), MS: $m/e=255.1$ ($M+H^+$).

Example 43

20 Furan-2-carboxylic acid benzothiazol-2-ylamide

Using 2-amino-benzothiazole and furan-2-carboxylic acid chloride in pyridine the title compound was obtained as a white solid (83 % yield), MS: $m/e=244$ (M^+).

Example 44

2-Chloro-N-(4-methyl-2-benzothiazolyl)-nicotinamide

25 Using 4-methyl-benzothiazol-2-ylamine and 2-chloronicotinic acid chloride the title compound was obtained as a yellow solid (50% yield), MS: $m/e=304$ ($M+H^+$).

Example 45

2-chloro-N-(4-methoxy-2-benzothiazolyl)-nicotinamide

Using 4-methoxy-benzothiazol-2-ylamine and 2-chloronicotinic acid chloride the title compound was obtained as a off-white solid (50% yield). MS: $m/e = 320$ ($M+H^+$).

5

Example 46

3-(4-Methoxy-benzothiazol-2-ylcarbamoyl)-acrylic acid ethyl ester

Using 4-methoxy-benzothiazol-2-ylamine and 3-chlorocarbonyl-acrylic acid methyl ester the title compound was obtained as a off-white solid (50% yield). MS: $m/e = 307$ (M^+).

Example 47

10 N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-oxalamic acid ethyl ester

The title compound is described in the following patent literature and was prepared according to the procedure described therein. *N-(Benzothiazol-2-yl)oxamic acid derivatives*. W. Winter, M. Thiel, A. Roesch and O. H. Wilhelms, German Patent, DE 2656468, 1978. Mp. 138-142°C, MS: $m/e = 357$ ($M+H^+$).

15

Example 48

4-Dimethylamino-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using pyridine-2-carboxylic acid, chloride hydrochloride salt in pyridine the title compound was obtained crude. This compound was purified further with preparative reversed phase HPLC using a Nucleosil N-protected column (20 mmx50 mm) and eluting
20 with a gradient of MeCN/ water (0.1 % TFA), The product fractions were pooled, evaporated and the residue partitioned between EtOAc (30 ml) and 10 % Na_2CO_3 (30 ml) and the aqueous phase extracted once with EtOAc (30 ml) The combined organic phases were then washed with saturated NaCl, dried, filtered and evaporated to afford the pure title compound as a beige solid (110 mg, 39 % yield), MS: $m/e = 361.1$ (M^+).

25

Example 49

4-Fluoro-N-(7-hydroxymethyl-4-methoxy-benzothiazol-2-yl)benzamide

To a solution of 2-(4-fluoro-benzoylamino)-4-methoxy-benzothiazole-7-carboxylic acid methyl ester (1.1 g, 3.05 mmol) in THF (250 ml) under argon at 5 °C was added a solution of 1N $LiAlH_4$ in THF (2 ml, 2 mmol) over 5 min., the mixture was stirred for 1 h at 5 °C,

then over 1 h allowed to warm to 20 °C. A further 3.5 ml of 1N LiAlH₄/THF was then added dropwise and the mixture stirred a further 2h at 20 °C. A solution of 5 ml THF/Water (4:1) was then added cautiously followed by 4N NaOH (2 ml), then water (2 ml) and the mixture stirred vigorously for 15 min. Excess Na₂SO₄ (50 g) was then added with vigorous stirring, then the solution was filtered and the solvent evaporated to afford the title compound as a white solid (0.9 g, 89 % yield), MS: m/e=333.2 (M+H⁺).

Example 50

4-Dipropylsulfamoyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

To a suspension of 4-dipropylsulfamoyl-benzoic acid (185 mg, 0.65 mmol) in toluene (10 ml) was added thionylchloride (600 mg, 5 mmol) and the mixture heated to 80 °C for 17 h. After cooling the solvent was evaporated and the residue was taken up in THF (20 ml), 2-amino-4-methoxy-7-phenyl-benzothiazole (128 mg, 0.5 mmol), triethylamine (105 µl, 0.75 mmol), and DMAP (6 mg, 0.05 mmol) were then added and the mixture was stirred for 1 hour at r.t. followed by 1 hour at 60 °C. After cooling to r.t. the reaction mixture was quenched by addition of 10 % aq. Na₂CO₃ solution (30 ml) and EtOAc (30 ml) and vigorous stirring. After separation of the phases the aqueous phase was extracted with EtOAc (30 ml) and the combined organic phases were washed with 10 % aq. Na₂CO₃, dried with Na₂SO₄, filtered and evaporated. The residue was then chromatographed over SiO₂ (Merck 230-400 mesh) eluting with a gradient of cyclohexane/EtOAc from (1:4) to 100 % EtOAc. After pooling and evaporation of the product fractions the title compound was obtained as a white solid (240 mg, 92 % yield), MS: m/e=524.2 (M+H⁺).

Following the general method of example 50 the compounds of examples 51 to 53 were prepared

Example 51

4-Diethylsulfamoyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-diethylsulfamoyl-benzoic acid the title compound was obtained as a light yellow solid (81 % yield), MS: m/e=496.2 (M+H⁺).

Example 52

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-(morpholine-4-sulfonyl)-benzamide

Using 4-(morpholine-4-sulfonyl)-benzoic acid the title compound was obtained as white amorphous solid (32 % yield), MS: m/e=510.3 (M+H⁺).

Example 53

4-Ethylsulfamoyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4-ethylsulfamoyl-benzoic acid the title compound was obtained as pale yellow amorphous solid (20 % yield), MS: m/e=466.2 (M-H)⁺.

5

Example 54

5-Methyl-thiophene-2-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide

Iodination of 5-methyl-thiophene-2-carboxylic acid (4-methoxy-benzothiazol-2-yl)-amide (5.17 g, 17 mmol) with iodine monochloride (2.26 ml, 44 mmol), sodium acetate (3.63 g, 44 mmol) and acetic acid (200 ml) in the same manner as described for (4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester affords the product as off-white solid in 93% yield. MS: m/e= 430 (M⁺).

10

(7-Aryl-4-methoxy-benzothiazol-2-yl)-carbamic acid ester, aryl-carboxylic acid (7-aryl-4-methoxy-benzothiazol-2-yl)-amides and substituted (4-methoxy-7-aryl-benzothiazol-2-yl)-ureas:

15 General procedure A: (7-Iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid ester or the respective aryl-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide or the respective (4-methoxy-7-aryl-benzothiazol-2-yl)-urea (1 part), the appropriate boronic acid (or its ester) (1.5 equivalents), palladium(II) acetate (0.05 equivalents), potassium phosphate (2.5 equivalents) and 2-biphenyl-dicyclohexyl phosphine (0.1 equivalents) are
20 combined in toluene (20 parts) and heated in an atmosphere of argon to 65 °C for 12 hours. The reaction mixture is evaporated to dryness and the product isolated by flash chromatography (silica, eluent ethyl acetate/cyclohexane 2:1).

General procedure B: (7-Iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid ester or the respective aryl-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide or the
25 respective (4-methoxy-7-aryl-benzothiazol-2-yl)-urea (1 part), the appropriate aryltrimethylstannane (1.5 equivalents), triphenylarsine (0.5 equivalents), tris-(dibenzylideneacetone)-dipalladium(0) (0.8 equivalents) and copper(I)iodide (0.8 equivalents) are combined in dimethylformamide (25 parts) and heated to 80 °C for 12 hours. The reaction mixture is evaporated to dryness and the product isolated by flash
30 chromatography (silica, eluent ethyl acetate).

Following the general method the compounds of examples 55 to 62 were prepared

Example 55

5-Methyl-thiophene-2-carboxylic acid [7-(2-chloro-phenyl)-4-methoxy-benzothiazol-2-yl]-amide

- 5 5-Methyl-thiophene-2-carboxylic acid [7-(2-chloro-phenyl)-4-methoxy-benzothiazol-2-yl]-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide (100 mg, 0.23 mmol) and 2-chlorophenylboronic acid (54 mg, 0.35 mmol) using the general procedure A as a light yellow solid in 80% yield. MS: $m/e = 415$ ($M+H^+$).

10

Example 56

5-Methyl-thiophene-2-carboxylic acid [4-methoxy-7-(3-nitro-phenyl)-benzothiazol-2-yl]-amide

- 5-Methyl-thiophene-2-carboxylic acid [7-(3-nitro-phenyl)-4-methoxy-benzothiazol-2-yl]-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide (155 mg, 0.36 mmol) and 3-nitrophenylboronic acid (135 mg, 0.81 mmol) using the general procedure A as a light yellow crystals in 42% yield. MS: $m/e = 425$ (M^+).
- 15

Example 57

5-Methyl-thiophene-2-carboxylic acid [7-(3-dimethylamino-phenyl)-4-methoxy-benzothiazol-2-yl]-amide

20

- 5-Methyl-thiophene-2-carboxylic acid [7-(3-dimethylamino-phenyl)-4-methoxy-benzothiazol-2-yl]-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide (100 mg, 0.23 mmol) and 3-dimethylaminophenylboronic acid (58 mg, 0.35 mmol) using the general procedure A as a light yellow solid in 71% yield. MS: $m/e = 424$ ($M+H^+$).
- 25

Example 58

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-4-yl-benzothiazol-2-yl)-amide

- 5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-4-yl-benzothiazol-2-yl)-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (7-bromo-4-methoxy-
- 30

- 44 -

benzothiazol-2-yl)-amide (192 mg, 0.50 mmol) and 4-pyridylboronic acid (92 mg, 0.75 mmol) using the general procedure A as a white solid in 6% yield. MS: $m/e = 381$ (M^+).

Example 59

5 5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-3-yl-benzothiazol-2-yl)-amide

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-3-yl-benzothiazol-2-yl)-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (7-bromo-4-methoxy-benzothiazol-2-yl)-amide (192 mg, 0.50 mmol) and 4-pyridylboronic acid (123 mg, 1.0 mmol) using the general procedure A as a white solid in 8% yield. MS: $m/e = 381$ (M^+).

10

Example 60

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-2-yl-benzothiazol-2-yl)-amide

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-2-yl-benzothiazol-2-yl)-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide (100 mg, 0.23 mmol) and 2-tri-n-butylstannane (130 mg, 0.35 mmol) using the general procedure B as a white solid in 23 % yield. MS: $m/e = 382$ ($M+H^+$).

15

Example 61

20 5-Methyl-thiophene-2-carboxylic acid [4-methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl]-amide

5-Methyl-thiophene-2-carboxylic acid [4-methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl]-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-iodo-benzothiazol-2-yl)-amide (260 mg, 0.60 mmol) and 2-methyl-4-trimethylstannanyl-pyridine (384 mg, 0.90 mmol) using the general procedure B as a light yellow solid in 50% yield. MS: $m/e = 396$ ($M+H^+$).

25

Example 62

5-Methyl-thiophene-2-carboxylic acid [7-(3-amino-phenyl)-4-methoxy-benzothiazol-2-yl]-amide

5-Methyl-thiophene-2-carboxylic acid [7-(3-amino-phenyl)-4-methoxy-benzothiazol-2-yl]-amide is synthesized from 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-iodo-

30

benzothiazol-2-yl)-amide (300 mg, 0.70 mmol) and 3-trimethylstannanyl-phenylamine (291 mg, 1.14 mmol) using the general procedure B as a light brown solid in 56 % yield. MS: $m/e = 396$ ($M+H^+$).

Example 63

5 5-Methyl-thiophene-2-carboxylic acid (4-hydroxy-7-phenyl-benzothiazol-2-yl)-amide

A solution of 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide (630 mg, 1.7 mmol) is slowly treated with boron tribromide (16 ml, 1.0 M in dichloromethane) at 0 °C. The reaction is slowly warmed to ambient temperature and stirred for further 72 h. The mixture is diluted with ethyl acetate and extracted twice with
10 water and once with brine. After drying over sodium sulfate, the solvent is removed in vacuo. Flash chromatography (silica, eluent ethyl acetate/hexane 1:1) and final recrystallization from tetrahydrofuran/hexane yields 118 mg (19 %) of the product as white solid. MS: $m/e = 367$ ($M+H^+$).

Example 64

15 4-{4-Methoxy-2-[(5-methyl-thiophene-2-carbonyl)-amino]-benzothiazol-7-yl}-piperazine-1-carboxylic acid benzyl ester

The title compound was synthesized starting from N-benzyloxycarbonylpiperazine and 4-bromo-2-nitroanisole as described for 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide and obtained as a white solid in 12 % overall
20 yield, MS: $m/e = 523$ ($M+H^+$).

Example 65 5-Methyl-thiophene-2-carboxylic acid [7-(3-dimethylamino-pyrrolidin-1-yl)-4-methoxy-benzothiazol-2-yl]-amide

The title compound is synthesized starting from 3-(dimethylamino)pyrrolidine and 4-bromo-2-nitroanisole as described for 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide and was obtained as yellow solid in 10%
25 overall yield, MS: $m/e = 417$ ($M+H^+$).

Example 66

5-Methyl-thiophene-2-carboxylic acid (5-methoxy-7-phenyl-benzothiazol-2-yl)-amide

2-Amino-5-methoxy-7-phenylbenzothiazol (45 mg, 0.18 mmol) is dissolved in
30 dichloromethane (2 ml) and subsequently treated with triethylamine (0.073 ml, 0.53 mmol) and 5-methyl-thiophene-2-carbonyl chloride (56 mg, 0.35 mmol). After 6 h,

- 46 -

further 0.073 ml, 0.53 mmol) and 5-methyl-thiophene-2-carbonyl chloride (56 mg, 0.35 mmol) are added and the mixture is stirred for additional 18 h at ambient. After addition of 0.1M aqueous sodium hydroxide, the mixture is stirred for additional 16 h. The organic layer is separated, dried and evaporated to dryness. Flash chromatography (silica, eluent ethyl acetate/cyclohexane 1:1, containing 0.5 % of 25 % aqueous ammonia) affords (10 mg, 5%) of the product as white solid. MS: $m/e = 380$ (M^+).

Example 67

5-Methyl-thiophene-2-carboxylic acid (4,5-dimethoxy-benzothiazol-2-yl)-amide

2-Amino-4,5-dimethoxybenzothiazole (1.1 g, 5.3 mmol) and N,N-dimethylaminopyridine (47 mg, 0.37 mmol) are dissolved in pyridine (17 ml) and slowly treated with 5-methyl-thiophene-2-carbonyl chloride (1.5 g, 9.0 mmol). After 48 h at ambient temperature, the solution is evaporated to dryness. Flash chromatography (silica, eluent diethyl ether/cyclohexane 2:1) affords the product (618 mg, 35 %) as light yellow solid.

Example 68

5-Methyl-thiophene-2-carboxylic acid (4-chloro-benzothiazol-2-yl)-amide

2-Amino-4-chlorobenzothiazol (92 mg, 0.50 mmol) is dissolved in dichloromethane (10 ml) and treated with pyridine (0.060 ml, 0.75 mmol) and 5-methyl-thiophene-2-carbonyl chloride (97 mg, 0.60 mmol). The reaction mixture is stirred at ambient temperature for 18 h and then evaporated to dryness. The residue is redissolved in ethyl acetate and water, the phases are separated and the organic layer extracted with brine. After drying with sodium sulfate, the solvent is removed in vacuo. Flash chromatography on silica (eluent ethyl acetate/cyclohexane 1:4) affords the product as white solid. (88 mg, 57 %). MS: $m/e = 308$ (M^+).

Example 69

5-Methyl-thiophene-2-carboxylic acid (7-bromo-4-methoxy-benzothiazol-2-yl)-amide

2-Amino-7-bromo-4-methoxybenzothiazol (2.33 g, 9 mmol) is dissolved in dichloromethane (100 ml) and at 0 °C treated with pyridine (2.2 ml, 27 mmol) and 5-methyl-thiophene-2-carbonyl chloride (2.2 g, 13.5 mmol). The reaction mixture is allowed to warm to room temperature and after stirring for additional 18 h quenched with water (100 ml). After separation of the phases, the aqueous phases are extracted twice with ethyl acetate. The combined organic layers are then washed with brine, dried and evaporated to

dryness. Flash chromatography on silica (eluent ethyl acetate/cyclohexane 1:1 to 4:1) and final recrystallization from ethyl acetate affords the product as off-white solid. (34 mg, 69%). MS: $m/e = 384$ (M^+).

Example 70

5 5-Methyl-thiophene-2-carboxylic acid (4-fluoro-benzothiazol-2-yl)-amide

2-Amino-4-fluorobenzothiazol (84 mg, 0.50 mmol) is dissolved in pyridine (3 ml) and treated with 4-dimethylaminopyridine (1 mg) and 5-methyl-thiophene-2-carbonyl chloride (161 mg, 1.0 mmol). After stirring for 1 h at ambient temperature, the reaction mixture was evaporated to dryness. Flash chromatography on silica (eluent diethyl ether/cyclohexane 1:1 containing 0.5 % of 25 % aqueous ammonia) and final recrystallization from ethyl acetate affords the product as off-white solid. (34 mg, 69 %). MS: $m/e = 292$ (M^+).

Example 71

5-Methyl-thiophene-2-carboxylic acid (4-trifluoromethoxy-benzothiazol-2-yl)-amide

15 2-amino-4-trifluoromethoxybenzothiazol (70 mg, 0.30 mmol) is dissolved in pyridine (3 ml) and treated with 4-dimethylaminopyridine (1 mg) and 5-methyl-thiophene-2-carbonyl chloride (96 mg, 0.60 mmol). After stirring for 4 h at ambient temperature, the reaction mixture was evaporated to dryness. Flash chromatography on silica (eluent ethyl acetate/cyclohexane 1:2) affords the product as white solid. (42 mg, 39 % yield). MS: $m/e =$
20 358 (M^+).

Following the general method of example 1, the compounds of examples 72 to 75 were prepared

Example 72

25 5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 5-methyl-thiophene-2-carbonyl chloride and 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol the title compound was obtained as a yellow solid in 97 % yield. MS: $m/e = 390$ ($M+H^+$).

Example 73

30 6-Hydroxy-pyridine-2-carboxylic acid (4-methoxy-benzothiazol-2-yl)-amide

Using 2-Amino-4-methoxybenzothiazole (450 mg, 2.5 mmol) and 6-hydroxypicolinic acid chloride (1.5 g, 10 mmol) the title compound was obtained as a beige powder in 5 % yield. MS: $m/e = 301$ (M^+).

Example 74

5 5-Methyl-thiophene-2-carboxylic acid (7-benzyloxy-4-methoxy-benzothiazol-2-yl)-amide

Using 5-methyl-thiophene-2-carboxylic acid chloride the title compound was obtained as an off-white solid (51 % yield). M.p.: 228-230 °C.

Following the general method of example 1, the compound of example 75 was prepared

Example 75

10 6-Chloro-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-nicotinamide

Using 6-chloro-nicotinyl chloride the title compound was obtained as a light yellow amorphous solid (79 % yield), MS: $m/e = 395.1$ (M^+).

Example 76

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-6-pyrrolidin-1-yl-nicotinamide

- 15 To a solution of 6-chloro-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-nicotinamide (297 mg, 0.75 mmol) in dioxane (10 ml) was added pyrrolidine (266 mg, 3.7 mmol, 5 eq.) and the mixture stirred at 100 °C for 2 h. After cooling the solvent was evaporated and the residue suspended in methanol (20 ml) at r.t., the solid was then filtered, washed with methanol and finally dried under vacuum (0.05 mmHg, 60 °C) to obtain the title
20 compound as a white solid (230 mg, 71 % yield), MS: $m/e = 431.4$ ($M+H^+$).

Following the general method of example 76, the compounds of examples 77 to 80 were prepared

Example 77

25 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using piperidine the title compound was obtained as a light brown solid (59 % yield), MS: $m/e = 445.3$ ($M+H^+$).

Example 78

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-6-morpholin-4-yl-nicotinamide

Using morpholine the title compound was obtained as a white solid (82 % yield), MS: $m/e=447.2$ ($M+H^+$).

5

Example 79

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-6-(4-methyl-piperazin-1-yl)-nicotinamide

Using N-methylpiperazine the title compound was obtained as a light brown solid (52 % yield), MS: $m/e=460.4$ ($M+H^+$).

Example 80

10 N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-6-thiomorpholin-4-yl-nicotinamide hydrochloride salt (1:1)

Using thiomorpholine the free base of the title compound was obtained, which was then converted to the hydrochloride salt by addition of 5N HCl/EtOH, affording the title compound as a white solid (78 % yield), MS: $m/e=463.1$ ($M+H^+$).

15

Example 81

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-6-(1-oxo-1,4-thiomorpholin-4-yl)-nicotinamide hydrochloride salt (1:1)

To a solution of N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-6-thiomorpholin-4-yl-nicotinamide hydrochloride salt (250 mg, 0.54 mmol) in chloroform (12 ml) was added 3-phenyl-2-(phenylsulfonyl)oxaziridine (211 mg, 0.81 mmol) and the mixture stirred at r.t.
20 for 2 hr. After evaporation of the solvent, the residue was suspended in CH_2Cl_2 , ultrasonicated, then the precipitate was filtered off, washed with CH_2Cl_2 , followed by ether and finally dried under vacuum (0.05 mmHg, 60 °C) to obtain the title compound as a light yellow solid (240 mg., 86 % yield), MS: $m/e=479.2$ ($M+H^+$).

25

Example 82

4-Bromomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

To a solution of 4-bromomethyl-benzoic acid (5.45 g, 25.3 mmol) in toluene (60 ml) was added thionyl chloride (18.25 ml, 25.3 mmol) and the mixture stirred at 80 °C for 16 h. The toluene and excess thionyl chloride were then evaporated in vacuo and replaced with

THF (100 ml). To this solution was added 2-amino-4-methoxy-7-phenyl-benzothiazole (5 g, 19.5 mmol), triethylamine (4.1 ml, 29.2 mmol) and DMAP (238 mg, 2 mmol) as catalyst, then the mixture stirred at 65 °C for 4 h. After cooling the reaction mixture was partitioned between 10% aq. Na₂CO₃ (200 ml) and EtOAc (100 ml), the aqueous phase was
5 extracted further with EtOAc/THF (1:1) (150 ml), then the combined organic phases were washed with satd. aq. NaCl (100 ml), dried (Na₂SO₄), filtered and evaporated in vacuo. The residue was then chromatographed over SiO₂ (Merck 230-400 mesh) eluting with a gradient of CH₂Cl₂/EtOAc (100 % CH₂Cl₂ to 1:1), the product fractions were pooled and evaporated in vacuo to afford the title compound as a pale yellow solid (4.9 g, 55 % yield),
10 MS: m/e=452.0 (M⁺).

Example 83

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-pyrrolidin-1-ylmethyl-benzamide hydrochloride salt (1:1)

To a solution of 4-formyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide (300 mg, 0.77 mmol) in THF (60 ml) was added pyrrolidine (82 mg, 1.16 mmol), acetic acid (70 mg, 1.16 mmol) and NaBH(OAc)₃ (246 mg, 1.16 mmol). This mixture was stirred for 16 h at r.t., then 5 % NaHCO₃ (30 ml) was added with vigorous stirring and the mixture extracted twice with EtOAc (50 ml). The organic phases were washed with saturates NaCl solution then dried, filtered and evaporated to afford the crude product which was
20 converted to its hydrochloride salt and purified by reversed phase preparative HPLC using a Nucleosil (Machery-Nagel) N-protected column (20 x50 mm) and an MeCN/water (0.1 % TFA) gradient. After pooling and evaporation of the product fractions the title compound was obtained as a white solid (217 mg, 59 % yield), MS: m/e=444.4 (M+H⁺).

25 *Following the general method of example 83, the compounds of examples 84 to 89 were prepared*

Example 84

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-piperidin-1-ylmethyl-benzamide hydrochloride salt (1:1)

Using piperidine the title compound was obtained as a light yellow solid (78 % yield), MS:
30 m/e=458.4 (M+H⁺).

Example 85

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-morpholin-4-ylmethyl-benzamide
hydrochloride salt (1:1)

Using morpholine the title compound was obtained as a light yellow solid (23 % yield),

5 MS: $m/e=460.5$ ($M+H^+$).

Example 86

4-Diethylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide
hydrochloride (1:1)

Using diethylamine the title compound was obtained as a white solid (39 % yield), MS:

10 $m/e=446.3$ ($M+H^+$).

Example 87

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(methyl-pyridin-3-ylmethyl-amino)-
methyl]-benzamide hydrochloride salt (1:2)

Using 3-(methylaminomethyl)-pyridine the title compound was obtained as a light yellow

15 solid (15 % yield), MS: $m/e=495.2$ ($M+H^+$).

Example 88

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-(4-methyl-piperazin-1-ylmethyl)-
benzamide hydrochloride salt (1:2)

Using N-methyl-piperazine the title compound was obtained as a white solid (21 % yield),

20 MS: $m/e=473.3$ ($M+H^+$).

Example 89

4-Dimethylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide
hydrochloride salt (1:1)

Using dimethylamine hydrochloride the title compound was obtained as a light yellow

25 solid (21 % yield), MS: $m/e=418.3$ ($M+H^+$).

Example 90

4-Ethylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

To a solution of 4-bromomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide (300 mg, 0.66 mmol) in THF (2 ml) was added ethylamine (2N in THF) (3 ml, 6.6 mmol) and the mixture stirred at 20 °C for 18 h. The reaction mixture was then evaporated to dryness and the residue treated with an excess of 5N HCl/EtOH (3 ml), the ethanol was then evaporated and the residue dissolved in DMSO and then subjected to preparative reversed phase HPLC purification using a C18 ODS-AQ column (20x50 mm), eluting with a gradient of MeCN/water (0.1% TFA). The product fractions were pooled and evaporated to afford the title compound as a light yellow solid (238 mg, 79 % yield), MS: m/e=418.3 (M+H⁺).

Following the general method of example 90, the compounds of examples 91 to 126 were prepared

Example 91

4-[(2-Methoxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using 2-methoxyethylamine in dioxane at 90 °C the title compound was obtained as a light yellow solid (66 % yield), MS: m/e=448.3 (M+H⁺).

Example 92

4-[(2-Hydroxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using ethanolamine in dioxane at 90 °C the title compound was obtained as a light yellow solid (68 % yield), MS: m/e=434.4 (M+H⁺).

Example 93

4-(Benzylamino-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using benzylamine in dioxane at 90 °C the title compound was obtained as a white solid (50 % yield), MS: m/e=480.3 (M+H⁺).

Example 94

4-[(Benzyl-methyl-amino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using N-methyl-benzylamine in dioxane at 90 °C the title compound was obtained as a
5 white solid (74 % yield), MS: m/e=494.3 (M+H⁺).

Example 95

4-[(3-Imidazol-1-yl-propylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:2)

Using 1-(3-aminopropyl)-imidazole in dioxane at 90 °C the title compound was obtained
10 as a pale yellow solid (58 % yield), MS: m/e=498.2 (M+H⁺).

Example 96

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(pyridin-4-ylmethyl)-amino]-methyl-benzamide hydrochloride salt (1:2)

Using 4-(aminomethyl)-pyridine in dioxane at 90 °C the title compound was obtained as a
15 beige solid (33 % yield), MS: m/e=481.2 (M+H⁺).

Example 97

4-[(2-Methoxy-ethyl)-methyl-amino]-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using N-(2-methoxyethyl)-methylamine in dioxane at 90 °C the title compound was
20 obtained as a light yellow solid (73 % yield), MS: m/e=462.3 (M+H⁺).

Example 98

4-(1,1-Dioxo-4-thiomorpholin-4-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

To a solution of N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-thiomorpholin-4-ylmethyl-
25 benzamide (350 mg, 0.73 mmol) in CH₂Cl₂ (10 ml) was added 3-phenyl-2-(phenylsulfonyl) oxaziridine (288 mg, 1.1 mmol) and the mixture stirred for 2 h at r.t. The reaction mixture was then evaporated to dryness, the residue suspended in ether, and the solid filtered off and washed with ether followed by acetone. This solid was dissolved in methanol (10 ml) and treated with 5N HCl/MeOH for 1 h at r.t., the resulting precipitate

was filtered off, washed with methanol and finally dried under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a white solid (270 mg, 68 % yield), MS: $m/e=508.3$ ($M+H^+$).

Example 99

- 5 N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-thiomorpholin-4-ylmethyl-benzamide hydrochloride salt (1:1)

Using thiomorpholine in dioxane at 90 °C the title compound was obtained as a yellow solid (68 % yield), MS: $m/e=476.1$ ($M+H^+$).

Example 100

- 10 4-Imidazol-1-ylmethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using imidazole in DMF at 90 °C the title compound was obtained as a pale yellow solid (92 % yield), MS: $m/e=441.3$ ($M+H^+$).

Example 101

- 15 4-(2-Hydroxymethyl-imidazol-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 2-hydroxymethyl-imidazole in DMF at 90 °C the title compound was obtained as a pale yellow solid (16 % yield), MS: $m/e=471.1$ ($M+H^+$).

Example 102

- 20 N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-(2-methylimidazol-1-ylmethyl)-benzamide

Using 2-methyl-imidazole in DMF at 90 °C the title compound was obtained as a white solid (79 % yield), MS: $m/e=455.5$ ($M+H^+$).

Example 103

- 25 4-(4,5-Dimethyl-imidazol-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide

Using 4,5-dimethyl-imidazole in DMF at 90 °C the title compound was obtained as a pale yellow solid (67 % yield), MS: $m/e=469.2$ ($M+H^+$).

Example 104

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-piperazin-1-ylmethyl-benzamide hydrochloride salt (1:2)

Using 1-tert-butoxycarbonyl-piperazine in dioxane at 90 °C the title compound was
5 obtained as a pale yellow solid (80 % yield), MS: m/e=459.5 (M+H⁺).

Example 105

4-Allylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using allylamine in dioxane at 90 °C the title compound was obtained as a pale yellow solid
10 (65 % yield), MS: m/e=430.5 (M+H⁺).

Example 106

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-propylaminomethyl-benzamide hydrochloride salt (1:1)

Using propylamine in dioxane at 90 °C the title compound was obtained as a pale yellow
15 solid (63 % yield), MS: m/e=432.4 (M+H⁺).

Example 107

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(pyridin-3-ylmethyl)-amino]-methyl-benzamide hydrochloride salt (1:2)

Using 3-(aminomethyl)-pyridine in THF at 65 °C the title compound was obtained as a
20 pale yellow solid (28 % yield), MS: m/e=481.3 (M+H⁺).

Example 108

4-(4-Hydroxy-piperidin-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using 4-hydroxy-piperidine in THF at 65 °C the title compound was obtained as a white
25 solid (61 % yield), MS: m/e=474.3 (M+H⁺).

Example 109

4-(3(S)-Hydroxy-pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using (S)-3-hydroxy-pyrrolidine in THF at 65 °C the title compound was obtained as a
5 white solid (74 % yield), MS: m/e=460.3 (M+H⁺).

Example 110

4-[1,4]Diazepan-1-ylmethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:2)

Using tert-butyl-1-homopiperazine carboxylate in THF at 65 °C the title compound was
10 obtained as a light yellow solid (87 % yield), MS: m/e=473.2 (M+H⁺).

Example 111

4-(3(R)-Dimethylamino-pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:2)

Using (3R)-(+)-3-dimethylamino-pyrrolidine in THF at 65 °C the title compound was
15 obtained as a light brown solid (51 % yield), MS: m/e=487.3 (M+H⁺).

Example 112

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-morpholin-4-yl-ethylamino)-methyl]-benzamide hydrochloride salt (1:2)

Using 4-(2-aminoethyl)-morpholine in THF at 65 °C the title compound was obtained as a
20 light yellow solid (44 % yield), MS: m/e=503.3 (M+H⁺).

Example 113

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-pyrrolidin-1-yl-ethylamino)-methyl]-benzamide hydrochloride salt (1:2)

Using N-(2-aminoethyl)-pyrrolidine in THF at 65 °C the title compound was obtained as a
25 light yellow solid (37 % yield), MS: m/e=487.3 (M+H⁺).

Example 114

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-piperidin-1-yl-ethylamino)-methyl]-benzamide hydrochloride salt (1:2)

Using N-(2-aminoethyl)-piperidine in THF at 65 °C the title compound was obtained as a
5 light yellow solid (50 % yield), MS: m/e=501.3 (M+H⁺).

Example 115

4-Cyclobutylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using cyclobutylamine in THF at 65 °C the title compound was obtained as a white solid
10 (68 % yield), MS: m/e=444.3 (M+H⁺).

Example 116

4-Cyclopentylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using cyclopentylamine in THF at 65 °C the title compound was obtained as a light brown
15 solid (46 % yield), MS: m/e=458.4 (M+H⁺).

Example 117

4-[(Furan-2-ylmethyl)-amino]-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using 2-(aminomethyl)-furan in THF at 65 °C the title compound was obtained as a beige
20 solid (57 % yield), MS: m/e=470.2 (M+H⁺).

Example 118

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(thiophen-2-ylmethyl)-amino]-methyl-benzamide hydrochloride salt (1:1)

Using 2-(aminomethyl)-thiophene in THF at 65 °C the title compound was obtained as a
25 light yellow solid (60 % yield), MS: m/e=486.3 (M+H⁺).

Example 119

4-Dipropylaminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using dipropylamine in THF at 65 °C the title compound was obtained as a white solid (64 % yield), MS: m/e=474.3 (M+H⁺).

5

Example 120

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[[methyl-(2-pyridin-2-yl-ethyl)-amino]-methyl]-benzamide hydrochloride salt (1:2)

Using 2-[(2-(methylamino)ethyl)-pyridine in THF at 65 °C the title compound was obtained as a beige solid (46 % yield), MS: m/e=509.3 (M+H⁺).

10

Example 121

4-Aminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using ammonia (7N in MeOH) in THF at 20 °C the title compound was obtained (after 4 days) as a white solid (34 % yield), MS: m/e=389.1 (M⁺).

15

Example 122

4-[(Cyclopropylmethyl-amino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:1)

Using aminomethyl-cyclopropane in dioxane at 90 °C the title compound was obtained as a light yellow solid (69 % yield), MS: m/e=444.3 (M+H⁺).

20

Example 123

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-methylsulfanyl-ethylamino)-methyl]-benzamide hydrochloride salt (1:2)

Using 2-(methylthio)-ethylamine in THF at 65 °C the title compound was obtained as a light yellow solid (74 % yield), MS: m/e=464.2 (M+H⁺).

25

Example 124

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-4-thiazolidin-3-ylmethyl-benzamide hydrochloride salt (1:1)

Using thiazolidine in THF at 65 °C the title compound was obtained as a white solid (48 % yield), MS: m/e=462.2 (M+H⁺).

Example 125

5 4-(3(S)-Dimethylamino-pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:2)

Using (3S)-(-)-3-(dimethylamino)-pyrrolidine in THF at 65 °C the title compound was obtained as a light brown solid (56 % yield), MS: m/e=487.3 (M+H⁺).

Example 126

10 4-[(2-Dimethylamino-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide hydrochloride salt (1:2)

Using 2-(dimethylamino)-ethylamine in THF at 65 °C the title compound was obtained as a light yellow solid (32 % yield), MS: m/e=461.3 (M+H⁺).

Preparation of the 4-(R¹R²-amino)-N-(4-methoxy-7-aryl-benzothiazol-2-yl)-benzamides:

General procedure C: The appropriate 2-amino-7-aryl-4-methoxy-benzothiazol is
15 converted with 4-(chloromethyl)benzoyl chloride using the general method of example 1. The product is then converted neat with the appropriate amine (10 equivalents) at 100 °C for 24 hours. The reaction mixture is then dissolved in ethyl acetate, extracted with water and brine, dried and evaporated in vacuo. Flash chromatography (silica, eluent dichloromethane containing 1.2 to 2.4 % methanol) affords the product in about 50 %
20 yield.

Example 127

4-Chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

and 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol (1.0 g, 3.8 mmol), 4-(chloromethyl) benzoyl chloride (810 mg, 4.2 mmol) and pyridine (0.36 ml, 4.5 mmol) are
25 reacted in dichloromethane (20 ml) for 18 h. The reaction is quenched with water (25 ml) and brought to pH 8.0 with sodium carbonate. The mixture is extracted with dichloromethane and the combined organic layers are dried and evaporated to dryness. Flash chromatography (silica, eluent methylene chloride containing 2.5 % methanol) affords the product as white crystals in 54 % yield. MS: m/e= 418 (M+H⁺).

Following the general method the compounds of examples 128 to 132 were prepared

Example 128

4-(4-Hydroxy-piperidin-1-yl methyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- 5 Conversion of 4-chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (84 mg, 0.20 mmol) with 4-hydroxypiperazin (200 mg, 2.0 mmol) using the general procedure C affords the product as white solid in 73% yield. MS: m/e= 483 (M+H⁺).

Example 129

- 10 4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Conversion of 4-chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (84 mg, 0.20 mmol) with N-(2-methoxyethyl)-methylamin (178 mg, 2.0 mmol) using the general procedure C affords the product as white solid in 55% yield. MS: m/e=

- 15 471 (M+H⁺).

Example 130

4-[[(2-Hydroxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- 3,4-Dimethoxy-benzoic acid 2-[[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl carbamoyl)-benzyl]-methyl-amino]-ethyl ester (63 mg, 0.10 mmol) are heated in aqueous sodium hydroxide (1M, 0.5 ml) and ethanol (2 ml) to 100 °C for 30 min. The mixture is diluted with water and extracted twice with ethyl acetate. The combined organic layers are extracted with saturated aqueous sodium hydrogencarbonate, dried and evaporated to dryness. Flash chromatography (silica, eluent methylene chloride containing 5 %
20 methanol) affords the product as white crystals in 48 % yield. MS: m/e= 457 (M+H⁺).

Example 131

3,4-Dimethoxy-benzoic acid 2-[[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl carbamoyl)-benzyl]-methyl-amino]-ethyl ester

- Conversion of 4-chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (84 mg, 0.20 mmol) with 3,4-dimethoxybenzoic acid 2-methylamino-ethyl
30

ester chlorohydrate (96 mg, 0.4 mmol) and N-ethyl diisopropylamine (0.14 ml, 0.80 mmol) using the general procedure C affords the product as light yellow solid in 57% yield. MS: m/e= 621 (M+H⁺).

Example 132

5 N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-piperazin-1-ylmethyl-benzamide

Conversion of 4-chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (84 mg, 0.20 mmol) with 1-BOC-piperazine (372 mg, 1.9 mmol) using the general procedure C and afterwards cleavage of the neat carbamate in trifluoroacetic acid (1 ml) followed by saturated aqueous sodium carbonate affords the product as colorless
10 crystals in 72% yield. MS: m/e= 468 (M+H⁺).

Example 133

N-(7-Benzyloxy-4-methoxy-benzothiazol-2-yl)-4-chloromethyl-benzamide

Following the general method of example 1 the title compound was obtained as a light yellow solid (70 % yield). MS (EI): m/e = 438 (M⁺).

15

Example 134

N-(7-Benzyloxy-4-methoxy-benzothiazol-2-yl)-4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-benzamide hydrochloride

According to general procedure C the title compound was obtained as a light brown solid (86 % yield). M.p.: 195° C (dec.).

20 Preparation of the 3-(7-aryl-4-methoxy-benzothiazol-2-yl)-1-R³-1-R⁴-ureas:

General procedure D: The appropriate 2-amino-7-aryl-4-methoxy-benzothiazol (1 part) and pyridine (1.2 equivalents) are dissolved in 40 parts tetrahydrofuran and treated with phosgene (20 % in toluene, 1 equivalent) at ambient temperature. After 60 min, the reaction mixture is concentrated to half the volume under reduced pressure and the
25 appropriate amine (1.25 equivalents) and pyridine (1.1 equivalents) are added. After 15 min at ambient temperature, the reaction mixture is evaporated to dryness. The product is isolated by flash chromatography (silica, eluent dichloromethane containing 2.5 % methanol).

Following the general method the compounds of examples 135 to 137 were prepared

Example 135

Thiomorpholine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- 5 Conversion of 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol (100 mg, 0.377 mmol) with phosgene (20 % in toluene, 0.2 ml) and thiomorpholine (0.045 ml, 0.47 mmol) using the general procedure D affords the product as white solid in 73 % yield. MS: $m/e = 395$ ($M+H^+$).

Example 136

- 10 Morpholine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Conversion of 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol (100 mg, 0.377 mmol) with phosgene (20% in toluene, 0.2 ml) and morpholine (0.041 ml, 0.47 mmol) using the general procedure D affords the product as white solid in 25 % yield. MS: $m/e = 379$ ($M+H^+$).

- 15 **Example 137**

3-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-1-(6-methyl-pyridin-3-ylmethyl)-urea

- Conversion of 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol (100 mg, 0.377 mmol) with phosgene (20 % in toluene, 0.2 ml) and methyl-(6-methyl-pyridin-3-ylmethyl)-amine
20 (0.064 ml, 0.47 mmol) using the general procedure D affords the product as white solid in 25 % yield. MS: $m/e = 429$ ($M+H^+$).

Example 138

1-Furan-2-yl-methyl-3-(4-methoxy-benzothiazol-2-yl)-urea

- To a solution of (4-Methoxy-benzothiazol-2-yl)-carbamic acid tert-butyl ester (80 mg, 0.29
25 mmol) in dioxane (2 ml) was added furfurylamine (55 mg, 0.57 mmol) and the mixture heated to 100 °C for 20 h. The reaction mixture was then evaporated to dryness and the residue recrystallised from ether/nHexane to afford the title compound as a beige solid (80 mg, 92% yield), MS: $m/e = 303$ (M^+).

Following the general method of example 138, the compounds of examples 139 to 163 were prepared

Example 139

1-Furan-2-yl-methyl-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea

- 5 Using (4-Methoxy-benzothiazol-2-yl)-carbamic acid tert-butyl ester and furfurylamine the title compound was obtained as a beige solid (66 % yield), MS: $m/e=380.3$ ($M+H^+$).

Example 140

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-thiophen-2-yl-methyl-urea

- 10 Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and thiophene-2-methylamine the title compound was obtained as a beige solid (62 % yield), MS: $m/e=396.3$ ($M+H^+$).

Example 141

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-pyridin-2-yl-methyl-urea

- 15 Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 2-(aminomethyl)-pyridine the title compound was obtained as a beige solid (18 % yield) following purification using reversed-phase preparative HPLC, C18 ODS-AQ, with an MeCN/ water gradient, MS: $m/e=391.2$ ($M+H^+$).

Example 142

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-pyridin-3-ylmethyl-urea

- 20 Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 3-(aminomethyl)-pyridine the title compound was obtained as a beige solid (18 % yield) following purification using reversed-phase preparative HPLC, C18 ODS-AQ, with a water/acetonitrile gradient, MS: $m/e=391.2$ ($M+H^+$).

Example 143

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-pyridin-4-ylmethyl-urea

- 25 Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 4-(aminomethyl)-pyridine the title compound was obtained as a beige solid (52 % yield), MS: $m/e=391.2$ ($M+H^+$).

Example 144

3-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-1-methyl-1-pyridin-3-yl-methyl-urea

Using (4-methoxy-7-phenyl-benzoyhiazol-2-yl)-carbamic acid tert-butyl ester and 3-(methylaminomethyl)-pyridine the title compound was obtained as a beige solid (23 %
5 yield), MS: $m/e=405.4$ ($M+H^+$).

Example 145

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-phenethyl-urea

Using (4-methoxy-7-phenyl-benzoyhiazol-2-yl)-carbamic acid tert-butyl ester and phenethylamine the title compound was obtained as a beige solid (77 % yield), MS:
10 $m/e=404.5$ ($M+H^+$).

Example 146

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-(3-phenyl-propyl)-urea

Using (4-methoxy-7-phenyl-benzoyhiazol-2-yl)-carbamic acid tert-butyl ester and 3-phenyl-propylamine the title compound was obtained as a beige solid (71 % yield), MS:
15 $m/e=417.5$ ($M+H^+$).

Example 147

1-(4-Methoxy-benzyl)-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea

Using (4-methoxy-7-phenyl-benzoyhiazol-2-yl)-carbamic acid tert-butyl ester and 4-methoxy-benzylamine the title compound was obtained as a beige solid (60 % yield), MS:
20 $m/e=420.3$ ($M+H^+$).

Example 148

3,4-Dihydro-1H-isoquinoline-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using (4-methoxy-7-phenyl-benzoyhiazol-2-yl)-carbamic acid tert-butyl ester and 1,2,3,4-tetrahydroisoquinoline the title compound was obtained as a beige solid (31 % yield)
25 following purification using reverse-phase prep. HPLC, C18 ODS-AQ, with a water/acetonitrile gradient, MS: $m/e=416.3$ ($M+H^+$).

Example 149

1-(2-Dimethylamino-ethyl)-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 2-dimethylamino-ethylamine the title compound was obtained as a beige solid (67 % yield),
5 MS: $m/e=371.3$ ($M+H^+$).

Example 150

1-(2-Hydroxy-ethyl)-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and ethanolamine the title compound was obtained as a beige solid (35 % yield), MS:
10 $m/e=344.3$ ($M+H^+$).

Example 151

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-(2-piperidin-1-yl-ethyl)-urea

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 1-(2-aminoethyl)-piperidine the title compound was obtained as a beige solid (67 % yield), MS:
15 $m/e=411.4$ ($M+H^+$).

Example 152

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-(2-morpholin-4-yl-ethyl)-urea

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 4-(2-aminoethyl)-morpholine the title compound was obtained as a beige solid (29 % yield),
20 MS: $m/e=413.4$ ($M+H^+$).

Example 153

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-(2-pyridin-2-yl-ethyl)-urea

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and 2-(2-aminoethyl)-pyridine the title compound was obtained as a beige solid (88 % yield), MS:
25 $m/e=405.4$ ($M+H^+$).

Example 154

1-(3-Imidazol-1-yl-propyl)-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea
hydrochloride salt (1:1)

Using (4-methoxy-7-phenyl-benzoyhiazol-2-yl)-carbamic acid tert-butyl ester and N-(3-aminopropyl)-imidazole the free base was obtained which was treated with 5N HCl/EtOH followed by crystallisation from methanol/ether to afford the title compound as a beige solid (72 % yield), MS: $m/e=408.3$ ($M+H^+$).

Example 155

1-Ethyl-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-1-pyridin-4-yl-methyl-urea
hydrochloride salt (1:1)

Using (4-methoxy-7-phenyl-benzoyl-2-yl)-carbamic acid tert-butyl ester and 4-(N-ethylaminomethyl)-pyridine the free base was obtained which was treated with 5N HCl/EtOH followed by crystallisation from acetonitrile to afford the title compound as a white solid (64 % yield), MS: $m/e=419.3$ ($M+H^+$).

Example 156

1-(2-Imidazol-1-yl-ethyl)-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea hydrochloride
salt (1:1)

15 Using (4-methoxy-7-phenyl-benzoyl-2-yl)-carbamic acid tert-butyl ester and N-(2-aminoethyl)-imidazole the free base was obtained which was treated with 5N HCl/EtOH followed by crystallisation from acetonitrile to afford the title compound as a light brown solid (65 % yield), MS: m/e=393.0 (M⁺).

Example 157

20 Morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using (4-methoxy-7-phenyl-benzoyl-2-yl)-carbamic acid tert-butyl ester and morpholine the title compound was obtained as a white solid, following crystallisation from ether/ nHexane (67 % yield), MS: m/e=370.3 (M+H⁺)

Example 158

25 Thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

Using (4-methoxy-7-phenyl-benzoylthiazol-2-yl)-carbamic acid tert-butyl ester and thiomorpholine the title compound was obtained as a white solid, following crystallisation from ether/nHexane (88 % yield), MS: m/e=386.2 (M+H⁺).

Example 159

1-Oxo-11 4-thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide

To a solution of thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide (240 mg, 0.62 mmol) in CH₂Cl₂ (10 ml) was added 3-phenyl-2-(phenylsulfonyl) oxaziridine (244 mg, 0.92 mmol) and the mixture stirred for 2 h at r.t. The solvent was then reduced to ca. 2 ml and the mixture ultrasonicated for 15 min. with addition of ether (10 ml). The solid precipitated was filtered off, then dried under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a light yellow solid (90 % yield), MS: m/e=402.9 (M+H⁺).

Example 160

1-[2-(1,1-Dioxo-11 6-thiomorpholin-4-yl)-ethyl]-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea hydrochloride (1:1)

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester 2-(1,1-Dioxo-thiomorpholin-4-yl)-ethylamine the free base was obtained, which was converted to the hydrochloride salt by treatment with 5N HCl/EtOH followed by under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a beige solid (87 % yield), MS: m/e=461.2 (M+H⁺).

Example 161

3-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-1-methyl-1-(6-methyl-pyridin-3-yl-methyl)-urea hydrochloride salt (1:2)

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and methyl-(6-methyl-pyridin-3-ylmethyl)-amine, the free base was obtained, which was converted to the hydrochloride salt by treatment with 5N HCl/EtOH followed by recrystallisation from acetonitrile then drying under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a white solid (61 % yield), MS: m/e=448.9 (M+H⁺).

Example 162

3-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-1-methyl-1-pyridin-2-yl-methyl-urea hydrochloride salt (1:2)

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester and methyl-pyridin-2-yl-methyl-amine, the free base was obtained, which was converted to the

hydrochloride salt by treatment with 5N HCl/EtOH followed by recrystallisation from EtOH/ether then drying under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a white solid (70 % yield), MS: $m/e=494.4$ ($M+H^+$).

Example 163

5 3-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-1-methyl-1-pyridin-4-yl-methyl-urea hydrochloride salt (1:2)

Using (4-methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester methyl-pyridin-4-ylmethyl-amine the free base was obtained, which was converted to the hydrochloride salt by treatment with 5N HCl/EtOH followed by recrystallisation from EtOH/ether then drying under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a white solid (65 % yield), MS: $m/e=480.3$ ($M+H^+$).

Example 164

3-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-1-methyl-1-(1-oxy-pyridin-3-yl-methyl)-urea

To an ice cooled solution of 3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-1-methyl-1-pyridin-3-yl-methyl-urea (405 mg, 1 mmol), in CH_2Cl_2 was added 3-chloro-perbenzoic acid (MCPBA) (295 mg, 1.2 mmol) and the mixture stirred at 0 °C for 1h, followed by 1 h at r.t. After this time the pale red reaction mixture was thoroughly washed with 5% $NaHCO_3$ solution (50 ml), and the aqueous phase was extracted with CH_2Cl_2 (2x 30 ml) then the combined extracts were dried with Na_2SO_4 , filtered and evaporated to affording a violet solid. This solid was then chromatographed over SiO_2 (Merck 230-400 mesh) eluting with a gradient of $CH_2Cl_2/(2N NH_3/MeOH)$ (97:3 to 9:1), to afford the title compound as a light brown solid (260 mg, 62 % yield), MS: $m/e=421.3$ ($M+H^+$).

Example 165

1-Benzyl-3-(4-methoxy-benzothiazol-2-yl)-urea

25 To a stirred solution of 2-amino-4-methoxy-benzothiazole (180 mg, 1 mol) in THF (5 ml) was added benzyliocyanate (166 mg, 1.25 mmol) and the mixture heated to 60 °C for 3 h. After evaporation of the solvent, ether (5 ml) was added and the suspension ultrasonicated for 10 min with addition of nHexane (5 ml). This suspension was filtered and washed further with ether/nHexane (1:1) to afford the title compound, after drying under vacuum, as a white solid (220 mg, 70 % yield), MS: $m/e=313$ (M^+).

Following the general method of example 165, the compound of example 166 was prepared

Example 166

1-Benzyl-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-urea

Using 2-amino-4-methoxy-7-phenyl-benzothiazole the title compound was obtained as a
5 white amorphous solid (92 % yield), MS: $m/e=389$ (M^+)

Example 167

1-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-3-pyridin-3-yl-thiourea

To a stirred solution of 2-amino-4-methoxy-7-phenyl-benzothiazole (80 mg, 0.3 mmol) in
dioxane (3 ml) was added pyridine-3-isothiocyanate (64 mg, 0.47 mmol) and the mixture
10 heated to 100 °C for 69 h. After cooling to r.t. the resulting yellow suspension was filtered,
washed with ether (5 ml) and dried under vacuum (0.05 mmHg, 50 °C, to afford the title
compound as a; light yellow solid (98 mg, 80 % yield), MS: $m/e=393.1$ ($M+H^+$).

Example 168

1-Benzoyl-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-thiourea

15 To a suspension of 2-amino-4-methoxy-7-phenyl-benzothiazole (1.52 g, 6 mmol) in
dioxane (60 ml) was added benzoylisothiocyanate (1.45 g, 8.9 mmol) and the mixture
heated to 100 °C for 2 h, during which time the suspension dissolved. After cooling the
solvent was removed and the solids suspended in hot acetonitrile (100 ml) and filtered
while warm (50 °C). The solid collected was washed with acetonitrile (20 ml) then dried
20 under vacuum (0.05 mmHg), at 60 °C. to afford the title compound as a pale yellow
amorphous solid (1.38 g, 55 % yield), MS: $m/e=419.0$ (M^+).

Example 169

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-thiourea

To a solution of 1-benzoyl-3-(4-methoxy-7-phenyl-benzothiazol-2-yl)-thiourea (1.3 g, 3.1
25 mmol) in methanol (20 ml)/THF (40 ml) was added NaOMe (250 mg, 4.6 mmol) and the
mixture stirred for 72 h at r.t. After evaporation of the solvents water (100 ml) was added
with stirring followed by acetic acid (1 ml) which caused a solid to precipitate. This solid
was collected and on a glass sinter, washed with water (100 ml), followed by EtOAc (30 ml)
then finally cyclohexane (30 ml). After drying the title compound was obtained as a white
30 solid (850 mg, 87 % yield), MS: $m/e=316.2$ ($M+H^+$).

Example 170

(4-Methoxy-benzothiazol-2-yl)-urea

A mixture of 2-amino-4-methoxy-benzothiazole (330 mg, 1.83 mmol) and urea (1.1 g, 1.83 mmol) were heated together for 1 h at 170 °C, with evolution of ammonia. After
5 allowing to cool to r.t., water (10 ml) was added and the mixture was vigorously stirred. The solid was then filtered, washed with water (10 ml) followed by ethanol (10 ml) and dried at 60 °C under vacuum (0.05 mmHg). The title product was afforded as an off-white solid (300 mg, 73 % yield), MS: m/e= 223 (M⁺).

Following the general method of example 170, the compounds of examples 171 to 173 were
10 prepared

Example 171

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-urea

Using 2-amino-4-methoxy-7-phenyl-benzothiazole the title compound was prepared as white solid (58 % yield), MS: m/e= 299 (M⁺). The preparation of this compound is
15 described in the following patent literature; *N-(Benzothiazol-2-yl)oxamic acid derivatives*. W. Winter, M. Thiel, A. Roesch and O. H. Wilhelms, German Patent, DE 2656468, 1978.

Example 172

(4,6-Difluoro-benzothiazol-2-yl)-urea

Using 2-amino-4,6-difluoro-benzothiazole the title compound was prepared as a light
20 yellow solid (42 % yield), MS: m/e= 229 (M⁺).

Example 173

(7-Isopropyl-4-methoxy-benzothiazol-2-yl)-urea

The title compound is described in the following patent literature and was prepared according to the procedure described therein; *N-(Benzothiazol-2-yl)oxamic acid derivatives*.
25 W. Winter, M. Thiel, A. Roesch and O. H. Wilhelms, German Patent, DE 2656468, 1978.

Example 174

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-pyridin-3-ylmethyl-amine

To a solution of 2-chloro-4-methoxy-7-phenyl-benzothiazole (150 mg, 0.54 mmol), in dioxane (5 ml) was added 3-(aminomethyl)-pyridine (176 mg, 1.6 mmol) and this mixture was stirred at 100 °C for 18 h.. The solvent was then evaporated and the mixture taken up in methanol (8 ml) and ultrasonicated for 10 min. to precipitate the product, which was
5 washed with methanol (5 ml), and dried under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a white solid (58 mg, 31 % yield), MS: m/e=348.3 (M+H⁺).

Following the general method of example 174, the compounds of examples 175 to 184 were prepared

Example 175

10 (4-Methoxy-7-phenyl-benzothiazol-2-yl)-pyridin-4-ylmethyl-amine

Using 4-(aminomethyl)-pyridine the title compound was obtained as a pale yellow solid (17 % yield), MS: m/e=343.3 (M+H⁺).

Example 176

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-pyridin-2-ylmethyl-amine

15 Using 2-(aminomethyl)-pyridine the title compound was obtained as a white solid (32 % yield), MS: m/e=343.3 (M+H⁺).

Example 177

Benzyl-(4-methoxy-7-phenyl-benzothiazol-2-yl)-amine

Using benzylamine the title compound was obtained as a white solid (54 % yield), MS:
20 m/e=347.3 (M+H⁺).

Example 178

(2-Methoxy-ethyl)-(4-methoxy-7-phenyl-benzothiazol-2-yl)-amine

Using 2-methoxy-ethylamine the title compound was obtained as a white solid (56 % yield), MS: m/e=315.3 (M+H⁺).

25

Example 179

Cyclopropylmethyl-(4-methoxy-7-phenyl-benzothiazol-2-yl)-amine

Using aminomethyl-cyclopropane the title compound was obtained as a white solid (68 % yield), MS: $m/e=311.2$ ($M+H^+$).

Example 180

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-(2-pyridin-2-yl-ethyl)-amine hydrochloride salt
5 (1:2)

Using 3-(2-aminoethyl)-pyridine the crude product was obtained which was converted to its hydrochloride salt with excess 5N HCl/EtOH (2.5 eq.) and then purified by reversed phase preparative HPLC, using a C18 ODS-AQ column, with a water (0.1% TFA) /acetonitrile gradient. After pooling the product fractions and evaporation of solvents the
10 title compound was obtained as a white foam (59 % yield), MS: $m/e=362.2$ ($M+H^+$).

Example 181

N-(4-Methoxy-7-phenyl-benzothiazol-2-yl)-N',N'-dimethyl-ethane-1,2-diamine
hydrochloride salt (1:2)

Using 2-(dimethylamino)-ethylamine the crude product was obtained which was
15 converted to its hydrochloride salt with excess 5N HCl/EtOH (2.5 eq.) and then purified by reversed phase preparative HPLC, using a C18 ODS-AQ column, with a water (0.1% TFA) /acetonitrile gradient. After pooling the product fractions and evaporation of solvents the title compound was obtained as a white foam (80 % yield), MS: $m/e=328.3$ ($M+H^+$).

Example 182

20 (4-Methoxy-7-phenyl-benzothiazol-2-yl)-(2-morpholin-4-yl-ethyl)-amine hydrochloride
salt (1:2)

Using 4-(2-aminoethyl)morpholine the crude product was obtained which was converted to its hydrochloride salt with excess 5N HCl/EtOH (2.5 eq.) and then purified by reversed phase preparative HPLC, using a C18 ODS-AQ column, with a water (0.1% TFA)
25 /acetonitrile gradient. After pooling the product fractions and evaporation of solvents the title compound was obtained as a white foam (67 % yield), MS: $m/e=370.3$ ($M+H^+$).

Example 183

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-(2-piperidin-1-yl-ethyl)-amine hydrochloride
salt (1:2)

- Using 1-(2-aminoethyl)-piperidine the crude product was obtained which was converted to its hydrochloride salt with excess 5N HCl/EtOH (2.5 eq.) and then purified by reversed phase preparative HPLC, using a C18 ODS-AQ column, with a water (0.1% TFA) /acetonitrile gradient. After pooling the product fractions and evaporation of solvents the title compound was obtained as a white foam (57 % yield), MS: m/e=368.2 (M+H⁺).

Example 184

2-(4-Methoxy-7-phenyl-benzothiazol-2-ylamino)-ethanol hydrochloride salt (1:1)

- Using ethanolamine the crude product was obtained which was converted to its hydrochloride salt with excess 5N HCl/EtOH (2.5 eq.) and then purified by reversed phase preparative HPLC, using a C18 ODS-AQ column, with a water (0.1% TFA) /acetonitrile gradient. After pooling the product fractions and evaporation of solvents the title compound was obtained as a white foam (60 % yield), MS: m/e=300.4 (M+H⁺).

Example 185

[4-Methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

- The title compound is synthesised from (7-iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and 2-methyl-4-trimethylstannanyl-pyridine using the general procedure B as a off-white solid in 20% yield. MS: m/e= 329 (M⁺).

Example 186

(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-carbamic acid methyl ester

- Carbamate formation using the same procedure as for (4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester yields the product as off-white solid in 58% yield. MS: m/e= 324 (M+H⁺).

Example 187

(4-Methoxy-7-phenyl-benzothiazol-2-yl)-carbamic acid benzyl ester

- To a stirred solution of 2-amino-4-methoxy-7-phenyl-benzothiazole (512 mg, 2 mmol) in pyridine at 90 °C was added benzyl chloroformate (3.3 ml, 23.4 mmol) in three portions over 6 hours. The reaction mixture was then evaporated to dryness and partitioned between CH₂Cl₂ (50 ml) and saturated aqueous NaCl solution (50 ml), the aqueous phase was separated and extracted further with CH₂Cl₂ (2x 50 ml) and the combined organic phases dried, filtered and evaporated. The crude residue was then chromatographed over SiO₂

(Merck 230-400 mesh) eluting with $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (4:1) to afford the title compound as a white foam (620 mg, 79 % yield), MS: $m/e=391.2$ ($M+H^+$).

Example 188

(4-Methoxy-7-vinyl-benzothiazol-2-yl)-carbamic acid methyl ester

5 a) (7-Iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester

(4-Methoxy-benzothiazol-2-yl)-carbamic acid methyl ester (31.0 g, 130 mmol) and sodium acetate (32.3 g, 394 mmol) are dissolved in 400 ml of glacial acetic acid and slowly treated with iodine monochloride (13.5 ml, 264 mmol) at 0 °C. The reaction mixture is then slowly warmed to room temperature and stirred for 15 hours. After addition of water (1.3 l), the formed precipitate is filtered off and washed with water. The filter cake is then dissolved in a minimal amount of tetrahydrofuran (about 150 ml) and decolorized with 1M aqueous sodium thiosulfate. The product is precipitated by the addition of water (about 2.0 l), filtered off and dried at 60 °C for 12 hours. 42.3 g (89 %) white solid. MS: $m/e=364$ (M^+).

15 b) (4-Methoxy-7-vinyl-benzothiazol-2-yl)-carbamic acid methyl ester

(7-Iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid ester (1 part), vinyltributylstannane (1.0 equivalents) and tetrakis-(triphenylphosphine)-palladium(0) (0.1 equivalents) are combined in dioxane (25 parts) containing 2M Na_2CO_3 (4.0 equivalents) and heated to reflux for 24 hours. The reaction mixture was evaporated, washed with brine and dried over MgSO_4 . After evaporation to dryness the product was isolated by flash chromatography (silica, eluent ethyl acetate/hexanes) as a white solid (60 %). F.p.: 138-139° C.

Example 189

4-Fluoro-N-(4-methoxy-7-vinyl-benzothiazol-2-yl)-benzamide

25 a) 4-Methoxy-7-vinyl-benzothiazol-2-ylamine

(4-Methoxy-7-vinyl-benzothiazol-2-yl)-carbamic acid methyl ester was dissolved in ethylenglycol/2N KOH (2:1) and stirred at 100 °C for 3 hrs. Then water was added and the mixture was extracted with CH_2Cl_2 , the organic phase was washed with brine and dried over MgSO_4 . After evaporation the residue was crystallized from CH_2Cl_2 . White crystals (64 %); F.p.: 155-159 °C.

b) 4-Fluoro-N-(4-methoxy-7-vinyl-benzothiazol-2-yl)-benzamide

Following the general method of example 1 the title compound was obtained from 4-methoxy-7-vinyl-benzothiazol-2-ylamine and 4-fluoro-benzoic acid chloride as a white solid (85 %); F.p.: 198-199° C.

5

Example 190

(4-Methoxy-7-propenyl-benzothiazol-2-yl)-carbamic acid methyl ester

Following the general method 188b) the title compound was obtained from (7-iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and tributyl-propenyl-stannane as a yellowish solid (75 %); F.p.: 153-156 °C.

10

Example 191

N-(7-Ethyl-4-methoxy-benzothiazol-2-yl)-4-fluoro-benzamide

100 mg of 4-fluoro-N-(4-methoxy-7-vinyl-benzothiazol-2-yl)-benzamide (0.3 mmol) were dissolved in methanol (100 ml) and Pd/C (4 mg) were added. The reaction mixture was hydrogenated for 2 hrs. After filtering and evaporation of the solvent the crude product
15 was subjected to column chromatography (silica gel, eluent MeOH/CH₂Cl₂ 1:9). The title compound was obtained in form of white crystals (79 %); F.p.: 165-167° C.

Example 192

(7-Acetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester

According to the method described for example 188b) the title compound was obtained
20 from (7-iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester (1 equivalent) and (1-ethoxy-vinyl)-tributylstannane (1 equivalent) as a white solid (34 %); F.p.: 238-240 °C.

Example 193

Rac-[7-(1-Hydroxy-ethyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

0.05 g of (7-acetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester (0.00018
25 Mol) were dissolved in ethanol (30 ml) and 0.028 g of NaBH₄ (0.00072 Mol) were added. After stirring at 40 °C for 24 hrs. the reaction mixture was diluted with water, extracted with CH₂Cl₂, the organic phase washed with brine and dried over MgSO₄. After chromatography on silicagel with CH₂Cl₂/MeOH 97:3 the title compound was obtained as a white solid (38 %); F.p.: 179 °C (dec.).

Example 194 (intermediate)

Rac-[7-(2-Bromo-1-hydroxy-ethyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

1.5 g of (4-methoxy-7-vinyl-benzothiazol-2-yl)-carbamic acid methyl ester (0.0057 Mol),
5 dissolved in THF (60 ml) were treated with H₂O (6 ml) and 1.0 g of NBS (0.006 Mol) at
room temperature for 15 min. Then the solvent was removed, the residue taken up in H₂O
(30 ml) and extracted four times with ethyl acetate (50 ml). The combined organic phases
were washed with brine and dried over MgSO₄. After evaporation the crude product was
subjected to column chromatography (silicagel, ethyl acetate). The title compound was
10 obtained as a white solid (78 %), F.p.: 150-155 °C.

Example 195 (intermediate)

[7-(2-Bromo-1-hydroxy-propyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described for the example above the title compound was
15 obtained from (4-methoxy-7-propenyl-benzothiazol-2-yl)-carbamic acid methyl ester as a
foam and carried on to the next step without further purification and characterization.

Example 196 (intermediate)

(7-Bromoacetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

1.6 g of rac-[7-(2-bromo-1-hydroxy-ethyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid
20 methyl ester (0.0044 Mol) were dissolved in CHCl₃ (100 ml) and treated with 3.8 g of
MnO₂ (0.044 Mol) for 3 hrs. at 70 °C. The hot reaction mixture was filtered and
subsequently concentrated. The crude product was crystallized from Et₂O to yield the title
compound as a beige solid (73 %); F.p.: 250-260 °C (dec.).

Example 197 (intermediate)

25 [7-(2-Bromo-propionyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

5.0 g of [7-(2-bromo-1-hydroxy-propyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid
methyl ester 0.0133 Mol) were suspended in water (30 ml) and 2.0 g of CrO₃ (0.02 Mol),
dissolved in acetic acid (30 ml), were added. The reaction mixture was heated to 70 °C for 2
hrs. and then evaporated to dryness. The residue was taken up in sat. NaHCO₃ (200 ml),

extracted 4x with ethyl acetate (200 ml each) and the combined organic phases were dried over MgSO₄. The title compound was obtained as orange crystals (74 %); F.p.: 199-201 °C.

Example 198

(4-Methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-carbamic acid methyl ester

- 5 Following the method described for (4-methoxy-7-vinyl-benzothiazol-2-yl)-carbamic acid methyl ester (Example 188b) the title compound was obtained from (7-iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and 2-tributylstannyl-thiophen as a yellowish solid (41 %); 160-165 °C.

Example 199

- 10 [4-Methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

Following the method described for (4-methoxy-7-vinyl-benzothiazol-2-yl)-carbamic acid methyl ester (Example 188b) the title compound was obtained from (7-iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and 2-tributylstannyl-5-methylthiophen as a yellowish solid (40 %); 267-274 °C (dec.).

- 15

Example 200

[4-Methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

- 1.3 g of (7-bromoacetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester (0.0036 Mol) and 0.27 g of thioacetamide (0.0036 Mol) were dissolved in dioxane (30 ml) and stirred for 4 hrs. at 70 °C. After evaporation of half of the solvent water (40 ml) was added and the pH adjust to 7 with sat. NaHCO₃. A solid precipitated, which was isolated and then subjected to column chromatography on silicagel using ethyl acetate as eluent. The title product was isolated as an off-white solid (27 %); F.p.: 186-188 °C.
- 20

Example 201

- 25 [4-Methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described above the title compound was obtained from (7-bromoacetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and 2-methylpyridine-5-thiocaboxamide as a yellowish solid (73 %); F.p.: 240-242 °C.

Example 202

[4-Methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described above the title compound was obtained from (7-bromoacetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and pyridine-2-thiocboxamide as a dark red solid (63 %); F.p.: 207 °C.

Example 203

[7-[2-(tert-Butoxycarbonylamino-methyl)-thiazol-4-yl]-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described above the title compound was obtained from (7-bromoacetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and thiocarbamoylmethyl-carbamic acid tert-butyl ester as a white solid (26 %); MS (ISP): m/e = 451 (M+H⁺).

Example 204

[7-(2-Aminomethyl-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester hydrochloride (1:1)

0.075 g of {7-[2-(tert-butoxycarbonylamino-methyl)-thiazol-4-yl]-4-methoxy-benzothiazol-2-yl}-carbamic acid methyl ester (0.00017 Mol) were stirred in 2 ml of 2.5 M HCl/MeOH for 4 hrs. Upon cooling to room temperature a precipitate formed, which was filtered off, washed with hexane and dried. The title compound was obtained as a white solid (70 %), F.p.: 220-230 °C.

Example 205

[7-(2-Dimethylaminomethyl-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described for [4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester the title compound was obtained from (7-bromoacetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester and dimethylamino-thioacetamide as an off-white solid (11 %); F.p.: 185-189 °C (dec.).

Example 206

[7-(2,5-Dimethyl-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described above the title compound was obtained from [7-(2-bromo-propionyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester and thioacetamide as an off-white solid (42 %); F.p.: 180-181 °C (dec.).

Example 207

- 5 {4-Methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described above the title compound was obtained from [7-(2-bromo-acetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester and trityl-thiourea as an off-white solid (53 %); F.p.: 135-140 °C.

10

Example 208

[7-(2-Amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

- 0.070 g of {4-methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-carbamic acid methyl ester (0.00012 Mol) were heated to reflux in 2 ml of 2.5 M HCl/MeOH for 4 hrs. After cooling to room temperature the pH was adjusted to 7 upon drop wise addition of
15 sat. NaHCO₃. A precipitate formed, which was filtered off, washed with ethyl acetate and dried. The title compound was obtained as a white solid (23 %), F.p.: 293-296 °C (dec.).

Example 209

[7-(2-Dimethylamino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

- 20 According to the method described above the title compound was obtained from [7-(2-bromo-acetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester, NN-dimethyl-thiourea and triethylamin as an off-white solid (86 %); F.p.: 185-195 °C.

Example 210

- 25 [4-Methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described for the example described above the title compound was obtained from [7-(2-bromo-acetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester and 1-pyrrolidine-carbothioamide as an off-white solid (16 %); F.p.: 199 °C.

Example 211

[4-Methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

- According to the method described above the title compound was obtained from [7-(2-bromo-acetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester and 1-piperidine-carbothioamide as an off-white solid (71 %); F.p.: 209-211 °C.

Example 212

[4-Methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

- According to the method described above the title compound was obtained from [7-(2-bromo-acetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester and 1-morpholine-carbothioamide as a yellowish solid (41 %); MS (ISP): m/e = 407 (M+H⁺).

Example 213

- [4-Methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl]-carbamic acid methyl ester

According to the method described above the title compound was obtained from [7-(2-bromo-acetyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester and 4-methyl-1-piperazinethiocarboxamide as a brownish solid (41 %); F.p.: 143 °C.

Example 214

- [7-(2-tert-Butoxycarbonylamino-1H-imidazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

- 0.25 g of (7-bromoacetyl-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester (0.0007 Mol) and 0.33 g of tert-butoxycarbonylguanidine (0.0021 Mol) were heated to reflux in acetonitril (3 ml) for 3 hrs. After evaporation of the solvent the residue was triturated with water (10 ml) and filtered. The filtrate was evaporated and the residue subjected to column chromatography (silicagel, ethyl-acetate/hexanes 1:1) to yield the title compound as a white solid (17 %); F.p.: 255-265 °C.

Example 215

[7-(2-Amino-1H-imidazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester

0.04 g of [7-(2-tert-butoxycarbonylamino-1H-imidazol-4-yl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl ester (0.0001 Mol) were heated to 60 °C in HCl/MeOH (2.5 M, 2 ml). After evaporation of the solvent the residue was dissolved in water (5 ml) and the pH was adjusted to 8 with sat. NaHCO₃. The water was evaporated and the residue triturated in ethyl acetate where a precipitation formed. This was isolated and dried to yield the title compound as a grey solid (16 %); F.p.: 225-235 °C.

- 10 The following examples were prepared according to the general method described for 4-methoxy-7-vinyl-benzothiazol-2-yl-amine (Example 189a) from the corresponding carbamic acid methyl ester:

4-Methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl-amine

Obtained as a white solid (73 %); F.p.: 289-292 °C.

- 15 4-Methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl-amine

Obtained as a light yellow solid (81 %); F.p.: 176 °C (dec.).

4-Methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl-amine

Obtained as an off-white solid (94 %); MS (ISP): m/e = 355 (M+H⁺).

7-(2-Amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl-amine

- 20 Obtained as a white solid (56 %); MS (ISP): m/e = 279 (M+H⁺).

7-(2-Dimethylamino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl-amine

Obtained as a beige solid (62 %); F.p.: 225-238 °C.

4-Methoxy-7-thiophen-2-yl-benzothiazol-2-yl-amine

Obtained as a light brown solid (85 %); F.p.: 215-219 °C.

- 25 4-Methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl-amine

Obtained as a light yellow solid (67 %); F.p.: 302 °C (dec.).

4-Methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl-amine

Obtained as a light brown solid (99 %); F.p.: 270 °C (dec.).

4-Methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl-amine

Obtained as a light brown solid (75 %); MS (ISP): $m/e = 347$ ($M+H^+$).

5 4-Methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl-amine

Obtained as an off-white solid (81 %); F.p.: 262-265 °C.

4-Methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl-amine

Obtained as an off-white solid (81 %); F.p.: 195-205 °C (dec.).

7-(2,5-Dimethyl-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl-amine

10 Obtained as a yellow solid (5 %); F.p.: 201-203 °C.

Following the general method of example 1 the following examples were obtained from corresponding benzothiazol-2-yl-amines and 4-fluoro-benzoic acid chloride:

Example 216

4-Fluoro-N-[4-methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

15 Obtained as an off-white solid (53 %); F.p.: 225-227 °C.

Example 217

N-[7-(2-Amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide

Obtained as a white solid (85 %); F.p.: 262-264 °C.

Example 218

20 4-Fluoro-N-[4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide

Obtained as an off-white solid (79 %); MS (ISP): $m/e = 477$ ($M+H^+$).

Example 219

N-[7-(2-Dimethylamino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide

Obtained as a light yellow solid (29 %); F.p.: 218-220 °C.

Example 220

5 4-Fluoro-N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-benzamide

Obtained as a light yellow solid (72 %); F.p.: 242-250°C.

Example 221

4-Fluoro-N-{4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-benzamide

10 Obtained as an off-white solid (66 %); F.p.: 138 °C (dec.).

Example 222

4-Fluoro-N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as an off-white solid (92 %); F.p.: 150 °C (dec.).

Example 223

15 4-Fluoro-N-[4-methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as an off-white solid (82 %); MS (ISP): m/e = 455 (M+H⁺).

Example 224

4-Fluoro-N-[4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as a white solid (36 %); F.p.: 217-219 °C.

20

Example 225

4-Fluoro-N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-benzamide

Obtained as an off-white solid (70 %); F.p.: 192-196 °C (dec.).

Example 226

N-[7-(2,5-Dimethyl-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide

Obtained as an off-white solid (42 %); F.p.: 205-206 °C (dec.).

Example 227

5 4-Chloromethyl-N-[4-methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

0.165 g of 4-methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-ylamine (0.00047 Mol) were dissolved in dioxane (5 ml) and combined with 0.1 ml of triethylamine (0.0007 Mol), 0.006 g DMAP (0.000047 Mol) and a solution of 0.116 g of 4-(chloromethyl)benzoylchlorid (0.00062 Mol) in dioxane (1 ml). The reaction mixture was stirred for 6 hrs. at 70° C. After cooling down to room temperature, water (10 ml) and sat. NaHCO₃ (10 ml) were added. A precipitation formed. It was filtered, washed with water and dried. This crude product was subjected to column chromatography (silicagel, CH₂Cl₂/MeOH 19:1). The title compound was obtained as a light yellow solid (65 %); F.p.: 15 166-168 °C.

The following examples were prepared from the corresponding 7- substituted 4-methoxy-benzothiazol-2-yl-amines according to the above described method:

Example 228

20 4-Chloromethyl-N-[4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide

Obtained as an off-white solid (68 %); F.p.: 230-250 °C.

Example 229

4-Chloromethyl-N-[4-methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide

25 Obtained as a white solid (42 %); F.p.: 163 °C (dec.).

Example 230

4-Chloromethyl-N-[7-(2-dimethylamino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-benzamide

Obtained as a light yellow solid (36 %); F.p.: 183-186 °C.

Example 231

4-Chloromethyl-N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-benzamide

Obtained as a light yellow solid (60 %); F.p.: 183-209 °C (dec.).

5

Example 232

4-Chloromethyl-N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as a light brown solid (79 %); F.p.: 195-201 °C.

Example 233

10 4-Chloromethyl-N-[4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as a white solid (72 %); F.p.: 140-145 °C.

Example 234

4-Chloromethyl-N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-benzamide

15 Obtained as a yellow solid (93 %); F.p.: 130-146 °C.

Example 235

4-[[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

0.035 g N-(2-methoxyethyl)-methylamine (0.00039 Mol) and 0.064 g (4-chloromethyl-N-[4-methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide (0.00013 Mol) dissolved in THF (2 ml) were heated to reflux for 4 hrs. After cooling to room temperature and evaporation of the solvent the residue was triturated with water (7 ml). A precipitation formed, which was filtered, washed with water and dried yielding the title product as an off-white solid (79 %); F.p.: 100-110 °C.

25 The following examples were prepared according to the method above from N-(2-methoxyethyl)methylamin and the corresponding 7- substituted 4-chloromethyl-N-[4-methoxy-benzothiazol-2-yl]-benzamides:

Example 236

4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide

- 5 Obtained as a white solid (79 %); F.p.: 119-128 °C.

Example 237

N-[7-(2-Amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-[[(2-methoxy-ethyl)-methyl-amino]-methyl]-benzamide

- 0.1 g of 4-[[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide (0.00014 Mol) were treated with cc
10 HCl (0.03 ml) in MeOH (1 ml) for 1 h at reflux. After evaporation of the solvent the residue was taken up in water (10 ml), treated with sat. NaHCO₃ (10 ml) and extracted 4x with ethyl acetate. The combined organic phases were dried over Na₂SO₄, filtered and concentrated. The residue was subjected to column chromatography (silicagel, ethyl
15 acetate, CH₂Cl₂/MeOH 19:1 and 9:1). The title compound was obtained as a white solid (53 %); F.p.: 199-206 °C.

Example 238

- 4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide

Obtained as a light yellow foam (69 %); MS (ISP): m/e = 560 (M+H⁺).

Example 239

- N-[7-(2-Dimethylamino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-[[(2-methoxy-ethyl)-methyl-amino]-methyl]-benzamide

Obtained as a light yellow solid (47 %); F.p.: 85-95 °C.

Example 240

- 4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-benzamide

Obtained as a light beige solid (44 %); F.p.: 58-78 °C.

Example 241

5 4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as a light yellow solid (54 %); MS (ISP): m/e = 546 (M+H⁺).

10

Example 242

4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide

Obtained as a white solid (36 %); F.p.: 140-145 °C.

15

Example 243

4-[[(2-Methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-benzamide

20 Obtained as a light beige solid (73 %); F.p.: 83-90 °C.

Example 244

N-[4-Methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

25

0.032 g pyrrolidine (0.00045 Mol) and 0.075 g (4-chloromethyl-N-[4-methoxy-7-(2-morpholin-4-yl-thiazol-4-yl)-benzothiazol-2-yl]-benzamide (0.00015 Mol) dissolved in THF (2 ml) were heated to reflux for 1 h. After cooling to room temperature and evaporation of the solvent the residue was triturated with water (7 ml). A precipitation
30 formed, which was filtered, washed with water and dried yielding the title product as an off-white solid (87 %); F.p.: 120-130 °C.

The following examples were prepared according to the method above from pyrrolidine and the corresponding 7- substituted 4-chloromethyl-N-[4-methoxy-benzothiazol-2-yl]-benzamides:

Example 245

N-[4-Methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

Obtained as a light brown solid (58 %); F.p.: 230-231 °C.

5

Example 246

N-[4-Methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

10 Obtained as a light yellow solid (89 %); F.p.: 122-135 °C.

Example 247

N-[7-(2-Amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide hydrochloride (1:1)

15 0.055 g of N-[4-methoxy-7-[2-(trityl-amino)-thiazol-4-yl]-benzothiazol-2-yl]-4-pyrrolidin-1-ylmethyl-benzamide (0.000078 Mol) were dissolved in MeOH (0.5 ml) and ccHCl (0.015 ml). After refluxing for 1 h the solvent was evaporated, the residue treated with ethyl acetate, filtered and isolated. This material was triturated in EtOH whereby crystals formed, which were washed with Et₂O. After drying the title compound was
20 obtained as a white solid (62 %); F.p.: 228-240 °C.

Example 248

N-[7-(2-Dimethylamino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

25

Obtained as a light yellow solid (75 %); F.p.: 120-136 °C.

Example 249

N-(4-Methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-4-pyrrolidin-1-yl-methyl-benzamide

Obtained as a light beige solid (47 %); F.p.: 174-190 °C (dec.).

30

Example 250

N-[4-Methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

- 5 Obtained as a light yellow foam (48 %); MS (ISP): m/e = 528 (M+H⁺).

Example 251

N-[4-Methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

Obtained as a light beige solid (67 %); F.p.: 140-149 °C (dec.).

10

Example 252

N-[4-Methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide

- 15 Obtained as a light yellow solid (44 %); F.p.: 123-134 °C.

Example 253

N-(4-Methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide

- 0.21 g of 4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl-amine (0.0008 Mol) together with
20 0.27 ml triethylamine (0.002 Mol), 0.01 g of DMAP and 0.20 g isonicotinic acid chloride
(0.001 Mol) were heated to reflux for 20 hrs. in dioxane (10 ml). After cooling to room
temperature water (20 ml) and sat. NaHCO₃ (15 ml) were added. A precipitation formed,
which was filtered, washed with water and dried. This crude product was subjected to
column chromatography (silicagel, ethyl acetate) to yield the title compound as a yellow
25 solid (58 %); F.p.: 203-211 °C (dec.).

The following examples were prepared according to the method above from isonicotinic acid chloride and the corresponding 7- substituted 4-methoxy-benzothiazol-2-yl-amines:

Example 254

N-[4-Methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide

30

Obtained as a light yellow solid (38 %); MS (ISP): m/e = 460 (M+H⁺).

Example 255

N-[4-Methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide

Obtained as a yellow solid (9 %); F.p.: 195-215 °C.

5

Example 256

N-[4-Methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl]-2-methyl-isonicotinamide

Obtained as a yellow foam (4 %); MS (ISP): m/e = 481 (M+H⁺).

Example 257

10 N-[4-Methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide

Obtained as a light orange foam (65 %); MS (ISP): m/e = 396 (M+H⁺).

Example 258

Morpholine-4-carboxylic acid {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-amide

- 15 0.1 g of 4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-ylamine (0.00028 Mol) were dissolved in dioxane (2 ml) and treated with 0.047 ml triethylamine (0.00034 Mol) and 0.164 ml of phosgene (20 % in toluene) (0.00031 Mol). After stirring for 2 hrs. at room temperature 0.122 ml of morpholine (0.0014 Mol) were added and the whole mixture was stirred for 16 hrs. at ambient temperature. Upon addition of water (5
- 20 ml) a precipitation formed, which was filtered, washed with water and dried. This crude material was triturated with hot MeOH and after cooling to room temperature filtered. The filtrate was evaporated and the residue subjected to column chromatography (silicagel, CH₂Cl₂/MeOH + 1 % NH₄OH). The title compound was obtained as a light yellow solid (7 %); MS (ISP): m/e = 468 (M+H⁺).

25

Example 259

Morpholine-4-carboxylic acid [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-amide

- 0.1 g of 4-methoxy-7-[2-pyridin-2-yl]-thiazol-4-yl]-benzothiazol-2-yl-amine (0.00029 Mol) were dissolved in THF (5 ml) and treated with 0.063 ml ethyldiisopropylamine
- 30 (0.00037 Mol), DMAP (1 mg) and 0.029 mg of triphosgene (0.0001 Mol). After heating to

- reflux for 30 min., 0.0322 ml of morpholine (0.00037 Mol) and another 0.062 ml of ethyldiisopropylamine were added and the whole mixture was stirred for 16 hrs. at reflux. After cooling to room temperature water (10 ml) was added and the reaction mixture was extracted with ethyl acetate (4x, 15 ml each). The combined organic phases were dried over
- 5 Na_2SO_4 , filtered and evaporated. The residue was subjected to column chromatography (silicagel, ethyl acetate). The title compound was obtained as a light yellow solid (7 %); F.p.: 152-178° C (dec.).

Example 260

- Morpholine-4-carboxylic acid [4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-
10 amide
- 0.07 g of 7-(2-Amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl-amine (0.00025 Mol) were suspended in dioxane (4 ml) and treated with 0.028 g of NaH (60 % dispersion in oil) (0.0006 Mol) for 1 h at room temperature. Then 0.11 ml of triethylamine (0.00076 Mol) and 0.07 ml of morpholine-4-carbonylchloride (0.0006 Mol) were added and the reaction
- 15 mixture was stirred at room temperature for 3 hrs. Then water (15 ml) was added and the reaction mixture was extracted with ethyl acetate (4x, 20 ml each). The combined organic phases were dried over Na_2SO_4 , filtered and evaporated. The residue was subjected to column chromatography (silicagel, ethyl acetate). The title compound was obtained as a light yellow solid (61 %); F.p.: 223-226 °C (dec.).
- 20 The following examples were prepared according to the method above from morpholin-4-carbonylchloride and the corresponding 7- substituted 4-methoxy-benzothiazol-2-ylamines:

Example 261

- Morpholine-4-carboxylic acid [4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-
25 benzothiazol-2-yl]-amide
- Obtained as a beige solid (40 %); F.p.: 150-170 °C.

Example 262

- Morpholine-4-carboxylic acid [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-
2-yl]-amide
- 30 Obtained as a light yellow solid (25 %); F.p.: 227-234 °C.

Example 263

Morpholine-4-carboxylic acid [4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl]-amide

Obtained as a light beige solid (37 %); F.p.: 175-182 °C (dec.).

Example 264

5 Morpholine-4-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-amide

Obtained as a light beige solid (59 %); F.p.: 173-180 °C (dec.).

Example 265

10 4-Hydroxy-piperidine-1-carboxylic acid [4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-amide

To a suspension of 0.070 g of 4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-ylamine (0.00025 Mol) in THF (4 ml) at room temperature were added 0.054 ml N-ethyl-diisopropylamine (0.00031 Mol) and 0.001 g DMAP. 0.025 g of triphosgen (0.000085 Mol) were added and the whole mixture was heated to 70 °C for 1 hr. Then another 0.054 ml N-ethyl-diisopropylamine (0.00031 Mol) and 0.031 g of 4-hydroxy-piperidin (0.00031 Mol) were added and the reaction mixture was stirred at 70 °C for 1.5 hrs. Upon cooling to room temperature a precipitation formed, which was filtered and washed with THF. The filtrate was evaporated and the residue was subjected to column chromatography (silicagel, CH₂Cl₂/MeOH 9:1). The title product was obtained as a white solid (11 %); F.p.: 145-150 °C.

The following example was prepared according to the above described methode from 4-methoxy-7-(5-methyl-thiophene-2-yl)-benzothiazol-2-yl-amine:

Example 266

25 4-Hydroxy-piperidine-1-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-amide

Obtained as a yellow solid (10 %); F.p.: 197-204 °C (dec.).

The following example was prepared according to the methode described above from N-methyl-piperazine and 4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-ylamine:

Example 267

4-Methyl-piperazine-1-carboxylic acid [4-methoxy-7-(2-methyl-thiazol-4-yl)-benzothiazol-2-yl]-amide

Obtained as a white solid (8 %); F.p.: 179-181 °C.

5

Example 268

{2-[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)carbamoyl]-phenyl}-ethyl}-methyl-carbamic acid tert-butyl ester

- 10 Using [2-(4-chlorocarbonyl-phenyl)-ethyl]-methyl-carbamic acid *tert*-butyl ester the title compound was prepared using the general method of example 1 as white solid (16 %), MS: m/e= 527 (M+H⁺).

Example 269

15

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(1,1,2,2-tetrafluoro-ethoxy)-benzamide

Using 4-(1,1,2,2-tetrafluoro-ethoxy)-benzoyl chloride the title compound was prepared using the general method of example 1 as light yellow solid (35%), MS: m/e= 486 (M+H⁺).

20

Example 270

4-[(2-Methoxy-ethyl)-methyl-sulfamoyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- 25 Using (2-methoxy-ethyl)-methyl-sulfamic acid chloride the title compound was prepared using the general method of example 1 as red solid (44%), MS: m/e= 521 (M+H⁺).

Example 271

- 30 N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-trifluoromethyl-benzamide

Using 4-(trifluoromethyl)-benzoyl chloride the title compound was prepared using the general method of example 1 as white solid (58 %), MS: m/e= 438 (M+H⁺).

Example 272

35

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-trifluoromethoxy-benzamide

Using 3-(trifluoro-methoxy)-benzoyl chloride the title compound was prepared using the general method of example 1 as light yellow solid (84%), MS: $m/e = 454$ ($M+H^+$).

Example 273

5

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-trifluoromethoxy-benzamide

Using 4-(trifluoro-methoxy)-benzoyl chloride the title compound was prepared using the general method of example 1 as yellow solid (77 %), MS: $m/e = 453$ (M^+).

10

Example 274

4-Ethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-ethyl-benzoyl chloride the title compound was prepared using the general method of example 1 as white solid (21 %), MS: $m/e = 397$ ($M+H^+$).

15

Example 275

4-Fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-fluoro-benzoyl chloride the title compound was prepared using the general method of example 1 as white solid (64 %), MS: $m/e = 388$ ($M+H^+$).

20

Example 276

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide

Using 2-methyl-isonicotinyl chloride the title compound was prepared using the general method of example 1 as white solid (72 %), MS: $m/e = 385$ ($M+H^+$).

25

Example 277

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using benzoyl chloride the title compound was prepared using the general method of example 1 as white solid (85 %), MS: $m/e = 370$ ($M+H^+$).

30

The following compounds are described according to the general procedure C in Example 126:

35

Example 278

4-Chloro-3-{{[ethyl-(2-methoxy-ethyl)-amino]-methyl}}-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-chloro-3-chloromethyl-benzoyl chloride and ethyl-(2-methoxy-ethyl)-amine the title compound was prepared using the general procedure C as off-white solid (69 %), MS: $m/e = 519$ ($M+H^+$).

5

Example 279

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-benzamide

Using 3-chloromethyl-benzoyl chloride and methylamine the title compound was prepared using the general procedure C as white solid (44 %), MS: $m/e = 413$ ($M+H^+$).

10

Example 280

4-Chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-benzamide

15 Using 4-chloro-3-chloromethyl-benzoyl chloride and methylamine the title compound was prepared using the general procedure C as light yellow solid (69 %), MS: $m/e = 447$ ($M+H^+$).

Example 281

20 4-Chloro-3-[(2-methoxy-ethyl)-methyl-amino]-methyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-chloro-3-chloromethyl-benzoyl chloride and (2-methoxy-ethyl)-methyl-amine the title compound was prepared using the general procedure C as off-white solid (54 %), MS: $m/e = 505$ ($M+H^+$).

25

Example 282

4-Chloro-3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

30 Using 4-chloro-3-chloromethyl-benzoyl chloride and 2-methoxy-ethylamine the title compound was prepared using the general procedure C as off-white solid (69 %), MS: $m/e = 491$ ($M+H^+$).

Example 283

35 4-Chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-ylmethyl-benzamide

Using 4-chloro-3-chloromethyl-benzoyl chloride and pyrrolidine the title compound was prepared using the general procedure C as light yellow solid (72 %), MS: $m/e = 487$ ($M+H^+$).

Example 284

5

1-[4-(4-Benzoyloxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-benzyl]-pyridinium; chloride

Using 4-benzoyloxy-7-morpholin-4-yl-benzothiazol-2-ylamine, 4-chloromethyl-benzoyl chloride and pyridine the title compound was prepared using the general procedure C as
10 white solid (80 %), MS: $m/e = 538$ (M^+).

Example 285

3-Fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-pyrrolidin-1-ylmethyl-benzamide

15

Using 4-chloromethyl-3-fluoro-benzoyl chloride and pyrrolidine the title compound was prepared using the general procedure C as yellow solid (25 %), MS: $m/e = 471$ ($M+H^+$).

Example 286

20

3-[(2-Methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 3-chloromethyl-benzoyl chloride and 2-methoxy-ethylamine the title compound was prepared using the general procedure C as light yellow solid (68 %), MS: $m/e = 457$
25 ($M+H^+$).

Example 287

3-[(2-Methoxy-ethyl)-methyl-amino]-methyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 3-chloromethyl-benzoyl chloride and (2-methoxy-ethyl)-methyl-amine the title compound was prepared using the general procedure C as yellow solid (75 %), MS: $m/e = 471$ ($M+H^+$).

35

Example 288

1-[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-benzyl]-pyridinium; chloride

Using 4-chloromethyl-benzoyl chloride and pyridine the title compound was prepared using the general procedure C as white solid (33 %), MS: $m/e = 462$ (M^+).

Example 289

5

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-ylmethyl-benzamide

Using 3-chloromethyl-benzoyl chloride and pyrrolidine the title compound was prepared using the general procedure C as light yellow solid (65%), MS: $m/e = 454$ ($M+H^+$).

10

Example 290

4-[(2-Ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-chloromethyl-benzoyl chloride and 2-ethoxy-ethylamine the title compound was prepared using the general procedure C as white solid (18 %), MS: $m/e = 471$ ($M+H^+$).

Example 291

[R]-N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(3-methoxy-pyrrolidin-1-yl-methyl)-benzamide

20

Using 4-chloromethyl-benzoyl chloride and [R]-3-methoxy-pyrrolidine the title compound was prepared using the general procedure C as light yellow solid (18 %), MS: $m/e = 483$ ($M+H^+$).

Example 292

25

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide

Using 4-chloromethyl-benzoyl chloride and methylamine the title compound was prepared using the general procedure C as light yellow solid (63 %), MS: $m/e = 413$ ($M+H^+$).

30

Example 293

[S]-N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(3-methoxy-pyrrolidin-1-ylmethyl)-benzamide

Using 4-chloromethyl-benzoyl chloride and [S]-3-methoxy-pyrrolidine the title compound was prepared using the general procedure C as light brown solid (13 %), MS: $m/e = 483$ ($M+H^+$).

35

Example 294

4-Azetidin-1-ylmethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-chloromethyl-benzoyl chloride and azetidine the title compound was prepared
5 using the general procedure C as light yellow solid (33 %), MS: $m/e = 439$ ($M+H^+$).

Example 295

4-[1-(2-Methoxy-ethylamino)-ethyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

10 Using 4-(1-chloro-ethyl)-benzoyl chloride and 2-methoxy-ethylamine the title compound was prepared using the general procedure C as yellow solid (52 %), MS: $m/e = 471$ ($M+H^+$).

Example 296

4-[1-[(2-Methoxy-ethyl)-methyl-amino]-ethyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

15 Using 4-(1-chloro-ethyl)-benzoyl chloride and (2-methoxy-ethyl)-methyl-amine the title
20 compound was prepared using the general procedure C as yellow solid (91 %), MS: $m/e = 485$ ($M+H^+$).

Example 297

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(1-pyrrolidin-1-yl-ethyl)-benzamide

25 Using 4-(1-chloro-ethyl)-benzoyl chloride and pyrrolidine the title compound was prepared using the general procedure C as yellow solid (68 %), MS: $m/e = 467$ ($M+H^+$).

Example 298

4-(2-Dimethylamino-ethylsulfanylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

30 Using 4-chloromethyl-benzoyl chloride and 2-dimethylamino-ethanethiol the title compound was prepared using the general procedure C as yellow solid (52 %), MS: $m/e =$
35 487 ($M+H^+$).

Example 299

(rac) N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-[[methyl-(4,4,4-trifluoro-3-hydroxy-butyl)-amino]-methyl]-benzamide

- 5 Using 4-chloromethyl-benzoyl chloride and (rac)-1,1,1-trifluoro-4-methylamino-butan-2-ol the title compound was prepared using the general procedure C as white solid (89 %), MS: m/e= 539 (M+H⁺).

Example 300

- 10 4-[[Ethyl-(2-methoxy-ethyl)-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-chloromethyl-benzoyl chloride and (2-methoxy-ethyl)-ethyl-amine the title compound was prepared using the general procedure C as light brown solid (62 %), MS: m/e= 485 (M+H⁺).

- 15 Example 301

4-[[2-Ethoxy-ethyl)-ethyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- Using 4-chloromethyl-benzoyl chloride and (2-ethoxy-ethyl)-ethyl-amine the title
20 compound was prepared using the general procedure C as light brown solid (66 %), MS: m/e= 499 (M+H⁺).

Example 302

- 3-Fluoro-4-[[2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 3-fluoro-4-chloromethyl-benzoyl chloride and (2-methoxy-ethyl)-methyl-amine the title compound was prepared using the general procedure C as light brown solid (52 %), MS: m/e= 489 (M+H⁺).

Example 303

- 30 4-[[Bis-(2-ethoxy-ethyl)-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- Using 4-chloromethyl-benzoyl chloride and bis-(2-ethoxy-ethyl)-amine the title compound was prepared using the general procedure C as light brown solid (49 %), MS:
35 m/e= 543 (M+H⁺).

Example 304

4-[(2-Ethoxy-ethyl)-methyl-amino]-methyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- 5 Using 4-chloromethyl-benzoyl chloride and (2-ethoxy-ethyl)-methyl-amine the title compound was prepared using the general procedure C as white solid (78 %), MS: m/e= 485 (M+H⁺).

Example 305

- 10 N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(4-methoxy-piperidin-1-yl-methyl)-benzamide

Using 4-chloromethyl-benzoyl chloride and 4-methoxy-piperidine the title compound was prepared using the general procedure C as white solid (33 %), MS: m/e= 497 (M+H⁺).

15

Example 306

4-Diethylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Using 4-chloromethyl-benzoyl chloride and diethylamine the title compound was prepared using the general procedure C as light yellow solid (64 %), MS: m/e= 456 (M+H⁺).

20

Example 307

4-[(2-Methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

- 25 Using 4-chloromethyl-benzoyl chloride and 2-methoxy-ethylamine the title compound was prepared using the general procedure C as white solid (64 %), MS: m/e= 457 (M+H⁺).

Example 308

- 30 N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(2-methyl-imidazol-1-yl-methyl)-benzamide

Using 4-chloromethyl-benzoyl chloride and 2-methyl-1H-imidazole the title compound was prepared using the general procedure C as white solid (87 %), MS: m/e= 464 (M+H⁺).

35

Example 309

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(4-methyl-piperazin-1-yl-methyl)-benzamide

Using 4-chloromethyl-benzoyl chloride and 1-methyl-piperazine the title compound was prepared using the general procedure C as white solid (78 %), MS: m/e= 482 (M+H⁺).

Example 310

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-pyrrolidin-1-yl-methyl-benzamide

Using 4-chloromethyl-benzoyl chloride and pyrrolidine the title compound was prepared using the general procedure C as white solid (81%), MS: m/e= 454 (M+H⁺).

Example 311

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-morpholin-4-yl-methyl-benzamide

Using 4-chloromethyl-benzoyl chloride and morpholine the title compound was prepared using the general procedure C as white solid (83%), MS: m/e= 469 (M+H⁺).

Example 312

N-(4-Benzoyloxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-[(2-methoxy-ethyl)-methyl-amino]-methyl-benzamide

Using N-(4-benzoyloxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-chloromethyl-benzamide and (2-methoxy-ethyl)-methyl-amine the title compound was prepared using the general procedure C as white solid (69 %), MS: m/e= 547 (M+H⁺).

Example 313

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-[(methyl-(3,3,3-trifluoro-propyl)-amino)-methyl]-benzamide; hydrochloride

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide (100 mg, 0.24 mmol), triethylamine (35 mg, 0.34 mmol), potassium iodide (0.4 mg, 0.02 mmol) and 3,3,3-trifluoro-propylamine (48 mg, 0.27 mmol) were dissolved in ethanol (1 ml) and dioxane (0.5 ml). The reaction vessel is sealed and heated to 90°C for 18 h. Workup and purification as described in the general procedure C afforded the title compound as light brown solid (28 %), MS: m/e= 509 (M+H⁺).

Example 314

4-(2-Methoxy-ethoxymethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

4-Chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (200 mg, 0.48 mmol) and sodium hydride (42 mg 55 % dispersion in mineral oil, 0.96 mmol) were dissolved in 2-methoxy-ethanol (3.8 ml, 48 mmol) and stirred at ambient temperature for 18 h. Workup and purification as described in the general procedure C afforded the title compound as white solid (70 %), MS: m/e= 458 (M+H⁺).

Example 315

4-Methoxymethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

4-Chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (200 mg, 0.48 mmol) were suspended in THF (5 ml) and sodium methoxide (0.27 ml 5.4 M in MeOH, 1.4 mmol) were added at 0 °C. The mixture was stirred at ambient temperature for 18 h. Workup and purification as described in the general procedure C afforded the title compound as light yellow solid (41 %), MS: m/e= 414 (M+H⁺).

Example 316

N-[4-Methoxy-7-(1-oxo-1λ⁴-thiomorpholin-4-yl)-benzothiazol-2-yl]-benzamide

To a solution of N-(4-methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl)-benzamide (80 mg, 0.21 mmol) in [1,4]dioxane (3 ml) was added sodium periodate (89 mg, 0.42 mmol) and the mixture stirred for 20 h at ambient temperature. To this mixture water (10 ml) and dichloromethane (10 ml) were added, the phases were separated and the aqueous layer extracted twice with dichloromethane. The combined organic extracts were dried with Na₂SO₄ and the solvent evaporated. Recrystallization from hot THF afforded the title compound as white solid (21 %), MS: m/e= 402 (M+H⁺).

Example 317

N-(4-Methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl)-benzamide

Following the general method of example 403 the title compound was synthesized from 3-(2-methoxy-5-thiomorpholin-4-yl-phenyl)-thiourea (synthesized from 4-bromo-1-methoxy-2-nitro-benzene and thiomorpholine as described for 1-benzoyl-3-(2-methoxy-5-morpholin-4-yl-phenyl)-thiourea) as a white solid (15 %), MS: m/e= 386 (M+H⁺).

Example 318

5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-piperazin-1-yl-benzothiazol-2-yl)-amide

- To a solution of 4-{4-methoxy-2-[(5-methyl-thiophene-2-carbonyl)-amino]-benzothiazol-7-yl}-piperazine-1-carboxylic acid benzyl ester (300 mg, 0.57 mmol) in dichloromethane (5 ml) were added boron trifluoride diethyl etherate (0.72 ml, 5.7 mmol) and ethane thiol (1.2 ml, 17 mmol) and the mixture stirred for 36 h. The volatile components are
- 5 evaporated and the residue codistilled twice with toluene. The residue was dissolved in dichloromethane (25 ml), extracted with 1N aqueous sodium carbonate and the organic phase dried with Na₂SO₄. Removal of the solvent and flash chromatography (silica, eluent CH₂Cl₂/MeOH/aqu. NH₄OH 100:10:1) afforded the title compound as light yellow solid (58 %), MS: m/e= 389 (M+H⁺).

10

Example 319

5-Methyl-thiophene-2-carboxylic acid [7-(4-acetyl-piperazin-1-yl)-4-methoxy-benzothiazol-2-yl]-amide

- 15 5-Methyl-thiophene-2-carboxylic acid (4-methoxy-7-piperazin-1-yl-benzothiazol-2-yl)-amide (100 mg, 0.26 mmol) were suspended in DMF (2 ml) and treated with acetyl chloride (22 µl, 0.30 mmol) and pyridine (27 µl, 0.34 mmol) and the mixture stirred for 5 h at ambient temperature. Workup and purification as described in the general procedure C afforded the product as a white solid (55 %), MS: m/e= 431(M+H⁺).

20

Example 320

4-{4-Methoxy-2-[(5-methyl-thiophene-2-carbonyl)-amino]-benzothiazol-7-yl}-piperazine-1-carboxylic acid methyl ester

- 25 Using methyl chloroformate the title compound was synthesized as described for example 319 and obtained as white solid (26 %), MS: m/e= 447(M+H⁺).

Example 321

30 5-Methyl-thiophene-2-carboxylic acid [4-methoxy-7-(4-methyl-piperazin-1-yl)-benzothiazol-2-yl]-amide

- To a solution of 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-piperazin-1-yl-benzothiazol-2-yl)-amide (100 mg, 0.26 mmol) in methanol (8 ml) were added formic acid (100 µl, 2.6 mmol) and formaldehyde (23 µl, 0.31 mmol) and the mixture refluxed for 18
- 35 h. Workup and purification as described for 5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-piperazin-1-yl-benzothiazol-2-yl)-amide afforded the product as light yellow powder (34 %), MS: m/e= 403(M+H⁺).

Example 322

5-Methyl-thiophene-2-carboxylic acid [7-(2,3-dihydro-1H-indol-6-yl)-4-methoxy-benzothiazol-2-yl]-amide

- 5 The title compound was prepared from 5-methyl-thiophene-2-carboxylic acid (7-iodo-4-methoxy-benzothiazol-2-yl)-amide (100 mg, 0.23 mmol) and 6-iodo-2,3-dihydro-1H-indole using the general procedure B in Example 54 as light brown crystals (26 %), MS: m/e= 422(M+H⁺).

Intermediate

10

4-(4-Benzyloxy-3-nitro-phenyl)-morpholine

The title compound was prepared using morpholine and 1-benzyloxy-4-bromo-2-nitro-benzene (prepared from 4-bromo-2-nitro-anisol and benzyl bromide) using the general method of example "4-(4-methoxy-3-nitro-phenyl)-morpholine" as yellow solid (58 %),

- 15 MS: m/e= 315(M+H⁺).

Intermediate

2-Amino-4-morpholin-4-yl-phenol

- Catalytic hydrogenation of 4-(4-benzyloxy-3-nitro-phenyl)-morpholine (5 g, 16 mmol) in
20 dichloromethane (500 ml) and ethanol (500 ml) using palladium on carbon (500 mg, 10%)
afforded the title compound as a grey solid (96 %), MS: m/e= 194(M⁺).

Example 323

- 25 N-(4-Hydroxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

The title compound was prepared using 2-amino-4-morpholin-4-yl-phenol as described for N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide and obtained as a light brown solid in 14 % overall yield, MS: m/e= 356(M+H⁺).

30

Example 324

5-Methyl-thiophene-2-carboxylic acid [7-(3-dimethylamino-pyrrolidin-1-yl)-4-methoxy-benzothiazol-2-yl]-amide

- Using 5-methyl-thiophene-2-carbonyl chloride and 7-(3-dimethylamino-pyrrolidin-1-yl)-
35 4-methoxy-benzothiazol-2-yl-amine the title compound was prepared using the general method of example 1 as yellow solid (90 %), MS: m/e= 417 (M+H⁺).

Intermediate

7-(3-Dimethylamino-pyrrolidin-1-yl)-4-methoxy-benzothiazol-2-yl-amine

- Following the general method of example 403 the title compound was synthesized from [5-(3-dimethylamino-pyrrolidin-1-yl)-2-methoxy-phenyl]-thiourea (synthesized from 4-bromo-1-methoxy-2-nitro-benzene and dimethyl-pyrrolidin-3-yl-amine as described for (2-methoxy-5-morpholin-4-yl-phenyl)-thiourea) as a white solid (25 %), MS: m/e= 293 (M+H⁺).

Example 325

- 10 Tetrahydro-pyran-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- To a solution of 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol (100 mg, 0.4 mmol) in tetrahydrofuran (2 ml) were subsequently added N-ethyl-diisopropylamine (194 μ l, 1.1 mmol) and tetrahydropyran-4-carbonyl chloride (77 mg, 0.52 mmol, dissolved in 0.5 ml tetrahydrofuran) and the mixture refluxed for 3 h. The mixture was then cooled to 0°C, methanol (0.4 ml) was added and the mixture slowly warmed to 20 °C. Then the mixture was evaporated to dryness, dichloromethane was added (3 ml) and extracted with saturated aqueous sodium carbonate. After back extraction of the aqueous phase with two portions of dichloromethane (3 ml), the combined organic phases were dried with Na₂SO₄ and the solvent evaporated. The crude product was then chromatographed over SiO₂, eluting with CH₂Cl₂/MeOH 98:2, the product fractions were pooled and the solvent evaporated, to afford the title compound as a beige powder (142 mg, 76 % yield), MS: m/e= 378(M+H⁺).

Following the general method of example 325 the following examples were prepared

25. Example 326

4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester

- Using 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol and 4-chlorocarbonyl-piperidine-1-carboxylic acid *tert*-butyl ester the title compound was obtained as a white solid (3 %), MS: m/e= 477(M+H⁺).

Example 327

- 35 1-Acetyl-piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol and 1-acetyl-piperidine-4-carbonyl chloride the title compound was obtained as a white solid (22 %), MS: $m/e = 419(M+H^+)$.

5

Example 328

Piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidine-1-carboxylic
acid tert-butyl ester (95 mg, 0.2 mmol) were dissolved in trifluoroacetic acid (0.8 ml). After
10 1 h at room temperature, the mixture was evaporated to dryness. Purification as described
for tetrahydro-pyran-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
amide afforded the title compound as a white solid (77 %), MS: $m/e = 377(M+H^+)$.

General procedure E (ureas): The appropriate substituted 2-amino-benzothiazol (1 part,
15 typically 500 mg) is dissolved in CH_2Cl_2 (100 parts) and treated with pyridine (3 parts) and
phenyl chloroformate (1.25 parts). After stirring for 30 min at room temperature the
mixture is refluxed for 2 h when the appropriate amine (5 equivalents) is added. After
refluxing for 18 h, the mixture is evaporated to dryness, dissolved in CH_2Cl_2 and extracted
with aqueous sodium carbonate. after back extraction of the aqueous phase with CH_2Cl_2
20 the combined organic layers were dried with Na_2SO_4 , and evaporated to dryness. The
product is isolated by flash chromatography (silica, eluent dichloromethane containing 2.5
% methanol).

Following the general method E the compounds of examples 329 to 367 and Example 370
25 *were prepared*

Example 329

4-[(4-Fluoro-phenylamino)-methyl]-piperidine-1-carboxylic acid (4-methoxy-7-
morpholin-4-yl-benzothiazol-2-yl)-amide
30 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine and 4-[(4-fluoro-
phenylamino)-methyl]-piperidine the title compound was obtained as off-white solid (25
%). MS: $m/e = 522(M+H^+)$.

35

Example 330

4-Hydroxymethyl-4-phenyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-
benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine and 4-hydroxymethyl-4-phenyl-piperidine the title compound was obtained as light yellow solid (50 %). MS: $m/e = 483$ ($M+H^+$).

5

Example 331

[1-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperidin-4-ylmethyl]-carbamic acid methyl ester

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and piperidin-4-ylmethyl-carbamic acid methyl ester the title compound was obtained as white solid (81 %). MS: $m/e = 464$ ($M+H^+$).

10

Example 332

15 4-Ethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine and 4-ethyl-piperidine the title compound was obtained as white solid (26 %). MS: $m/e = 406$ ($M+H^+$).

Example 333

20

4-(2-Oxo-pyrrolidin-1-ylmethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-(2-oxo-pyrrolidin-1-ylmethyl)-piperidine the title compound was obtained as white solid (29 %). MS: $m/e = 474$ ($M+H^+$):

25

Example 334

4-(2-Methoxy-ethyl)-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

30 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-(2-methoxy-ethyl)-piperazine the title compound was obtained as off-white solid (79 %). MS: $m/e = 437$ ($M+H^+$).

Example 335

35

4-Cyanomethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-cyanomethyl-piperidine the title compound was obtained as white solid (46 %). MS: $m/e = 416$ ($M+H^+$).

Example 336

5

[1-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and piperidin-4-ylmethyl-carbamic acid tert-butyl ester the title compound was obtained as white solid (11 %). MS: $m/e = 506$ ($M+H^+$).

Example 337

4-[2-(4-Chloro-phenyl)-tetrahydro-furan-2-yl]-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

15 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-[2-(4-chloro-phenyl)-tetrahydro-furan-2-yl]-piperidine the title compound was obtained as white solid (43 %). MS: $m/e = 557$ ($M+H^+$).

Example 338

20 4-(2-Hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-(2-hydroxy-ethyl)-piperidine the title compound was obtained as white solid (64 %). MS: $m/e = 421$ ($M+H^+$).

25

Example 339

1-(2-Methoxy-ethyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and (2-methoxy-ethyl)-methyl-amine the title compound was obtained as white solid (65 %). MS: $m/e = 381$ ($M+H^+$).

30

Example 340

4-Methoxyacetyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

35 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-methoxyacetyl-piperazine the title compound was obtained as beige solid (84 %). MS: $m/e = 450$ ($M+H^+$).

Example 341

4-Methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- 5 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-methyl-piperidine the title compound was obtained as white solid (47 %). MS: $m/e = 391$ ($M+H^+$).

Example 342

- 10 4-Oxo-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and piperidin-4-one the title compound was obtained as white solid (38 %). MS: $m/e = 391$ ($M+H^+$).

- 15 Example 343

4-Cyclopropyl-4-hydroxy-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-cyclopropyl-4-hydroxy-piperidine the title compound was obtained as white solid (27 %). MS: $m/e = 434$ ($M+H^+$).
- 20

Example 344

- 1,1-Dioxo-1 λ^6 -thiomorpholine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
- 25

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and thiomorpholine 1,1-dioxide the title compound was obtained as white solid (50 %). MS: $m/e = 427$ ($M+H^+$).

Example 345

- 30 4-Hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine and 4-hydroxymethyl-piperidine the title compound was obtained as white solid (31 %). MS: $m/e = 407$ ($M+H^+$).

35

Example 346

Octahydro-quinoline-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and octahydro-quinoline the title compound was obtained as white solid (79 %). MS: m/e= 432 (M+H⁺).

5

Example 347

2,3-Benzo-1,4-dioxo-8-aza-spiro[4,5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- 10 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 2,3-benzo-1,4-dioxo-8-aza-spiro[4,5]decane the title compound was obtained as white solid (63 %). MS: m/e= 483 (M+H⁺).

Example 348

- 15 4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperazine-1-carboxylic acid methyl ester

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and piperazine-1-carboxylic acid methyl ester the title compound was obtained as white solid (90%). MS: m/e= 436 (M+H⁺).

20

Example 349

Octahydro-isoquinoline-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- 25 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and octahydro-isoquinoline the title compound was obtained as white solid (53%). MS: m/e= 432 (M+H⁺).

Example 350

- 30 3-Methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 3-methyl-piperidine the title compound was obtained as white solid (50 %). MS: m/e= 391 (M+H⁺).

Example 351

35

3-Hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine and 3-hydroxymethyl-piperidine the title compound was obtained as white solid (69 %). MS: $m/e = 436$ ($M+H^+$).

Example 352

5

3,4-Benzo-1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 3,4-benzo-1-oxa-8-aza-spiro[4.5]decane the title compound was obtained as light yellow solid (67 %). MS: $m/e =$
10 481 ($M+H^+$).

Example 353

4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperazine-1-carboxylic acid tert-butyl ester

15 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and piperazine-1-carboxylic acid *tert*-butyl ester the title compound was obtained as light yellow solid (66 %). MS: $m/e = 478$ ($M+H^+$).

Example 354

20 4-Hydroxy-4-phenyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-hydroxy-4-phenyl-piperidine the title compound was obtained as light yellow solid (36 %). MS: $m/e = 469$ ($M+H^+$).

25

Example 355

4-Methyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-methyl-piperazine the
30 title compound was obtained as beige solid (20 %). MS: $m/e = 392$ ($M+H^+$).

Example 356

35 4-Trifluoromethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-trifluoromethyl-piperidine the title compound was obtained as white solid (16 %). MS: $m/e = 445$ ($M+H^+$).

Example 357

[1,4']Bipiperidinyl-1'-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- 5 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and [1,4']bipiperidinyl the title compound was obtained as white solid (35 %). MS: $m/e = 461$ ($M+H^+$).

Example 358

- 10 3-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-(4-methoxy-phenyl)-1-methyl-urea
Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-methoxy-phenyl-methyl-amine the title compound was obtained as light yellow solid (40 %). MS: $m/e = 430$ ($M+H^+$).

Example 359

- 15 1,4-Dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 1,4-dioxa-8-aza-spiro[4,5]decane the title compound was obtained as beige solid (28 %). MS: $m/e = 435$
20 ($M+H^+$).

Example 360

- 3,4-Dihydro-1H-isoquinoline-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
25 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 1,2,3,4-tetrahydro-isoquinoline the title compound was obtained as orange solid (63 %). MS: $m/e = 425$ ($M+H^+$).

Example 361

- 30 3-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-1-phenyl-urea
Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and methyl-phenyl-amine the title compound was obtained as white solid (19 %). MS: $m/e = 399$ ($M+H^+$).

Example 362

- 35 4-Hydroxy-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and piperidin-4-ol the title compound was obtained as yellow solid (50 %). MS: $m/e = 393$ ($M+H^+$).

Example 363

5

4-Methoxy-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-methoxy-piperidine the title compound was obtained as yellow solid (33 %). MS: $m/e = 407$ ($M+H^+$).

10

Example 364

1-Oxo-1 \square ⁴-thiomorpholine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

15 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and thiomorpholine 1-oxide the title compound was obtained as white solid (87 %). MS: $m/e = 411$ ($M+H^+$).

Example 365

Methanesulfonic acid 1-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidin-4-yl-methyl ester

4-Hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide (300 mg, 0.43 mmol) and N-ethyl-diisopropylamine (95 μ l, 0.56 mmol) were dissolved in CH_2Cl_2 (10 ml), methanesulfonyl chloride (36 μ l, 0.47 mmol) was added and the mixture stirred at ambient temperature for 3 days. Purification as described in the general procedure E afforded the product as a white solid (34 %). MS: $m/e = 466$ ($M+H^+$).

25

Example 366

Piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Following the general method for piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide the title compound was prepared from 4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperazine-1-carboxylic acid tert-butyl ester as a light yellow solid (99 %). MS: $m/e = 378$ ($M+H^+$).

35

Example 367

4-Aminomethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Following the general method for piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide the title compound was prepared from [1-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester as a white solid (50 %). MS: $m/e = (M+H^+)$.

5

Example 368

(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-carbamic acid 2-methoxy-ethyl ester
4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine (300 mg, 1.1 mmol) and N-ethyl-diisopropylamine (0.56 ml, 3.4 mmol) were dissolved in tetrahydrofuran (11 ml) and 2-methoxyethyl chloroformate (0.19 ml, 1.4 mmol) were added over 5 min. Then the mixture was heated to 70 °C for 3 h. The mixture was cooled to room temperature, water added and extracted twice with ethyl acetate. The combined organic phases were dried with Na_2SO_4 and evaporated to dryness. The title compound was obtained as off-white solid (52 %). MS: $m/e = 368 (M+H^+)$.

15

Example 369

[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-benzyl]-methyl-carbamic acid methyl ester
N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide (100 mg, 0.24 mmol), pyridine (29 μ l, 0.36 mmol) and methyl chloroformate (24 μ l, 0.32 mmol) were dissolved in dichloromethane (5 ml) and stirred at ambient temperature for 18 h. Workup and purification as described in the general procedure C afforded the title compound as light yellow solid (66 %), MS: $m/e = 471 (M+H^+)$.

25

Example 370

1-Oxo-1 λ^4 -thiomorpholine-4-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide hydrochloride
Using 4-methoxy-7-piperidin-1-yl-benzothiazol-2-ylamine and thiomorpholine 1-oxide the title compound was obtained as white solid in accordance with general procedure E (80 %). MS: $m/e = 409 (M+H^+)$.

35

Example 371

N-(4-Ethoxy-7-piperidin-1-yl-benzothiazol-2-yl)-4-fluoro-benzamide

The title compound was prepared starting from 4-bromo-1-ethoxy-2-nitro-benzene and piperidine as described for 4-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-

benzamide (Example 275) and obtained as a yellow solid in 10 % overall yield, MS: m/e= 400 (M+H⁺).

Example 372

5 4-Fluoro-N-(4-isopropoxy-7-piperidin-1-yl-benzothiazol-2-yl)-benzamide

The title compound was prepared starting from 4-bromo-1-isopropoxy-2-nitro-benzene and piperidine as described for 4-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (Example 275) and obtained as a light brown solid in 10 % overall yield, MS: m/e= 414 (M+H⁺).

10 Example 373

4-Fluoro-N-(4-methoxy-7-pyrrolidin-1-yl-benzothiazol-2-yl)-benzamide

The title compound was prepared starting from 4-bromo-1-methoxy-2-nitro-benzene and pyrrolidine as described for 4-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (Example 275) and obtained as a light brown solid in about 10 % overall yield, MS: m/e= 372 (M+H⁺).

Example 374

4-Fluoro-N-(4-methoxy-7-[1,4]oxazepan-4-yl-benzothiazol-2-yl)-benzamide

20 The title compound was prepared starting from 4-bromo-1-methoxy-2-nitro-benzene and [1,4]Oxazepane as described for 4-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide (Example 275) and obtained as a light yellow solid in about 10 % overall yield, MS: m/e= 402 (M+H⁺).

25 Example 375

Morpholine-4-carboxylic acid [4-methoxy-7-(4-methoxy-piperidin-1-yl)-benzothiazol-2-yl]-amide

30 The title compound was prepared starting from 4-bromo-1-methoxy-2-nitro-benzene and 4-methoxy-piperidine as described for morpholine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide (Example 136) and obtained as a light yellow solid in about 10 % overall yield, MS: m/e= 407 (M+H⁺).

Example 376

35 N-(7-Azepan-1-yl-4-methoxy-benzothiazol-2-yl)-4-nitro-benzamide

The title compound was prepared using 4-bromo-1-methoxy-2-nitro-benzene, azepane and 4-nitro-benzoyl chloride as described for 4-fluoro-N-(4-methoxy-7-morpholin-4-yl-

benzothiazol-2-yl)-benzamide (Example 275) and obtained as a light yellow solid in about 10 % overall yield, MS: $m/e = 427$ ($M+H^+$).

Example 377

5

Morpholine-4-carboxylic acid (4-methoxy-7-thiophen-3-yl-benzothiazol-2-yl)-amide

The title compound was prepared starting from 4-bromo-1-methoxy-2-nitro-benzene and trimethyl-thiophen-3-yl-stannane as described for morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide (Example 157) and obtained as a light yellow solid in about 10 % overall yield, MS: $m/e = 376$ ($M+H^+$).

Example 378

4-Fluoro-N-[4-methoxy-7-(2-methyl-imidazol-1-yl)-benzothiazol-2-yl]-benzamide

15 N-(7-Acetylamino-4-methoxy-benzothiazol-2-yl)-4-fluoro-benzamide (100 mg, 0.28 mmol) and Lawessons reagent (135 mg, 0.33 mmol) were dissolved in THF (10 ml) and stirred at ambient temperature for 18 h. Removal of the solvent and flash chromatography (silica, eluent $CH_2Cl_2/2N$ aqu. NH_3 in MeOH 99:1 to 19:1) afforded a yellow solid which was dissolved in acetone (10 ml) and treated with iodomethane (19.8 mg, 1.4 mmol). After
20 3 h at ambient temperature the solvent was removed and after dissolution in ethanol (10 ml), aminoacetaldehyde dimethyl acetal (15 mg, 1.4 mmol) were added and the mixture stirred for 18 h at room temperature. The solvent was removed and the residue refluxed for 24 h in ethanol (10 ml) and conc. sulfuric acid (1 ml). The mixture was diluted with water (50 ml) and the pH adjusted to 8 with sodium carbonate. It was extracted three times with
25 dichloromethane. The combined organic extracts were dried with sodium sulfate and the solvent removed. Flash chromatography (silica, eluent $CH_2Cl_2/2N$ aqu. NH_3 in MeOH 96:4 to 9:1) afforded the title compound as brown solid, MS: $m/e = 383$ ($M+H^+$).

Example 379

2-Chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-6-methyl-isonicotinamide

30 To a stirred suspension of 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine (13.3 g, 50.1 mmol) in THF (700 ml) was added N-ethyldiisopropylamine (21.3 ml, 125 mmol). The mixture was then cooled to 5 °C and a solution of 2-chloro-6-methyl-isonicotinoyl chloride (10.5 g, 55.1 mmol) in dichloromethane (350 ml) was added dropwise over 2 hours. The reaction mixture was then stirred overnight at 20 °C. To this mixture was added
35 methanol (40 ml) and stirring continued for ten minutes. The mixture was then concentrated *in vacuo* and the residue partitioned between ethyl acetate and saturated

sodium bicarbonate solution. The organic phases were then dried over Na_2SO_4 and the solvent evaporated. The crude product was then chromatographed over SiO_2 (Merck 230-400 mesh) eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (98:2), the product fractions were pooled and the solvent evaporated, to afford the title compound as a brown solid (16.0 g, 76 % yield), MS: $m/e = 421$ ($\text{M}\{^{37}\text{Cl}\} + \text{H}^+$), 419 ($\text{M}\{^{35}\text{Cl}\} + \text{H}^+$).

Following General Procedure E the compounds of examples 380 and 381 were prepared

Example 380

(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and ammonia the title compound was obtained as a white solid (20%), MS: $m/e = 309$ ($\text{M} + \text{H}^+$).

Example 381

(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-carbamic acid phenyl ester

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and without adding an amine the title compound was obtained as a white foam (75%), MS: $m/e = 386$ ($\text{M} + \text{H}^+$).

Following the general method of example 379 the following compound was prepared

Example 382

2-Chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 2-chloro-isonicotinoyl chloride the title compound was obtained as a brown solid (59%), MS: $m/e = 407$ ($\text{M}\{^{37}\text{Cl}\} + \text{H}^+$), 405 ($\text{M}\{^{35}\text{Cl}\} + \text{H}^+$).

Example 383

2-Iodo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-6-methyl-isonicotinamide

To a stirred suspension of 2-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-6-methyl-isonicotinamide (1.00 g, 2.39 mmol) in ethyl methyl ketone (10 ml) and dioxane (20 ml) were added sodium iodide (2.0 g, 13.3 mmol) and hydriodic acid (0.95 ml, 7.2 mmol, 57 % aqueous). The mixture was then heated at 100 °C for 96 hours. The mixture was then concentrated *in vacuo* and the residue resuspended in dichloromethane and washed sequentially with saturated sodium bicarbonate solution, 0.1 M sodium thiosulfate solution, and saturated brine. The organic phase was then dried over Na_2SO_4 and the

solvent evaporated. The crude product was then chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂/MeOH (99:1 then 98:2), the product fractions were pooled and the solvent evaporated, to afford the title compound as a brown solid (80 mg, 7 % yield), MS: m/e = 511 (M+H⁺).

5 *Following General Procedure E the compounds of examples 384 and 385 were prepared*

Example 384

1-Benzyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and N-benzylmethylamine the title compound was obtained as an off-white solid (94 %), MS: m/e = 413 (M+H⁺).

10

Example 385

3-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-1-phenethyl-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and N-methyl-2-phenylethylamine the title compound was obtained as an off-white solid (53 %), MS: m/e = 427 (M+H⁺).

15 *Following the general method of example 379 the compounds of examples 386 to 391 were prepared*

Example 386

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-phenyl-acetamide

20 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and phenylacetyl chloride the title compound was obtained as a light yellow solid (37 %), MS: m/e = 384 (M+H⁺).

Example 387

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-propionamide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and propionyl chloride the title compound was obtained as a light yellow solid (5 %), MS: m/e = 322 (M+H⁺).

25

Example 388

2-Methoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-acetamide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and methoxyacetyl chloride the title compound was obtained as a light yellow solid (37 %), MS: $m/e = 338 (M+H^+)$.

Example 389

Pentanoic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

- 5 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and valeroyl chloride the title compound was obtained as a light yellow solid (48 %), MS: $m/e = 350 (M+H^+)$.

Example 390

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isobutyramide

- 10 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and isobutyryl chloride the title compound was obtained as a light yellow solid (8 %), MS: $m/e = 336 (M+H^+)$.

Example 391

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-phenyl-propionamide

- 15 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 3-phenylpropionyl chloride the title compound was obtained as a light yellow solid (3 %), MS: $m/e = 398 (M+H^+)$.

Following General Procedure E the compounds of examples 392 to 396 were prepared

Example 392

1-Benzyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea

- 20 Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and benzylamine the title compound was obtained as an off-white solid (99 %), MS: $m/e = 399 (M+H^+)$.

Example 393

1-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-phenethyl-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 2-phenylethylamine the title compound was obtained as an off-white solid (87 %), MS: $m/e = 413 (M+H^+)$.

25

Example 394

1-(2-Methoxy-ethyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 2-methoxyethylamine the title compound was obtained as an off-white solid (80 %), MS: $m/e = 367$ ($M+H^+$).

Example 395

5 1-(2-Dimethylamino-ethyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and N,N,N' -trimethylethylenediamine the title compound was obtained as an off-white solid (61 %), MS: $m/e = 394$ ($M+H^+$).

Example 396

10 1-(2-Dimethylamino-ethyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 2-dimethylaminoethylamine the title compound was obtained as an off-white solid (79 %), MS: $m/e = 380$ ($M+H^+$).

Following the general method of example 379 the compound of example 397 was prepared

15 Example 397

4-Dimethylamino-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-butyramide

Using 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine and 4-dimethylamino-butryl chloride the title compound was obtained as a light yellow solid (10 %), MS: $m/e = 379$ ($M+H^+$).

20 Preparation of intermediates for examples 1 to 187

Example 398

(7-Iodo-4-methoxy-benzothiazol-2-yl)-carbamic acid methyl ester

(4-Methoxy-benzothiazol-2-yl)-carbamic acid methyl ester (31.0 g, 130 mmol) and sodium acetate (32.3 g, 394 mmol) are dissolved in 400 ml of glacial acetic acid and slowly
25 treated with iodine monochloride (13.5 ml, 264 mmol) at 0 °C. The reaction mixture is then slowly warmed to room temperature and stirred for 15 hours. After addition of water (1.3 l), the formed precipitate is filtered off and washed with water. The filter cake is then dissolved in a minimal amount of tetrahydrofuran (about 150 ml) and decolorized with 1M aqueous sodium thiosulfate. The product is precipitated by the addition of water

- 121 -

(about 2.0 l), filtered off and dried at 60 °C for 12 hours. 42.3 g (89 %) white solid. MS: $m/e = 364$ (M^+).

Example 399

(4-Methoxy-benzothiazol-2-yl)-carbamic acid methyl ester

- 5 2-Amino-4-methoxybenzothiazol (23.6 g, 131 mmol) and pyridine (12.6 ml, 157 mmol) in dichloromethane (230 ml) are slowly treated with methyl chloroformate (10.6 ml, 137 mmol) at 0 °C. After 10 minutes, further methyl chloroformate (1.0 ml, 13 mmol) and pyridine (1.0 ml, 12 mmol) are added. After 10 minutes, the mixture is poured into 200 ml 1M aqueous hydrochloric acid, the organic layer is separated, diluted with
- 10 dichloromethane (250 ml) and washed with brine (50 ml). The organic phase is dried and the solvent evaporated in vacuo. 31.0 g (99.4 %) white solid. MS: $m/e = 238$ ($M+H^+$).

Example 400

(4-Methoxy-7-phenyl-benzoythiazol-2-yl)-carbamic acid tert-butyl ester

- To a suspension of 2-amino-4-methoxy-7-phenyl-benzothiazole (1.0 g, 3.9 mmol) in THF
- 15 (50 ml) was added di(tert-butoxycarbonyl)-anhydride ($(BOC)_2O$) and DMAP (47 mg, 0.04 mmol) and the mixture stirred for 1 h at r.t., followed by 3 h at 60 °C. After cooling the solvent was evaporated and the residue chromatographed over SiO_2 (Merck 230-400 mesh) eluting with a gradient of cyclohexane/EtOAc (10 % to 50 % EtOAc), after pooling the product fractions and evaporation of the solvents the title compound was obtained as a
- 20 white foam (1.1 g, 79 % yield), MS: $m/e = 356$ (M^+).

Example 401

(4-Methoxy-benzothiazol-2-yl)-carbamic acid tert-butyl ester

Using 2-amino-4-methoxy-benzothiazole the title compound was obtained as a white solid (60 % yield), MS: $m/e = 281.2$ ($M+H^+$).

25

Example 402

2-Amino-4-methoxy-7-phenyl-benzothiazole

The title compound was prepared from 3-amino-4-methoxy-biphenyl, according to the patent literature *N-(Benzothiazol-2-yl)oxamic acid derivatives*. W. Winter, M. Thiel, A.

Roesch and O. H. Wilhelms, German Patent, DE 2656468, 1978. and is obtained as a white solid, MS: $m/e=256$ (M^+), mp. 207-208 °C.

Example 403

4-Methoxy-7-phenoxy-benzothiazol-2-yl-amine

- 5 To a suspension of 2-methoxy-5-phenoxy-phenyl)-thiourea (8.25 g, 30 mmol) in $CHCl_3$ (70 ml) was added bromine (4.8 g, 30 mmol) in $CHCl_3$ (10 ml) dropwise over 10 min. The mixture was then heated to reflux for 3 h, then cooled to r.t., the solvent was evaporated and the residue crystallised from MeOH/ether (1:4). The filter cake was then further washed with saturated aqueous $NaHSO_3$ solution /water (1:1), (100 ml), water (200 ml),
10 1N NaOH (60 ml), then water (100 ml), and finally ether (100 ml). The solid material thus obtained was dried under vacuum (0.05 mmHg, 60 °C) to afford the title compound as a white solid (6.7 g, 82 % yield), MS: $m/e=272.1$ (M^+).

Following the general method of example 403, the compounds of examples 404 to 409 were prepared

15 Example 404

2-Amino-4-methoxy-benzothiazole-7-carboxylic acid methyl ester

Using 4-methoxy-3-thioureido-benzoic acid methyl ester the title compound was obtained as a white solid (55 % yield), MS: $m/e=239.2$ ($M+H^+$).

Example 405

20 7-Bromo-4-methoxy-benzothiazole-2-yl-amine

Using (5-bromo-2-methoxy-phenyl)-thiourea the title compound was obtained as a white solid (46 % yield), MS: $m/e=258$ (M^+).

Example 406

7-tert-Butyl-4-methoxy-benzothiazole-2-yl-amine

- 25 Using (5-tert-butyl-2-methoxy-phenyl)-thiourea the title compound was obtained as a white solid (79 % yield), MS: $m/e=238.1$ (M^+).

Example 407

7-Acetylamino-4-methoxy-benzothiazole-2-yl-amine

Using (5-acetylamino-2-methoxy-phenyl)-thiourea the title compound was obtained as a purple solid (49 % yield), MS: $m/e=238.2$ ($M+H^+$.)

5

Example 408

4-methoxy-7-(1H-tetrazol-5-yl)-benzothiazol-2-yl-amine

Using 2-methoxy-5-(1H-tetrazol-5-yl)-phenyl]-thiourea the title compound was obtained as a tan solid (54 % yield), MS: $m/e=248.2$ (M^+)

Example 409

10 (4-Methoxy-7-phenyl-benzothiazol-2-yl)-methyl-amine

Using (4-methoxy-biphenyl-3-yl)-thiourea the title compound was obtained as a white solid (71 % yield), MS: $m/e=270.1$ (M^+).

Example 410

5-Methoxy-7-phenyl-benzothiazol-2-yl-amine

- 15 (5-Methoxy-biphenyl-3-yl)-thiourea (109 mg, 0.42 mmol) in chloroform (2 ml) are treated with bromine (22 μ l) and the mixture heated to 61 °C for 5 hours. After removal of the volatile components in vacuo, the product (93 g, 86 %) is isolated by flash chromatography (silica, eluent ethyl acetate/cyclohexane 2:1 to 5:1) as beige solid. The regiochemistry of the cyclization was checked by transfer-NOE measurements. MS: $m/e=$
- 20 256 (M^+).

Example 411

2-Amino-4,5-dimethoxybenzothiazol

- 2-Amino-4,5-dimethoxybenzothiazol is synthesized starting from 2,3-dimethoxyaniline (1.0 g, 6.5 mmol) in the same manner as described for 5-methoxy-7-phenyl-benzothiazol-
- 25 2-yl-amine in 72 % total yield over three steps. MS: $m/e= 210$ (M^+).

Example 412

6-Bromo-4-trifluoromethoxy-benzothiazol-2-yl-amine

4-Bromo-2-trifluoromethoxy)aniline (768 mg, 3 mmol) and potassium thiocyanate (875 mg, 9 mmol) are dissolved in acetic acid (5 ml) and at 0 °C, bromine (0.19 ml, 3.6 mmol) are slowly added. After stirring for 1 h, acetic acid (2 ml) are added and the mixture heated to 100 °C for 3 h. After cooling to room temperature, aqueous sodium hydroxide (10M, 25 ml) is added and the mixture extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried and the solvent removed in vacuo. Flash chromatography (silica, eluent ethyl acetate/cyclohexane 1:4) and final recrystallization from ethyl acetate/cyclohexane affords the product as white solid. 170 mg (18 %). MS: m/e= 315 (M+H⁺).

Example 413

4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine

(2-Methoxy-5-morpholin-4-yl-phenyl)-thiourea (5.0 g, 19 mmol) in chloroform (130 ml) are treated with bromine (960 µl) and the mixture refluxed for 18 hours. After removal of the volatile components in vacuo, the product is recrystallized from THF (2.8 g, 57 %). MS: m/e= 266 (M⁺).

Example 414

7-Benzyloxy-4-methoxy-benzothiazole-2-yl-amine

Synthesized starting from (5-Benzyloxy-2-methoxy-phenyl)-thiourea in the same manner as described for 5-methoxy-7-phenyl-benzothiazol-2-yl-amine in 82 % yield as a beige solid. Mp: 165 °C (dec.).

Example 415

4-Trifluoromethoxy-benzothiazol-2-yl-amine

6-Bromo-4-trifluoromethoxy-benzothiazol-2-ylamine (157 mg, 0.50 mmol), triethylamine (0.21 ml, 1.5 mmol) and palladium on carbon (10 %, 15 mg) are suspended in ethanol (12 ml) and hydrogenated at atmospheric pressure for 96 h. The catalyst was filtered off and the solution evaporated to dryness. The residue was dissolved in ethyl acetate, washed three times with water, dried and the solvent removed in vacuo. The product is obtained as brown solid (85 mg, 73%). MS: m/e= 235 (M+H⁺).

Example 416

2-Amino-4-methoxy-benzothiazole-7-carbaldehyde

Using (5-Formyl-2-methoxy-phenyl)-thiourea the title compound was synthesised as described for 4-methoxy-7-phenoxy-benzothiazol-2-yl-amine and obtained as a beige solid
5 (70 % yield), MS: m/e=208.0 (M^+).

Example 417

4-Methoxy-7-morpholin-4-ylmethyl-benzothiazol-2-yl-amine

To a suspension of 2-amino-4-methoxy-benzothiazole-7-carbaldehyde (440 mg, 2.1 mmol) in THF (100 ml) was added morpholine (276 mg, 3.2 mmol), acetic acid (190 mg,
10 3.2 mmol) followed by $\text{NaBH}(\text{OAc})_3$ (672 mg, 3.2 mmol). This mixture was stirred vigorously at 20 °C for 48 hours, after which time water (50 ml) and 5 % NaHCO_3 solution (50 ml) were added and the mixture agitated vigorously. After separating the organic and aqueous layers, the aqueous phase was extracted with EtOAc (50 ml) and the combined
15 organic phase was washed with saturated NaCl solution (100 ml) then dried with Na_2SO_4 , filtered and evaporated. The solid residue was suspended in ether (20 ml) and filtered then the filter cake was washed with ether (10 ml), and dried under vacuum (0.05 mmHg, 50 °C) to afford the title compound as a yellow solid (430 mg, 73 % yield), MS: m/e=280.2 (M^+).

Example 418

20 2-Chloro-4-methoxy-7-phenyl-benzothiazole

To a suspension of 2-amino-4-methoxy-7-phenyl-benzothiazole (5.1 g, 20 mmol) in ethylene glycol (75 ml) were added hydrazine monohydrate (4 g, 80 mmol) and hydrazine dihydrochloride (4.2 g, 40 mmol) and the suspension was heated for 18 h at 140 °C. After cooling to r.t. the suspension was filtered, then the filter cake was washed with water (200
25 ml) followed by ether (100 ml), and dried under vacuum (0.05 mmHg, 70 °C) to afford 2-hydrzino-4-methoxy-7-phenyl-benzothiazole as a white solid (5.2 g, 96 % yield). The 2-hydrzino-4-methoxy-7-phenyl-benzothiazole (4.5 g, 16.6 mmol) was then added in portions over 20 min. to stirred neat thionyl chloride (12 ml, 165 mmol), the mixture was then heated to 50 °C for 2 h to complete the reaction. The reaction mixture was then
30 cooled and poured on to ice/water (300 ml) and stirred for 20 min. at 0-10 °C. The whole mixture was then filtered and the filter cake was washed with water (100 ml). The filter cake was then dissolved in CH_2Cl_2 (250 ml) and washed with saturated NaCl solution. The

organic phase was dried with Na_2SO_4 filtered and evaporated to afford a red oil which was chromatographed over SiO_2 (Merck 230-400 mesh) eluting with CH_2Cl_2 . The product fractions were pooled and evaporated to afford the title compound as a brown solid (4.24 g, 93 % yield), MS: $m/e=275.0$ (M^+).

- 5 Lit: *Synth. Commun.*, 1992, 2769-80.

Example 419

4-(Morpholine-4-sulfonyl)-benzoic acid

- To a solution of 4-(chlorosulfonyl)-benzoic acid (0.5 g, 2.2 mmol) in THF (20 ml) was added morpholine (0.434 ml, 5 mmol) dropwise over 5 min, and this mixture stirred at
10 r.t. for 1 h. Water (50 ml) was then added and the mixture agitated, the phases were separated and the aqueous phase extracted with EtOAc (2x50 ml). The combined organic phases were washed with satd. aq. NaCl solution, dried, filtered and evaporated. The residue was chromatographed over SiO_2 (Merck 230-400 mesh) eluting with a
15 CHCl_3 /(acetone + 10 % HCO_2H) (9:1), the product fractions were pooled, evaporated and dried in vacuo (0.05 mmHg, 50 °C) to afford the title compound as a beige solid (270 mg, 20 % yield), MS: $m/e=271$ (M^+).

Following the general method of example 419, the compounds of examples 420 to 422 were prepared

Example 420

20 4-Dipropylsulfamoyl-benzoic acid

Using dipropylamine the title compound was obtained as a beige solid, MS: $m/e=285$ (M^+).

Example 421

4-Ethylsulfamoyl-benzoic acid

- Using ethylamine the title compound was obtained as a white solid (85 % yield), MS:
25 $m/e=228.1$ ($\text{M}-\text{H}$)⁻.

Example 422

4-Diethylsulfamoyl-benzoic acid

Using diethylamine the title compound was obtained as a white solid (44 % yield), MS: $m/e=257 (M^+)$.

Example 423

2-(1,1-Dioxo-thiomorpholin-4-yl)-ethylamine

- 5 The title compound was prepared according to the following patent literature: W. R. Baker, S. A. Boyd, A. K. L Fung, H. H Stein, J. F. Denissen, C. W. Hutchins and S. H. Rosenberg, WO 9203429 (1992).

Example 424

Methyl-(6-methyl-pyridin-3-ylmethyl)-amine

- 10 To a suspension of $LiAlH_4$ in THF (120 ml) at 10 °C was added a solution of methyl-6-methyl nicotinate (12 g, 79 mmol) in THF (80 ml) dropwise with cooling over 45 min. After stirring 1.5 h at 20 °C, a mixture of THF/water (4:1) 60 ml was added to the reaction over 30 min. at 0 °C, Na_2SO_4 (50 g) was then added directly to the reaction mixture which was stirred vigorously, then filtered and the THF evaporated in vacuo. The residue was
- 15 chromatographed over SiO_2 (Merck 230-400 mesh) eluting with a gradient of $CH_2Cl_2/MeOH$ (97:3 to 9:1), affording a colourless oil (7.5 g, 77 % yield). This material was dissolved in $CHCl_3$ (100 ml) and treated dropwise with thionyl chloride (17.2 ml, 237 mmol) stirred at 5 °C to 20 °C over 16 h. The solvents were then removed in vacuo and the residue partitioned between CH_2Cl_2 (100 ml) and aq. 5% $NaHCO_3$ (100 ml), the aqueous
- 20 phase was further extracted with CH_2Cl_2 (2x 50 ml) and the combined extracts washed with satd. aq. NaCl solution (1x50 ml), then dried and the solvent evaporated in vacuo. The resulting red oil was dissolved in EtOH (80 ml) cooled to 0 °C and treated with 33% methylamine /EtOH (50 ml) dropwise over 1 h, then the mixture was stirred to 20 °C over 3 h. After evaporation of all the solvents the residue was partitioned between CH_2Cl_2 and
- 25 water (100 ml ea.), the aqueous phase was further extracted with CH_2Cl_2 (2x 100 ml), dried (Na_2SO_4), filtered and the solvent evaporated in vacuo. The brown oily residue was then distilled under high vacuum (0.1 mm Hg, 68-70 °C) over a Vigreux column to afford the title compound as a pale yellow liquid (6.03 g, 75 % yield), MS: $m/e=136.1 (M^+)$.

Lit: *J. Med. Chem.*, 1996, 5053-63.

- 30 Following the general method of example 424, the compounds of examples 425 to 4266 were prepared

Example 425

Methyl-pyridin-2-yl-methyl-amine

Using 2-chloromethyl-pyridine hydrochloride salt and 33 % methylamine/EtOH the title compound was obtained as a colourless liquid (0.1 mm Hg, 47-48 °C) (20 % yield), MS:

5 m/e=93.1 (M-NHCH₃).

Example 426

Methyl-pyridin-4-ylmethyl-amine

Using 4-chloromethyl-pyridine hydrochloride salt and 33 % methylamine/EtOH the title compound was obtained as a colourless liquid (0.1 mm Hg, 60-62 °C) (79 % yield), MS:

10 m/e=122.1 (M⁺).

Preparation of intermediates for examples 188 to 208

Example 427

2-Methoxy-5-phenoxy-phenyl)-thiourea

To a solution of 2-methoxy-5-phenoxy-aniline (9.9 g, 46 mmol) in acetone (60 ml) was
15 added benzoylisothiocyanate (9 g, 55 mmol) and the mixture heated to reflux (56 °C) for 4
h. After cooling to r.t., the solvent was evaporated and the oily orange residue was
precipitated from ether (20 ml) under ultrasonication, the solid was then washed on the
filter with ether/ nHexane (1:3) (50 ml). The solid thus obtained was further dried under
vacuum (0.05 mmHg, 50 °C) to afford the benzoylated thiourea as a beige solid (17.2 g, 99
20 %, yield). Fresh sodium methoxide (14.5 g, 38 mmol) was then added to a suspension of
the benzoylated thiourea (14.5 g, 38 mmol) in methanol (70 ml) and this mixture stirred
for 1 h at r.t. Water was then added (210 ml) and the precipitated solid was collected, then
washed on the filter with water (100 ml), followed by ether (100 ml), then dried under
vacuum (0.05 mmHg, 50 °C) to afford the title compound as a white solid (8.5 g, 81 %
25 yield), MS: m/e=274.1 (M⁺).

Following the general method of example 427 the compounds of examples 428 to 433 were prepared

Example 428

(5-tert-Butyl-2-methoxy-phenyl)-thiourea

Using 4-tert-butyl-2-methoxy-aniline the title compound was obtained as a white solid (79 % yield), MS: $m/e=238.1$ (M^+).

Example 429

(5-Acetylamino-2-methoxy-phenyl)-thiourea

- 5 Using 3-amino-4-methoxyacetanilide the title compound was obtained as a grey solid (69 % yield), MS: $m/e=240.3$ ($M+H^+$).

Example 430

4-Methoxy-3-thioureido-benzoic acid methyl ester

- 10 Using 3-Amino-4-methoxy-benzoic acid methyl ester the title compound was obtained as a tan solid (78 % yield), MS: $m/e=240.0$ (M^+).

Example 431

(5-Bromo-2-methoxy-phenyl)-thiourea

Using 5-bromo-2-methoxy-aniline the title compound was obtained as a white solid (88 % yield), MS: $m/e=260$ (M^+).

- 15 **Example 432**

2-methoxy-5-(1H-tetrazol-5-yl)-phenyl]-thiourea

Using 2-methoxy-5-(1H-tetrazol-5-yl)-aniline the title compound was obtained as a tan solid (92 % yield), MS: $m/e=250.1$ (M^+).

Exempl 433

- 20 1-(4-Methoxy-biphenyl-3-yl)-3-methyl-thiourea

Using 4-methoxy-biphenyl-3-ylamine and N-methyl-isothiocyanate the title compound was directly obtained as a white solid (96 % yield), MS: $m/e=273.2$ ($M+H^+$).

Example 434

(5-Methoxy-biphenyl-3-yl)-thiourea

- 25 1-Benzoyl-3-(5-methoxy-biphenyl-3-yl)-thiourea (183 mg, 0.51 mmol) in methanol (5 ml) are treated with sodium methoxide (5.4M in methanol, 0.14 ml) and the formed precipitate is filtered off. Washing with methanol yields the product (115 mg, 88 %) as off-white powder. MS: $m/e=258$ (M^+).

Example 435

1-Benzoyl-3-(5-methoxy-biphenyl-3-yl)-thiourea

- 5-Methoxy-biphenyl-3-ylamine (129 mg, 0.65 mmol) are dissolved in acetone (5 ml) and slowly treated with a solution of benzoyl isothiocyanate (0.096 ml, 0.71 mmol) in acetone (2 ml). After stirring at ambient temperature for 18 h, the solvent is removed in vacuo and the residue crystallized from hexane. The product (203 mg, 86 %) is obtained as colorless crystals. Mp 149 °C.

Example 436

(2-Methoxy-5-morpholin-4-yl-phenyl)-thiourea

- 1-Benzoyl-3-(2-methoxy-5-morpholin-4-yl-phenyl)-thiourea (8.0 g, 21 mmol), suspended in methanol (260 ml), are treated with 6 ml sodium methanolate (5.4M in methanol) and the mixture stirred until a white precipitate forms. The mixture is concentrated in vacuo, the crystals are isolated by filtration and washed with methanol and hexane (5.0 g 86 %). MS: m/e= 268 (M⁺).

Example 437

1-Benzoyl-3-(2-methoxy-5-morpholin-4-yl-phenyl)-thiourea

- To a solution of 2-methoxy-5-morpholin-4-yl-phenylamine (4.6 g, 22 mmol) in acetone (140 ml) is added a solution of benzoyl isithiocyanate (3.4 ml, 25 mmol) in acetone (80 ml) and the reaction mixture is stirred for further 30 min at ambient temperature. After removal of the volatile components in vacuo, the product is isolated by flash chromatography (silica, eluent ethyl acetate/n-hexane 1:4, then 1:2) as a yellow solid (8.0 g, 97 %). MS: m/e= 272 (M⁺).

Example 438

(5-Benzyloxy-2-methoxy-phenyl)-thiourea

- 25 Synthesized from 5-benzyloxy-2-methoxy-aniline as described for example 427 in 80 % overall yield. Obtained as white crystals. M.p. 130 °C (dec.).

Example 439

(5-Formyl-2-methoxy-phenyl)-thiourea

To a solution of 2-(4-methoxy-3-nitro-phenyl)-[1,3]dioxolane (13 g, 57.7 mmol) in MeOH (400 ml) was added Adams catalyst-Pt(O₂) (700 mg) and the mixture stirred vigorously under an atmosphere of hydrogen at 20 °C until 4l of hydrogen had been taken up. The catalyst was then filtered off and methanol evaporated and replaced with acetone (150 ml). Benzoyl isothiocyanate was then added dropwise (8.5 ml, 63.5 mmol) over 15 min at r.t. and the mixture then heated to reflux for 1.5 h. After cooling the solvent was evaporated and the residue was chromatographed over SiO₂ (Merck 230-400 mesh) eluting with CH₂Cl₂ affording a yellow oil (10 g). This oil was taken up in MeOH (150 ml) and sodium methoxide was added (3.7 g, 69 mmol) and the mixture stirred at 20 °C for 1 h. Following this the solvent was evaporated and the residue dissolved in THF (200 ml) and 2N HCl (100 ml) was added and the mixture stirred for 30 min. EtOAc (200 ml) was then added and the aqueous phase separated and extracted with EtOAc/THF (1:1) (200 ml). The combined organic phases were washed with satd. aq. NaCl solution (2x 200 ml), dried, filtered and the solvent evaporated. The solid residue was suspended in ether (100 ml) and filtered off, washed with ether (50 ml) and dried under vacuum (0.05 mmHg, 50 °C) to afford the title compound as a yellow solid (4.7 g, 39 % yield). MS: m/e=210.1 (M⁺).

Example 440

2-(4-Methoxy-3-nitro-phenyl)-[1,3]dioxolane

To a solution of 4-methoxy-3-nitro-benzaldehyde (11.2 g, 61.8 mmol) in toluene (300 ml) was added ethylene glycol (5.2 ml, 92.7 mmol) and Amberlyst A15 resin acid catalyst (0.6 g). This mixture was stirred vigorously at reflux for 16 h. in a Dean-Stark apparatus. Upon cooling the Amberlyst resin was filtered off and the filtrate washed with satd. aq. NaCl solution (3x150 ml), then dried with Na₂SO₄, filtered and evaporated to afford the title compound as an orange oil (14 g, 100 % yield), MS: m/e=224.1 (M-H)⁺.

Example 441

2-Methoxy-5-(1H-tetrazol-5-yl)-aniline

To a solution of 4-methoxy-3-nitro-benzonitrile (2.5 g, 1.4 mmol) in toluene (20 ml) was added sodium azide (1.3 g, 1.8 mmol) and triethylamine hydrochloride (1.5 g, 1.8 mmol), and this mixture stirred at 100 °C for 48 h. Water was then added (200 ml) and the mixture agitated, the aqueous phase was further washed with water (2x30 ml). The organic phase was then adjusted to pH 2 and the solid which precipitated was filtered off and washed further with water (100 ml) then dried in vacuo (0.05 mmHg, 60 °C) to afford the crude tetrazole. This material was then directly dissolved in MeOH (80 ml), Pd/C (10%) (250

mg) was added and the mixture stirred under 1 atm of hydrogen at 20 °C for ca. 1 h until the theoretical amount of hydrogen (ca. 880 ml) had been taken up. The catalyst was then filtered off and the solvent evaporated to afford the title compound as a white solid (2.2 g, 82 % yield), MS: $m/e=191.1$ (M^+).

5 Lit: *Synthesis* 1998, p910.

Example 442

1-Iodo-3-methoxy-5-nitro-benzene

1-Iodo-3,5-dinitrobenzene (1.8 g, 6.1 mmol) are dissolved in methanol (12 ml) and treated with a solution of sodium methoxide in methanol (5.4M, 1.2 ml). The mixture is then
10 stirred at 65°C for 52 h. After cooling to ambient temperature, water (50 ml) is added and the mixture extracted three times with ethyl acetate (50 ml). The combined organic layers are extracted with brine (100 ml), dried and evaporated to dryness. Flash chromatography (silica, eluent ethyl acetate/cyclohexane 1:1) affords the product (1.7 g, 99 %) as light yellow solid. MS: $m/e=279$ (M^+).

15

Example 443

5-Methoxy-biphenyl-3-yl-amine

3-Methoxy-5-nitro-biphenyl (176 mg, 0.77 mmol) are hydrogenated in ethanol (5 ml) using palladium on carbon (10 %, 17 mg) at atmospheric pressure for 2h. The catalyst is filtered off and the solvent removed in vacuo. Flash chromatography (silica, eluent ethyl
20 acetate/cyclohexane 1:1) affords the product (139 mg, 91 %) as a brown oil. MS: $m/e=199$ (M^+).

Example 444

2-Methoxy-5-morpholin-4-yl-phenylamine

4-(4-Methoxy-3-nitro-phenyl)-morpholine (6 g) is hydrogenated in dichloromethane (100
25 ml) and methanol (600 ml) using palladium on carbon (10 %, 600 mg) for 12 hours. The catalyst is removed by filtration and the solution evaporated in vacuo. Purification by flash chromatography (silica, eluent ethyl acetate/n-hexane 1:1, then) affords the product as off-white solid (4.6 g, 88 %). MS: $m/e=209$ ($M+H^+$).

Example 445

4-(4-Methoxy-3-nitro-phenyl)-morpholine

4-Bromo-2-nitroanisole (8.5 g, 36 mmol), morpholine (3.8 ml, 44 mmol), potassium phosphate (11 g, 51 mmol), 2-biphenyl-dicyclohexyl phosphine (960 mg, 2.7 mmol) and
5 palladium(II)acetate (411 mg, 1.8 mmol) are dissolved in dimethoxyethane (80 ml) and stirred at 80 °C for 96 hours. The mixture is then cooled to room temperature, diluted with ethyl acetate (50 ml) and filtrated through dicalite. Flash chromatography on silica (eluent dichloromethane/methanol 99:1) affords the product as red solid (6.0 g, 69 %). MS: m/e= 238 (M⁺).

10

Example 446

3-Methoxy-5-nitro-biphenyl

1-Iodo-3-methoxy-5-nitro-benzene (279 mg, 1 mmol), phenylboronic acid (146 mg, 1.2 mmol), potassium carbonate (2M, 1.0 ml) and tetrakis(triphenylphosphino)palladium(0) are dissolved in ethanol (0.5 ml) and toluene (10 ml) and the mixture heated to 90 °C for
15 24 h. The volatile components are removed in vacuo and the residue codistilled twice with toluene. Flash chromatography (silica, eluent dichloromethane/cyclohexane 1:2) affords the product (185 mg, 81 %) as light brown solid. MS: m/e= 229 (M⁺).

Example 447

5-Bromo-2-methoxy-aniline

20 A solution of 4-bromo-2-nitro-anisole (7.7 g, 33.1 mmol), triethylamine (4.6 ml, 33.1 mmol) and Raney Nickel catalyst (4 g) was vigorously stirred in ethanol (300 ml) under an atmosphere of hydrogen for 1 h at 20 °C. After this time the theoretical amount of hydrogen had been absorbed (2.5 l), so the catalyst was filtered off and the solvent evaporated to afford the title compound as a light yellow solid (7 g, 104 % yield), MS: m/e=
25 201 (M⁺).

intermediates for the preparation of benzylic amines

Example 448

4-Chloromethyl-N-(4-hydroxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

30 N-(4-Benzoyloxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-chloromethyl-benzamide (1.0 g, 2.0 mmol) were dissolved in CH₂Cl₂ (10 ml) and treated at -78 °C with tetrabutyl

ammonium iodide (0.95 g, 2.6 mmol) and a solution of boron trichloride in CH_2Cl_2 (1M, 7.4 ml). After subsequent warming to 0° and stirring for additional 2 h, ice (2 g) and then water (10 ml) and methanol (2 ml) were added and the phases separated. The aqueous phases were extracted twice with $\text{CH}_2\text{Cl}_2/\text{MeOH}$, the combined organic layers were dried
5 with Na_2SO_4 and evaporated to dryness. Recrystallization from $\text{CH}_2\text{Cl}_2/\text{MeOH}$ afforded the title compound as an off-white solid (18 %). MS: $m/e = 403$ ($[\text{M}-\text{H}^+]$).

Example 449

4-(1-Bromo-ethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

10 Following the general method of example 1 the title compound was obtained as a yellow solid (63 %). MS: $m/e = 478$ ($\text{M}+\text{H}^+$).

Example 450

3-Chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Following the general method of example 1 the title compound was obtained as a light
15 yellow solid (59 %). MS: $m/e = 418$ ($\text{M}+\text{H}^+$).

Example 451

4-Chloromethyl-3-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Following the general method of example 1 the title compound was obtained as a light
20 brown solid (99 %). MS: $m/e = 436$ ($\text{M}+\text{H}^+$).

Example 452

4-Chloro-3-chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide

Following the general method of example 1 the title compound was obtained only in 75%
25 purity (68 %) and used in the subsequent steps without further purification. MS: $m/e = 452$ ($\text{M}+\text{H}^+$).

Example 453

4-[(2-Methoxy-ethyl)-methyl-sulfamoyl]-benzoic acid

30 4-Chloro-sulfonyl-benzoic acid (100 mg, 0.45 mmol) were dissolved in (2-methoxy-ethyl)-methyl-amine (1.0 g, 11.2 mmol) and heated to 50°C for 18 h. Removal of the volatile components in vacuo and flash chromatography (silica, eluent $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{H}_2\text{O}/\text{AcOH}$ 90:10:1:1) afforded the product as white solid (65 %). MS: $m/e = 272$ ($[\text{M}-\text{H}]^-$).

35 intermediates for the preparation of benzylic amines for 2-OBn:

Example 454

4-Benzoyloxy-7-morpholin-4-yl-benzothiazol-2-yl-amine

Using 2-benzoyloxy-5-morpholin-4-yl-phenyl)-thiourea following the general method of example 403 the title compound was obtained as off-white solid (69 %). MS: m/e= 342

5 (M+H⁺).

Example 455

N-(4-Benzoyloxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-chloromethyl-benzamide

Following the general method of example 1 the title compound was obtained as a pale yellow solid (81 %). MS: m/e= 494 (M+H⁺).

10

intermediates for the preparation of benzylic amines for changed 7-position:

Example 456

4-Methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl-amine

Using 2-methoxy-5-thiomorpholin-4-yl-phenyl)-thiourea following the general method of example 403 the title compound was obtained as light brown solid (31 %). MS: m/e= 282

15

(M+H⁺).

Example 457

[4-Methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester

Using the general procedure B the title compound was prepared from 4-methoxy-7-

20 morpholin-4-yl-benzothiazol-2-yl-amine and 2-methyl-4-trimethylstannanyl-pyridine as a white solid (8%). MS: m/e= 329 (M⁺).

Example 458

4-Methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl-amine

25 [4-Methoxy-7-(2-methyl-pyridin-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester (100 mg, 0.24 mmol) were dissolved in ethyleneglycol (3.0 ml) and treated with potassium hydroxide (528 mg, 1.1 mmol) and heated to 100 °C for 6.5 h. The reaction mixture was cooled to room temperature, diluted with water, neutralized with 1N HCl and extracted four times with ethyl acetate. The organic layers were combined and washed with water

30

and saturated aqueous NaCl. The organic phases were then dried and the solvent removed in vacuo. The product was obtained as a light brown solid (83 %). MS: m/e= 272 (M+H⁺).

Example ATablet Formulation (Wet Granulation)

	<u>Item</u>	<u>Ingredients</u>	<u>mg/tablet</u>			
			5 mg	25 mg	100 mg	500 mg
5	1.	Compound of formula I	5	25	100	500
	2.	Lactose Anhydrous DTG	125	105	30	150
	3.	Sta-Rx 1500	6	6	6	30
	4.	Microcrystalline Cellulose	30	30	30	150
	5.	Magnesium Stearate	1	1	1	1
10		Total	167	167	167	831

Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
- 15 4. Add item 5 and mix for three minutes; compress on a suitable press.

Example BCapsule Formulation


	<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
			5 mg	25 mg	100 mg	500 mg
20	1.	Compound of formula I	5	25	100	500
	2.	Hydrous Lactose	159	123	148	---
	3.	Corn Starch	25	35	40	70
	4.	Talc	10	15	10	25
	5.	Magnesium Stearate	1	2	2	5
25		Total	200	200	300	600

Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

Claims

1. The use of a compound of the general formula



wherein

- 5 R¹ is hydrogen, lower alkyl, lower alkoxy, benzyloxy, cycloalkyloxy, halogen, hydroxy or trifluoromethyloxy;

R², R³ are independently from each other hydrogen, halogen, lower alkyl or lower alkyloxy;

- R⁴ is hydrogen, lower alkyl, lower alkenyl, halogen, -C(O)OH, -C(O)-lower alkyl, -C(O)-halogen-lower alkyl, -CH(OH)-halogen-lower alkyl, -C(O)O-lower alkyl, -NHC(O)-lower alkyl, -(CH₂)_n-OH, or is phenyl, which is optionally attached to the benzo group via the linker -(O)_m-(CH₂)_n- and is optionally substituted by N(R⁵)(R⁶), halogen, alkoxy or nitro, or is 2,3-dihydro-1H-indolyl, azepan-1-yl, [1,4]oxazepan-4-yl, or is a five or six membered aromatic or non aromatic heterocycle, which may be attached to the benzo group via the linker -(O)_m-(CH₂)_n or -N=C(CH₃)- and is optionally substituted by one or two group(s) R⁷, wherein R⁷ is defined below;

R is

- (a) phenyl, optionally substituted by lower alkyl, halogen-lower alkyl, lower alkoxy, cyano, nitro, $-C(O)H$, $-C(O)OH$ or by the following groups
- 20 $-(CH_2)_n-C(O)-N(R^5)-(CH_2)_o$ -lower alkoxy,
 $-(CH_2)_nO$ -halogen-lower alkyl,
 $-(CH_2)_nO-(CH_2)_{n+1}-O$ -lower alkyl,
 $-S(O)_2-N(R^5)-(CH_2)_n-O$ -lower alkyl,
 $-(CH_2)_n-OR^5$,
- 25 $-(CH_2)_nN(R^5)-(CH_2)_o$ -lower alkoxy,
 $-(CH_2)_nN[(CH_2)_o$ -lower alkoxy] $_2$,
 $-(CH_2)_nN(R^5)(R^6)$,
 $-(CH_2)_nN[S(O)_2CH_3]_2$,
 $-(CH_2)_nN[R^5][S(O)_2CH_3]$,

- 5 $-(CH_2)_nN(R^5)-(CH_2)_oNR^5R^6$,
 $-(CH_2)_nN(R^5)$ -lower alkenyl,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -cycloalkyl,
 $-(CH_2)_nN(R^5)-C(O)O$ -lower alkyl,
 $-(CH_2)_n-S-(CH_2)_n-N(R^5)(R^6)$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-S$ -lower alkyl,
 $-S(O)_2-N(R^5)(R^6)$,
 $-(CH_2)_nN(R^5)-S(O)_2CH_3$
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -phenyl,
 10 $-(CH_2)_nN(R^5)-(CH_2)_oOH$,
 $-(CH_2)_nN(R^5)-(CH_2)_oCH(OH)-CF_3$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-CF_3$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-O-CH(OH)-C_6H_3(OCH_3)_2$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-O-C(O)-C_6H_3(OCH_3)_2$,
 15 $-N(R^5)-C(O)$ -morpholin,
 $-N(R^5)-C(O)-N(R^5)$ -phenyl, substituted by alkoxy,
 $-S(O)_2$ -morpholin,

or is phenyl, which is optionally substituted by

- 20 $-(CR^5R^6)_n$ -five to seven membered aromatic or non aromatic heterocycle, and
 wherein the heterocycle may further substituted by hydroxy, $-N(R^5)(R^6)$, lower
 alkoxy or lower alkyl, or by
 $-(CH_2)_nN(R^5)(CH_2)_o$ -five or six membered aromatic or non aromatic heterocycle
 and wherein the heterocycle may further substituted by hydroxy, $-N(R^5)(R^6)$ or
 lower alkyl, or

25 is

- b) $-(CH_2)_n$ -five or six membered aromatic or non aromatic heterocycle, with the
 exception of the the piperazinyl group in case if $n=0$, which rings may be optionally
 substituted by one or two substituents, selected from the group consisting of
 2-oxo-pyrrolidin, piperidinyl, phenyl, $-(CH_2)_nOH$, halogen, CF_3 , $=O$, lower alkyl,
 30 cycloalkyl, $-(CH_2)_n-O$ -lower alkyl, $-(CH_2)_nNH_2$, $-(CH_2)_nCN$, $-C(O)O$ -lower alkyl,
 $-CH_2-O-S(O)_2CH_3$, $-C(O)$ -lower alkyl, $-C(O)-(CH_2)_n$ -lower alkoxy,
 $-CH_2-N(R^6)C_6H_4F$, $-CH_2-N(R^6)C(O)O$ -lower alkyl,
 $-N(R^6)-C(O)-N(R^5)-(CH_2)_n-O$ -lower alkyl, -or by tetrahydrofuran, substituted by
 4-Cl-phenyl, or by piperazin-1-yl, morpholinyl, thiomorpholinyl,

thiomorpholin-1-oxo, pyrrolidin-1-yl or by piperidin-1-yl or is benzopiperidin-1-yl or benzothien-2-yl, or

is

c) $-(CH_2)_{n+1}$ -phenyl,

5 $-N(R^5)(CH_2)_n$ -phenyl, optionally substituted by lower alkoxy,

$-O(CH_2)_n$ -phenyl, or

$-N(R^5)C(O)$ -phenyl, or

is

10 d) $-N(R^5)(CH_2)_n$ -5-or 6 membered aromatic or non aromatic heterocycle, optionally substituted by lower alkyl, $-(CH_2)_n$ -5-or 6 membered aromatic or non aromatic heterocycle

or is

15 e) $-(CH_2)_n-N(R^5)(R^6)$, lower alkyl, $-O-(CH_2)_n$ -lower alkoxy, $-(CH_2)_n$ -lower alkoxy, lower alkoxy, cycloalkyl, $-N(R^5)(CH_2)_nO$ -lower alkyl, $-N(R^5)(CH_2)_nOH$, $-N(R^5)(CH_2)_nN(R^5)(R^6)$, $-C(O)O$ -lower alkyl, $-(CH_2)_nOH$, $-(HC=CH)_nC(O)O$ -lower alkyl, octahydro-quinoline, 3,4-dihydro-1H-isoquinoline, 2,3-benzo-1,4-dioxo-8-aza-spiro[4,5]decane or 1,4-dioxo-8-aza-spiro[4,5]decane;

X is O, S or two hydrogen atoms;

20 R^5, R^6 are independently from each other hydrogen or lower alkyl,

R^7 is lower alkyl, lower alkoxy, $-C(O)$ -lower alkyl, $-C(O)O$ -benzyl, $-C(O)O$ -lower alkyl, $-(CH_2)_nNR^5R^6$, pyridinyl, optionally substituted by lower alkyl, or is $-CH_2N(R^5)-C(O)O$ -lower alkyl, $-NH-C(phenyl)_3$, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, optionally substituted by lower alkyl;


25 n is 0, 1, 2, 3 or 4;

m is 0 or 1;

o is 0, 1, 2, 3 or 4;

and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to the adenosine receptor.

2. The use of a compound of the general formula



according to claim 1,

wherein

5 R^1 is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy or trifluoromethoxy;

R^2, R^3 are independently from each other hydrogen, halogen, lower alkyl or lower alkoxy;

10 R^4 is hydrogen, lower alkyl, halogen, $-C(O)OH$, $-C(O)O$ -lower alkyl, $-NHC(O)$ -lower alkyl, $-(CH_2)_n-OH$, or is phenyl, which is optionally attached to the benzo group via the linker $-(O)_m-(CH_2)_n-$ and is optionally substituted by $N(R^5)(R^6)$, halogen, alkoxy or nitro; or is
a five or six membered aromatic or non aromatic heterocycle, which is attached to the benzo group via the linker $-(O)_m-(CH_2)_n$ and is optionally substituted by lower alkyl, $-C(O)O$ -benzyl or $-NR^5R^6$;

15 R is
(a) phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, cyano, $-C(O)H$, $-C(O)OH$ or by the following groups

20 $-(CH_2)_n\text{hal}$
 $-(CH_2)_nOH$
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -lower alkoxy,
 $-(CH_2)_nN(R^5)(R^6)$,
 $-(CH_2)_nN(R^5)-(CH_2)_oNR^5R^6$,
 $-(CH_2)_nN(R^5)$ -lower alkenyl,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -cycloalkyl,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -S-lower alkyl,
25 $-S(O)_2-N(R^5)(R^6)$,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -phenyl,
 $-(CH_2)_nN(R^5)-(CH_2)_oOH$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-O-CH(OH)-C_6H_3(OCH_3)_2$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-O-C(O)-C_6H_3(OCH_3)_2$

-S(O)₂-morpholin

or is phenyl, which is optionally substituted by

-(CH₂)_n-five to seven membered aromatic or non aromatic heterocycle, and wherein the heterocycle may further substituted by hydroxy, -N(R⁵)(R⁶) or lower alkyl, or by

5 -(CH₂)_nN(R⁵)(CH₂)_o-five or six membered aromatic or non aromatic heterocycle and wherein the heterocycle may further substituted by hydroxy, -N(R⁵)(R⁶) or lower alkyl, or

is

10 b) -(CH₂)_n-five or six membered aromatic or non aromatic heterocycle, with the exception of the the piperazinyl group in case if n=0, which rings may be optionally substituted by halogen, hydroxy, lower alkyl, or by piperazin-1-yl, morpholinyl, thiomorpholinyl, thiomorpholin-1-oxo, pyrrolidin-1-yl or by piperidin-1-yl or is benzopiperidin-1-yl or benzothien-2-yl, or

is

15 c) -(CH₂)_{n+1}-phenyl,
-N(R⁵)(CH₂)_n-phenyl, optionally substituted by lower alkoxy,
-O(CH₂)_n-phenyl, or
-N(R⁵)C(O)-phenyl, or

is

20 d) -N(R⁵)(CH₂)_n-5-or 6 membered aromatic or non aromatic heterocycle, optionally substituted by lower alkyl, -(CH₂)_n-5-or 6 membered aromatic or non aromatic heterocycle

or is

25 e) -N(R⁵)(R⁶), lower alkyl, lower alkoxy, cycloalkyl, lower alkyl-lower alkoxy,
-N(R⁵)(CH₂)_nN(R⁵)(R⁶), -C(O)O-lower alkyl, -(CH₂)_nOH,
-(HC=CH)_nC(O)O-lower alkyl or -(CH₂)_nN(R⁵)(R⁶);

X is O, S or two hydrogen atoms;

R⁵, R⁶ are independently from each other hydrogen or lower alkyl,

n is 0, 1, 2, 3 or 4;

30 m is 0 or 1;

o is 0, 1, 2, 3 or 4;

and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to the adenosine receptor.

3. The use of a compound of formula I according to claim 1, wherein R¹ is methoxy, X is oxygen and R²/R³ are hydrogen.

5 4. The use of a compound according to claim 3, wherein R is an unsubstituted or substituted five or six membered aromatic heterocycle.

5. The use of a compound according to claim 4, wherein the compounds are
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
10 5-methyl-furan-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-4-yl-benzothiazol-2-yl)-
amide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-3-yl-benzothiazol-2-yl)-
15 amide,
5-methyl-thiophene-2-carboxylic acid [4-methoxy-7-(2-methyl-pyridin-4-yl)-
benzothiazol-2-yl]-amide,
5-methyl-thiophene-2-carboxylic acid [7-(3-amino-phenyl)-4-methoxy-benzothiazol-2-
yl]-amide,
20 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,
N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-
isonicotinamide,
N-[4-methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-
isonicotinamide,
25 N-[4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl]-2-methyl-
isonicotinamide and
N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide.

6. The use of a compound according to claim 3, wherein R is an unsubstituted or
30 substituted five or six membered non aromatic heterocycle.

7. The use of a compound according to claim 6, which compounds are
morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
1-oxo-11 4-thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-

- amide,
 morpholine-4-carboxylic acid {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-
 benzothiazol-2-yl}-amide,
 morpholine-4-carboxylic acid [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-
 5 yl]-amide,
 morpholine-4-carboxylic acid {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-
 benzothiazol-2-yl}-amide,
 morpholine-4-carboxylic acid [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-
 2-yl]-amide,
 10 morpholine-4-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-
 yl]-amide,
 4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperidine-1-carboxylic
 acid tert-butyl ester,
 1-acetyl-piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 15 amide,
 4-oxo-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 amide and
 1-oxo-1 λ^4 -thiomorpholine-4-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-
 2-yl)-amide.

20

8. The use of compounds according to claim 3, wherein R is methoxy.

9. The use of compounds according to claim 8, which compounds are
 rac-[7-(2-bromo-1-hydroxy-ethyl)-4-methoxy-benzothiazol-2-yl]-carbamic acid methyl
 25 ester,
 {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-carbamic acid
 methyl ester,
 [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl ester,
 [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-carbamic acid methyl
 30 ester and
 {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-carbamic
 acid methyl ester.

10. The use of a compound according to claim 3, wherein R is
 phenyl, optionally substituted by halogen, CF₃, -CH₂OH, -CH₂NHCH₂CH₂OCH₃,
 35 -CH₂NHCH₂CH₂OH, -CH₂NHCH₂-pyridinyl, -CH₂NH₂, -CH₂NHCH₂CH₂SCH₃,
 -CH₂N(CH₃)CH₂CH₂SCH₃, -CH₂N(CH₃)CH₂CH₂OCH₃,

-CH₂N(CH₂ CH₃)CH₂CH₂OCH₃, -CH₂NHCH₃, -CH₂SCH₂CH₂N(CH₃)₂, -CH₂OCH₃,
-CH₂OCH₂CH₂OCH₃ or -CH₂N(CH₃)C(O)OCH₃.

11. The use of a compound according to claim 10, which compounds are
- 4-hydroxymethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
- 5 4-fluoro-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
- 2-(4-fluoro-benzoylamino)-4-methoxy-benzothiazole-7-carboxylic acid methyl ester,
- 4-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
benzamide,
- 4-[(2-hydroxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
10 benzamide,
- N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-4-yl-methyl]-amino]-methyl]-
benzamide,
- N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-3-yl-methyl]-amino]-methyl]-
benzamide,
- 15 4-aminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
- N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-methylsulfanyl-ethylamino)-methyl]-
benzamide,
- 4-[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl)-
benzothiazol-2-yl)-benzamide,
- 20 N-[7-(2-amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide,
- 4-fluoro-N-[4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl]-
benzamide,
- 4-fluoro-N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-benzamide,
- 4-fluoro-N-[4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl]-
25 benzamide,
- 4-[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-[2-(6-methyl-pyridin-3-
yl)-thiazol-4-yl]-benzothiazol-2-yl]-benzamide,
- 4-[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-thiophen-2-yl)-
benzothiazol-2-yl)-benzamide,
- 30 4-[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-
4-yl)-benzothiazol-2-yl]-benzamide,
- N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-trifluoromethyl-benzamide,
- 4-fluoro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
- N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
- 35 4-chloro-3-[[ethyl-(2-methoxy-ethyl)-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl)-
benzothiazol-2-yl)-benzamide,

- N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-benzamide,
 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-
 benzamide,
 4-chloro-3-[[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-
 5 yl-benzothiazol-2-yl)-benzamide,
 4-chloro-3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 yl)-benzamide,
 10 3-[[(2-methoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 4-[(2-ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide,
 15 4-(2-dimethylamino-ethylsulfanylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-
 2-yl)-benzamide,
 4-[[(2-ethoxy-ethyl)-ethyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 4-[[(2-ethoxy-ethyl)-methyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 20 benzothiazol-2-yl)-benzamide,
 4-(2-methoxy-ethoxymethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 benzamide,
 4-methoxymethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl)-benzamide and
 25 [4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-benzyl]-methyl-carbamic
 acid methyl ester.

12. The use of a compound according to claim 3, wherein R is phenyl, substituted by
 an optionally substituted $-(CH_2)_n$ -five to seven membered aromatic or non aromatic
 heterocycle.

- 30 13. The use of a compound according to claim 12, which compounds are

- 4-imidazol-1-yl-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-(4-hydroxy-piperidin-1-yl-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-
 benzamide,
 4-[1,4]diazepan-1-yl-methyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 35 4-(3(S)-dimethylamino-pyrrolidin-1-yl-methyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-


- yl)-benzamide,
 N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-4-pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-4-pyrrolidin-1-yl-methyl-benzamide,
 5 N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide,
 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-benzamide,
 10 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(2-methyl-imidazol-1-yl-methyl)-benzamide and
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(4-methyl-piperazin-1-yl-methyl)-benzamide.

14. The use of a compound according to claim 1, wherein R⁴ is an optionally
 15 substituted five to seven membered aromatic or non aromatic heterocycle.

15. The use of a compound according to claim 14, wherein the heterocycle is morpholine or piperazine.

16. A medicament containing one or more compounds as claimed in any one of claims 1 – 15 and pharmaceutically acceptable excipients for the treatment of diseases
 20 related to the adenosine receptor.

17. Novel compounds of formula IA in accordance with claim 1



wherein

- R¹ is hydrogen, lower alkyl, lower alkoxy, benzyloxy, cycloalkyloxy, halogen, hydroxy or
 25 trifluoromethyloxy;
 R², R³ are independently from each other hydrogen, halogen, lower alkyl or lower alkyloxy;
 R⁴ is hydrogen, lower alkyl, lower alkenyl, halogen, -C(O)-lower alkyl,
 -C(O)-halogen-lower alkyl, -CH(OH)-halogen-lower alkyl, -C(O)O-lower alkyl,

-NHC(O)-lower alkyl, $-(CH_2)_n-OH$,
 or is phenyl, which is optionally attached to the benzo group via the linker
 $-(O)_m-(CH_2)_n-$ and is optionally substituted by $N(R^5)(R^6)$, halogen or nitro,
 or is 2,3-dihydro-1H-indolyl, azepan-1-yl, [1,4]oxazepan-4-yl, or is
 5 a five or six membered aromatic or non aromatic heterocycle, which may be
 attached to the benzo group via the linker $-(O)_m-(CH_2)_n$ or $-N=C(CH_3)-$
 and is optionally substituted by one or two group(s) R^7 , wherein R^7 is defined below;

R^7 is

(a) phenyl, optionally substituted by halogen-lower alkyl, $-C(O)H$ or by the
 10 following groups
 $-(CH_2)_n-C(O)-N(R^5)-(CH_2)_n$ lower alkoxy,
 $-(CH_2)_nO$ -halogen-lower alkyl,
 $-(CH_2)_nO-(CH_2)_{n+1}O$ -lower alkyl,
 $-S(O)_2-N(R^5)-(CH_2)_nO$ -lower alkyl,
 15 $-(CH_2)_nOR^5$,
 $-(CH_2)_nN(R^5)-(CH_2)_6$ -lower alkoxy,
 $-(CH_2)_nN[(CH_2)_6$ -lower alkoxy] $_2$,
 $-(CH_2)_nN[S(O)_2CH_3]_2$,
 $-(CH_2)_nN[R^5][S(O)_2CH_3]$,
 20 $-(CH_2)_nN(R^5)$ -lower alkenyl,
 $-(CH_2)_nN(R^5)-(CH_2)_6$ -cycloalkyl,
 $-(CH_2)_nN(R^5)-C(O)O$ -lower alkyl,
 $-(CH_2)_n-S-(CH_2)_n-N(R^5)(R^6)$,
 $-(CH_2)_nN(R^5)-(CH_2)_6-S$ -lower alkyl,
 25 $-(CH_2)_nN(R^5)-S(O)_2CH_3$,
 $-(CH_2)_nN(R^5)-(CH_2)_6$ -phenyl,
 $-(CH_2)_nN(R^5)-(CH_2)_6OH$,
 $-(CH_2)_nN(R^5)-(CH_2)_6CH(OH)-CF_3$,
 $-(CH_2)_nN(R^5)-(CH_2)_6-CF_3$,
 30 $-(CH_2)_nN(R^5)-(CH_2)_6-O-CH(OH)-C_6H_3(OCH_3)_2$,
 $-(CH_2)_nN(R^5)-(CH_2)_6-O-C(O)-C_6H_3(OCH_3)_2$,
 $-N(R^5)-C(O)$ -morpholin,
 $-N(R^5)-C(O)-N(R^5)$ -phenyl, substituted by alkoxy,
 $-S(O)_2$ -morpholin,

or is phenyl, which is optionally substituted by

-(CR⁵R⁶)_n-five to seven membered aromatic or non aromatic heterocycle, and wherein the heterocycle may further substituted by hydroxy, -N(R⁵)(R⁶) or lower alkyl, or by -(CH₂)_nN(R⁵)(CH₂)_o-five or six membered aromatic or non aromatic heterocycle and wherein the heterocycle may further substituted by hydroxy, -N(R⁵)(R⁶) or lower alkyl,
 5 or is -N(R⁵)-phenyl, which is optionally substituted by lower alkoxy, or

is

b) -(CH₂)_n-five or six membered aromatic or non aromatic heterocycle, with the exception of the the piperazinyl group in case if n=0, which rings may be optionally substituted by

2-oxo-pyrrolidin, piperidinyl, phenyl, -(CH₂)_nOH, halogen, CF₃, =O, lower alkyl, cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_nNH₂, -(CH₂)_nCN, -C(O)O-lower alkyl, -CH₂-O-S(O)₂CH₃, -C(O)-lower alkyl, -C(O)-(CH₂)_n-lower alkoxy,
 15 -CH₂-N(R⁶)C₆H₄F, -CH₂-N(R⁶)C(O)O-lower alkyl,
 -N(R⁶)-C(O)-N(R⁵)-(CH₂)_n-O-lower alkyl, -or by tetrahydrofuran, substituted by 4-Cl-phenyl, or by piperazin-1-yl, morpholinyl, thiomorpholinyl, thiomorpholin-1-oxo, pyrrolidin-1-yl or by piperidin-1-yl or is benzopiperidin-1-yl or benzothien-2-yl, or

is

c) -N(R⁵)(CH₂)_{n+1}-phenyl, optionally substituted by lower alkoxy, -O(CH₂)_n-phenyl, or -N(R⁵)C(O)-phenyl, or

is

d) -N(R⁵)(CH₂)_n-5-or 6 membered aromatic or non aromatic heterocycle, optionally substituted by lower alkyl, -(CH₂)_n-5-or 6 membered aromatic or non aromatic heterocycle

or is

e) -O-(CH₂)_n-lower alkoxy, lower alkyl-lower alkoxy, -N(R⁵)(CH₂)_nN(R⁵)(R⁶),
 30 -(CH₂)_nOH, -(HC=CH)_nC(O)O-lower alkyl, octahydro-quinoline, 3,4-dihydro-1H-isoquinoline, 2,3-benzo-1,4-dioxo-8-aza-spiro[4,5]decane or 1,4-dioxo-8-aza-spiro[4,5]decane.

X is O, S or two hydrogen atoms;

R^5, R^6 are independently from each other hydrogen or lower alkyl,

R^7 is lower alkyl, lower alkoxy, $-C(O)$ -lower alkyl, $-C(O)O$ -benzyl, $-C(O)O$ -lower alkyl, $-(CH_2)_nNR^5R^6$, pyridinyl, optionally substituted by lower alkyl, or is $-CH_2N(R^5)-C(O)O$ -lower alkyl, $-NH-C(phenyl)_3$, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, optionally substituted by lower alkyl;


n is 0, 1, 2, 3 or 4;

m is 0 or 1;

o is 0, 1, 2, 3 or 4;

and to their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to the adenosine receptor.

18. Novel compounds of formula IA according to claim 17,



wherein

R^1 is hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy or trifluoromethoxy;

R^2, R^3 are independently from each other hydrogen, halogen, lower alkyl or lower alkyloxy;

R^4 is hydrogen, lower alkyl, halogen, $-C(O)OH$, $-C(O)O$ -lower alkyl, $-NHC(O)$ -lower alkyl, $-(CH_2)_n-OH$, or is phenyl, which is optionally attached to the benzo group via the linker $-(O)_m-(CH_2)_n-$ and is optionally substituted by $N(R^5)(R^6)$, halogen or nitro; or is

a five or six membered aromatic or non aromatic heterocycle, which is attached to the benzo group via the linker $-(O)_m-(CH_2)_n$ and is optionally substituted by lower alkyl, $-C(O)O$ -benzyl or $-NR^5R^6$;

R' is

(a) phenyl, substituted by $-C(O)H$, or by the following groups

$-(CH_2)_nOH$

$-(CH_2)_nN(R^5)-(CH_2)_o$ -lower alkoxy,

- $-(CH_2)_nN(R^5)$ -lower alkenyl,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -cycloalkyl,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -S-lower alkyl,
 $-(CH_2)_nN(R^5)-(CH_2)_o$ -phenyl,
5 $-(CH_2)_nN(R^5)-(CH_2)_oOH$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-O-CH(OH)-C_6H_3(OCH_3)_2$,
 $-(CH_2)_nN(R^5)-(CH_2)_o-O-C(O)-C_6H_3(OCH_3)_2$,
 $-S(O)_2$ -morpholin
or is phenyl, which is optionally substituted by
10 $-(CH_2)_n$ -five to seven membered aromatic or non aromatic heterocycle, and wherein
the heterocycle may further substituted by hydroxy, $-N(R^5)(R^6)$ or lower alkyl, or by
 $-(CH_2)_nN(R^5)(CH_2)_o$ -five or six membered aromatic or non aromatic heterocycle
and wherein the heterocycle may further substituted by hydroxy, $-N(R^5)(R^6)$ or
lower alkyl, or
15 is
b) a five or six membered aromatic or non aromatic heterocycle, with the
exception of the the piperazinyl group, wherein the aromatic
heterocycle is substituted by piperazin-1-yl, morpholinyl, thiomorpholinyl,
thiomorpholin-1-oxo, pyrrolidin-1-yl or by piperidin-1-yl or is benzopiperidin-1-yl
20 or benzothien-2-yl, or
is
c) $-N(R^5)(CH_2)_{n+1}$ -phenyl, optionally substituted by lower alkoxy,
 $-O(CH_2)_{n+1}$ -phenyl, or
 $-N(R^5)C(O)$ -phenyl, or
25 is
d) $-N(R^5)(CH_2)_n$ -5-or 6 membered aromatic or non aromatic heterocycle,
optionally substituted by lower alkyl, $-(CH_2)_n$ -5-or 6 membered aromatic or non
aromatic heterocycle,
or is
30 e) lower alkyl-lower alkoxy, $-N(R^5)(CH_2)_nN(R^5)(R^6)$, $-(CH_2)_nOH$ or
 $-(HC=CH)_nC(O)O$ -lower alkyl;
X is O, S or two hydrogen atoms;
 R^5, R^6 are independently from each other hydrogen or lower alkyl,

n is 0, 1, 2, 3 or 4;

m is 0 or 1;

o is 0, 1, 2, 3 or 4;

and their pharmaceutically acceptable salts.

- 5 19. Compounds of formula IA in accordance with claim 17, wherein R¹ is methoxy, X is oxygen and R²/R³ are hydrogen.

20. Compounds of formula IA in accordance with claim 19, wherein R' is an unsubstituted or substituted five or six membered aromatic heterocycle.

21. Compounds of formula IA in accordance with claim 20, which compounds are
- 10 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
5-methyl-furan-2-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-4-yl-benzothiazol-2-yl)-
15 amide,
5-methyl-thiophene-2-carboxylic acid (4-methoxy-7-pyridin-3-yl-benzothiazol-2-yl)-
amide,
5-methyl-thiophene-2-carboxylic acid [4-methoxy-7-(2-methyl-pyridin-4-yl)-
benzothiazol-2-yl]-amide,
20 5-methyl-thiophene-2-carboxylic acid [7-(3-amino-phenyl)-4-methoxy-benzothiazol-2-
yl]-amide,
N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide,
N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-
isonicotinamide,
25 N-[4-methoxy-7-(2-pyrrolidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-2-methyl-
isonicotinamide,
N-{4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-2-methyl-
isonicotinamide and
N-[4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-2-methyl-isonicotinamide.

30

22. Compounds of formula IA in accordance with claim 17, wherein R' is an unsubstituted or substituted five or six membered non aromatic heterocycle.

23. Compounds of formula IA in accordance with claim 22, which compounds are morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide, thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide, 1-oxo-11 4-thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzothiazol-2-yl)-amide,
- 5 morpholine-4-carboxylic acid {4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-amide,
- morpholine-4-carboxylic acid [4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-amide,
- 10 morpholine-4-carboxylic acid {4-methoxy-7-[2-(4-methyl-piperazin-1-yl)-thiazol-4-yl]-benzothiazol-2-yl}-amide,
- morpholine-4-carboxylic acid [4-methoxy-7-(2-piperidin-1-yl-thiazol-4-yl)-benzothiazol-2-yl]-amide,
- morpholine-4-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-benzothiazol-2-yl]-amide,
- 15 4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-piperidine-1-carboxylic acid tert-butyl ester,
- 1-acetyl-piperidine-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 20 4-oxo-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide and
- 1-oxo-11⁴-thiomorpholine-4-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide.

24. Compounds of formula IA in accordance with claim 17, wherein R' is
- 25 phenyl, optionally substituted by -CH₂OH, -CH₂NHCH₂CH₂OCH₃, -CH₂NHCH₂CH₂OH, -CH₂NHCH₂-pyridinyl, -CH₂NH₂, -CH₂NHCH₂CH₂SCH₃, -CH₂N(CH₃)CH₂CH₂SCH₃, -CH₂N(CH₃)CH₂CH₂OCH₃, -CH₂N(CH₂CH₃)CH₂CH₂OCH₃, -CH₂NHCH₃, -CH₂SCH₂CH₂N(CH₃)₂, -CH₂OCH₃, -CH₂OCH₂CH₂OCH₃ or -CH₂N(CH₃)C(O)OCH₃.

25. Compounds of formula IA in accordance with claim 24, which compounds are
- 4-hydroxymethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
- 4-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
- 4-[(2-hydroxy-ethylamino)-methyl]-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
- 35 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[[pyridin-4-ylmethyl]-amino]-methyl-

- benzamide,
 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[(pyridin-3-ylmethyl)-amino]-methyl)-
 benzamide,
 4-aminomethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 5 N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-4-[(2-methylsulfanyl-ethylamino)-methyl]-
 benzamide,
 4-[(2-methoxy-ethyl)-methyl-amino]-methyl}-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 N-[7-(2-amino-thiazol-4-yl)-4-methoxy-benzothiazol-2-yl]-4-fluoro-benzamide,
 10 4-fluoro-N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-
 benzamide,
 4-[(2-methoxy-ethyl)-methyl-amino]-methyl}-N-{4-methoxy-7-[2-(6-methyl-pyridin-3-
 yl)-thiazol-4-yl]-benzothiazol-2-yl}-benzamide,
 4-[(2-Methoxy-ethyl)-methyl-amino]-methyl}-N-(4-methoxy-7-thiophen-2-yl-
 15 benzothiazol-2-yl)-benzamide,
 4-[(2-methoxy-ethyl)-methyl-amino]-methyl}-N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-
 4-yl)-benzothiazol-2-yl]-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-trifluoromethyl-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 20 4-chloro-3-[(ethyl-(2-methoxy-ethyl)-amino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-benzamide,
 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-methylaminomethyl-
 benzamide,
 25 4-chloro-3-[(2-methoxy-ethyl)-methyl-amino]-methyl}-N-(4-methoxy-7-morpholin-4-
 yl-benzothiazol-2-yl)-benzamide,
 4-chloro-3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 3-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 30 yl)-benzamide,
 3-[(2-methoxy-ethyl)-methyl-amino]-methyl}-N-(4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-benzamide,
 4-[(2-ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 benzamide,
 35 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-methylaminomethyl-benzamide,
 4-(2-dimethylamino-ethylsulfanylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-
 2-yl)-benzamide,

- 4-[(2-ethoxy-ethyl)-ethyl-amino]-methyl}-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 4-[(2-ethoxy-ethyl)-methyl-amino]-methyl}-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 5 4-(2-methoxy-ethoxymethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 4-methoxymethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-benzamide,
 N-(4-methoxy-7-thiomorpholin-4-yl-benzothiazol-2-yl)-benzamide and
 [4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-benzyl]-methyl-carbamic
 10 acid methyl ester.

26. Compounds of formula IA in accordance with claim 17, wherein R' is phenyl, substituted by a optionally substituted $-(CR^5R^6)_n$ -five to seven membered aromatic or non aromatic heterocycle.

27. Compounds of formula IA in accordance with claim 26, which compounds are


- 15 4-imidazol-1-ylmethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-(4-Hydroxy-piperidin-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-[1,4]diazepan-1-ylmethyl-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 4-(3(S)-dimethylamino-pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-yl)-benzamide,
 20 N-{4-methoxy-7-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-benzothiazol-2-yl}-4-pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-thiophen-2-yl-benzothiazol-2-yl)-4-pyrrolidin-1-yl-methyl-benzamide,
 N-[4-methoxy-7-(2-pyridin-2-yl-thiazol-4-yl)-benzothiazol-2-yl]-4-pyrrolidin-1-yl-methyl-benzamide,
 25 4-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-pyrrolidin-1-yl-methyl-benzamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(2-methyl-imidazol-1-yl-methyl)-benzamide and
 30 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-(4-methyl-piperazin-1-yl-methyl)-benzamide.

28. Compounds of formula IA in accordance with claim 17, wherein R⁴ is an optionally substituted five to seven membered aromatic or non aromatic heterocycle.


29. Compounds of formula IA in accordance with claim 28, wherein the five to seven membered aromatic or non aromatic heterocycle is morpholine or piperazine.

30. A process for preparing a compound of formulas I and I-A as defined in claims 1 and 17, which process comprises

5 a) reacting a compound of formula




with a compound of formula



and an amine of the formula R^5R^6NH or an appropriate cyclic amine


10 to a compound of formula



or to compounds of formula I-1, wherein the group $-NR^5R^6$ is replaced by a cyclic amine,


wherein $R^1 - R^6$ and X have the significances given above, or

b) reacting a compound of formula



15


with a compound of formula




- 156 -

to a compound of formula I-A, wherein R^1 , R^4 , R^5 and X have the significances given above, or


c) reacting a compound of formula



5 with a compound of formula




to a compound of formula



wherein R^1 - R^5 have the significances given above, or


10 d) hydrogenating a compound of formula I-3 with $H_2/Pd/C$ to give a compound of formula



wherein R^1 - R^5 have the significances given above, or


15 e) reacting a compound of formula I-3 with N-bromosuccinimide/ H_2O to give a compound of formula

- 157 -




wherein R^1 - R^5 have the significances given above, or

f) oxidizing a compound of formula I-4 to a compound of formula




5 wherein R^1 - R^5 have the significances given above, or

g) reacting a compound of formula I-5 with a compound of formula




to a compound of formula




10 wherein R^1 - R^5 and R^7 have the significances given above, or

h) reacting a compound of formula I-5 with a compound of formula




to a compound of formula




wherein $R^1 - R^6$ have the significances given above, or

i) reacting a compound of formula I-5 with a compound of formula




5

to a compound of formula



cleaving off the boc-group to a compound of formula



10 wherein $R^1 - R^5$ have the significances given above, or

j) modifying one or more substituents $R^1 - R^7$ within the definitions given above,

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

31. A compound according to any one of claims 17 - 29, whenever prepared by a process as claimed in claim 30 or by an equivalent method.

5 32. The use of a compound in any one of claims 17 - 29 for the treatment of diseases.

33. The use of a compound in any one of claims 17 - 29 for the manufacture of corresponding medicaments for the treatment of diseases related to the adenosine A_{2A} receptor.

34. The invention as hereinbefore described.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/097786 A3

(51) International Patent Classification⁷: A61K 31/422,
31/423, 31/444, 31/4439, 31/455, 31/541, 31/5513, C07D
277/82, 417/12, 417/14

(74) Agent: POPPE, Regina; 124 Grenzacherstrasse,
CH-4070 Basle (CH).

(21) International Application Number: PCT/EP01/06506

(22) International Filing Date: 8 June 2001 (08.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00113219.0 21 June 2000 (21.06.2000) EP

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH];
124, Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors: ALANINE, Alexander; 11a, rue de Bale,
F-68440 Schlierbach (FR). FLOHR, Alexander; 142 St.
Galler-Ring, CH-4054 Basle (CH). MILLER, Aubry,
Kern; 72A Alvarado St., San Francisco, CA 94110 (US).
NORCROSS, Roger, David; Alte Saline 20, CH-4310
Rheinfelden (CH). RIEMER, Claus; Optizstrasse 5,
79110 Freiburg (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(88) Date of publication of the international search report:
12 December 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/097786 A3

(54) Title: BENZOTHAZOLE DERIVATIVES



seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

(57) Abstract: The present invention relates to compounds of the general formula (I) and to their pharmaceutically acceptable salts for the treatment of diseases related to the adenosine A2 receptor, novel compounds of formula I-A per se, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses hypoxia, ischaemia,

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/422 A61K31/423 A61K31/444 A61K31/4439 A61K31/455
 A61K31/541 A61K31/5513 C07D277/82 C07D417/12 C07D417/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ, CHEM ABS Data, EPO-Internal, WPI Data, EMBASE, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 10, 31 August 1999 (1999-08-31) & JP 11 130761 A (OTSUKA PHARMACEUT CO LTD), 18 May 1999 (1999-05-18) abstract the whole document	1-3,10, 12, 14-19, 24,26, 28-34
X	GB 1 345 552 A (SOCIETE NATIONALE DES PETROLES D'AQUITAINE) 30 January 1974 (1974-01-30) page 1, line 6-36; claims 1-22; examples 3,7-12,16,17,19-23 --- -/-	1-3,10, 16-19, 31-34

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.*** Special categories of cited documents :**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "a" document member of the same patent family

Date of the actual completion of the international search

28 March 2002

Date of mailing of the international search report

25. 07. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3018

Authorized officer

A. Jakobs

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 753 970 A (SYNTHELABO) 3 April 1998 (1998-04-03) abstract page 1, line 1 -page 4, line 38; examples 1-3; table 1 page 11, line 1 -page 14, line 15 ---	1-4,6, 16-18, 30-34
X	PANDEYA, SURENDRA N. ET AL: "Synthesis of benzothiazole derivatives and their insecticidal and larvicidal activities" INDIAN DRUGS (1985), 23(3), 146-51, XP008000199 the whole document ---	1-3,10, 14, 16-19, 24,26, 30-34
X	EP 0 199 400 A (JANSSEN PHARMACEUTICA NV) 29 October 1986 (1986-10-29) abstract page 26, column 2, line 34 -page 27, column 1, line 34; claims 1-13; examples 22-34; tables 2-4 ---	1-4,6, 16-18, 30-34
X	GB 1 538 822 A (BOEHRINGER MANNHEIM GMBH) 24 January 1979 (1979-01-24) page 1, column 1, paragraph 2 -column 2, line 54; claims 1-36; examples 1-30 ---	1-3,10, 16-19, 31-34
X	WO 00 27819 A (MANLEY PAUL WILLIAM ;NOVARTIS AKTIENGESELLSCHAFT (CH); BRUEGGEN JO) 18 May 2000 (2000-05-18) abstract page 25, line 15 -page 27, line 31 page 53; example 5.8 page 60; example 8.3 page 61; examples 8.13,8.16-18,8.21 page 62; example 8.22 ---	1,2,17, 18,30-34
X	US 3 725 428 A (JANIAK S) 3 April 1973 (1973-04-03) abstract column 1, line 1 -column 6, line 22; claims 1-3; examples 1-3 ---	17,18, 30-34
X	EP 0 404 440 A (PFIZER) 27 December 1990 (1990-12-27) abstract page 2, line 1-5; claims 1-11; example 14 ---	1-3, 17-19, 30-34

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 199944 Derwent Publications Ltd., London, GB; Class A96, AN 1999-527215 XP002189638 & WO 99 37630 A (VERICOR INC), 29 July 1999 (1999-07-29) abstract page 107, paragraphs 2-4 ---</p>	1,2,17, 18,31-34
X	<p>EP 0 604 657 A (OTSUKA PHARMA CO LTD) 6 July 1994 (1994-07-06) the whole document ---</p>	1
X	<p>US 4 028 374 A (PELOSI JR STANFORD SALVATORE ET AL) 7 June 1977 (1977-06-07) abstract; claims 1-10; examples 1-9 ---</p>	1,2,17, 18,31-34
X	<p>EP 0 343 893 A (PFIZER) 29 November 1989 (1989-11-29) abstract; examples 18-20,23 ---</p>	1,2, --- 16-18, 22,30-34
X,P	<p>DATABASE WPI Section Ch, Week 200131 Derwent Publications Ltd., London, GB; Class B02, AN 2001-299901 XP002189639 & WO 01 19360 A (CAN-FITE TECHNOLOGIES LTD), 22 March 2001 (2001-03-22) abstract</p>	1,2, 16-18, 22,30-34
X	<p>DAIDONE G. ET AL.: "SYNTHESIS AND EVALUATION OF THE ANALGESIC AND ANTIINFLAMMATORY ACTIVITIES OF n-SUBSTITUTED SALICYLAMIDES" IL FARMACO, vol. 44, no. 5, 1989, pages 465-473, XP001053114 abstract page 468, paragraph 7 page 469, paragraph 3 -page 472, paragraph 3; table 1 ---</p>	1,2, 31-34
A	<p>WO 99 24035 A (SQUIBB BRISTOL MYERS CO) 20 May 1999 (1999-05-20) the whole document -----</p>	1-34

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/06506

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 34
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 14-19, 24, 26, 28-33 (partially), 10-13, 25, 27

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3,14-19,24,26,28-33 (partially), 10-13,25,27

Compounds of formula (I) or (I-A) wherein $R=R'=\text{phenyl}$ (optionally substituted) and $X=O$ or S , processes for preparing these compounds, and their use for the treatment of diseases.

2. Claims: 1-3,14-19,24,26,28-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'=\text{phenyl}$ (optionally substituted) and $X = \text{two hydrogen}$, processes for preparing these compounds, and their use for the treatment of diseases.

3. Claims: 1-3,14-19,28-33 (partially), 4,5,20,21

Compounds of formula (I) or (I-A) wherein $R=R'=-\text{(CH}_2\text{)}_n\text{-unsubstituted or substituted five or six membered aromatic heterocycle}$, processes for preparing these compounds, and their use for the treatment of diseases.

4. Claims: 1-3,14-19,28-33 (partially), 6,7,22,23

Compounds of formula (I) or (I-A) wherein $R=R'=-\text{(CH}_2\text{)}_n\text{-unsubstituted or substituted five or six membered non-aromatic heterocycle}$, processes for preparing these compounds, and their use for the treatment of diseases.

5. Claims: 1-3,14-19,28-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'=\text{(CH}_2\text{)}_{n+1}\text{-phenyl}$, processes for preparing these compounds, and their use for the treatment of diseases.

6. Claims: 1-3,14-19,28-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'=\text{N-(R}_5\text{)C--}$ (as far as not comprised in inventions 3 or 4 for $n=0$), processes for preparing these compounds, and their use for the treatment of diseases.

7. Claims: 1-3,14-19,28-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'=\text{(CH}_2\text{)}_n\text{-N-(R}_5\text{)C--}$, as far as not comprised in inventions 3,4 or 6, processes for preparing these compounds, and their use

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

for the treatment of diseases.

8. Claims: 1-3,14-19,28-34 (partially), 8,9,

Compounds of formula (I) or (I-A) wherein $R=R'=(CH_2)_n-O-(CH_2)_n$ -phenyl or methoxy, processes for preparing these compounds, and their use for the treatment of diseases.

9. Claims: 1-3,14-19,28-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'$ =lower alkyl, cycloalkyl, processes for preparing these compounds, and their use for the treatment of diseases.

10. Claims: 1-3,14-19,28-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'=-COO-$ or $-(CH=CH)-COO-$, processes for preparing these compounds, and their use for the treatment of diseases.

11. Claims: 1,17,30-33 (partially)

Compounds of formula (I) or (I-A) wherein $R=R'$ =octahydroquinoline, 3,4-dihydro-1H-isoquinoline, 2,3-benzo-1,4-dioxo-8-aza-spiro[4,5]decane or 1,4-dioxo-8-aza-spiro[4,5]decane, processes for preparing these compounds, and their use for the treatment of diseases.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 34

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty of claims 1,2,17,18,31-33. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of these claim(s) is impossible.

Present claims 1,2,17,18,31-33 relate to an extremely large number of possible compounds/therapeutic applications. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/therapeutic applications claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Present claims 1-29,31-33 relate to a product/therapeutic application defined by reference to a desirable characteristic or property, namely diseases related to the adenosine receptor.

The claims cover all product/therapeutic application having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/therapeutic applications. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the therapeutic application by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

there is no technical feature in claim 34.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the individual compounds of the claims, their use in therapy, and processes for obtaining these individual compounds as far as comprised within invention 1.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 11130761	A	18-05-1999	NONE	
GB 1345552	A	30-01-1974	FR 2097405 A5	03-03-1972
			FR 2140862 A6	19-01-1973
			BE 769490 A1	16-11-1971
			DE 2133649 A1	13-01-1972
			IT 1005045 B	20-08-1976
			LU 63457 A1	12-11-1971
			NL 7109150 A	10-01-1972
FR 2753970	A	03-04-1998	FR 2753970 A1	03-04-1998
			AU 722147 B2	20-07-2000
			AU 4463897 A	24-04-1998
			BG 103271 A	31-05-2000
			BR 9711842 A	24-08-1999
			CN 1230959 A	06-10-1999
			CZ 9901126 A3	16-06-1999
			EE 9900135 A	15-12-1999
			EP 0929550 A1	21-07-1999
			WO 9814444 A1	09-04-1998
			HU 9904091 A2	28-05-2000
			IL 128902 A	24-07-2001
			JP 2001501217 T	30-01-2001
			NO 991581 A	01-06-1999
			NZ 334553 A	24-11-2000
			PL 332648 A1	27-09-1999
			SK 42299 A3	10-12-1999
			TR 9900634 T2	21-06-1999
			TW 438800 B	07-06-2001
			ZA 9708772 A	27-03-1998
EP 0199400	A	29-10-1986	AT 56972 T	15-10-1990
			AU 582642 B2	06-04-1989
			AU 5613586 A	23-10-1986
			CA 1271474 A1	10-07-1990
			CN 86102349 A ,B	19-11-1986
			DE 3674448 D1	31-10-1990
			DK 169486 A ,B,	16-10-1986
			EP 0199400 A2	29-10-1986
			ES 553936 D0	01-01-1987
			ES 8702403 A1	16-03-1987
			FI 861562 A ,B,	16-10-1986
			GR 861014 A1	07-08-1986
			HU 40633 A2	28-01-1987
			IE 59040 B	15-12-1993
			IL 78487 A	15-12-1989
			JP 2093142 C	18-09-1996
			JP 8000824 B	10-01-1996
			JP 62129282 A	11-06-1987
			KR 9305004 B1	11-06-1993
			NO 861442 A ,B,	16-10-1986
			NZ 215700 A	28-07-1988
			PH 26181 A	18-03-1992
			PT 82368 A ,B	01-05-1986
			SU 1524809 A3	23-11-1989
			US 4749702 A	07-06-1988
			US 4826848 A	02-05-1989
			US 4689330 A	25-08-1987

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0199400	A	ZA 8602776 A	25-11-1987
GB 1538822	A	24-01-1979	
		DE 2656468 A1	15-06-1978
		AR 216496 A1	28-12-1979
		AT 360523 B	12-01-1981
		AT 890777 A	15-06-1980
		AU 510730 B2	10-07-1980
		AU 3137777 A	14-06-1979
		BE 861794 A1	13-06-1978
		CS 203179 B2	27-02-1981
		DD 133329 A5	27-12-1978
		ES 465034 A1	01-09-1978
		FI 773738 A ,B,	15-06-1978
		FR 2374317 A1	13-07-1978
		HU 175340 B	28-07-1980
		JP 53077058 A	08-07-1978
		NL 7713580 A	16-06-1978
		SE 7714074 A	15-06-1978
		SU 680647 A3	15-08-1979
		ZA 7707236 A	29-11-1978
WO 0027819	A	18-05-2000	
		DE 19910396 A1	07-09-2000
		AU 1045400 A	29-05-2000
		BG 105588 A	30-04-2002
		BR 9915553 A	14-08-2001
		CN 1325384 T	05-12-2001
		CZ 20011631 A3	17-10-2001
		WO 0027819 A2	18-05-2000
		EP 1129074 A2	05-09-2001
		NO 20012245 A	10-07-2001
		PL 348349 A1	20-05-2002
		TR 200101307 T2	21-05-2002
		AU 1381100 A	29-05-2000
		BR 9915210 A	24-07-2001
		CN 1331680 T	16-01-2002
		CZ 20011615 A3	15-08-2001
		WO 0027820 A1	18-05-2000
		EP 1129075 A1	05-09-2001
		NO 20011894 A	04-07-2001
		PL 347589 A1	08-04-2002
		SK 6282001 A3	11-09-2001
		TR 200101237 T2	21-08-2001
		US 2002019414 A1	14-02-2002
US 3725428	A	03-04-1973	
		CH 505543 A	15-04-1971
		AT 295922 B	15-12-1971
		BE 741093 A	30-04-1970
		BG 17439 A3	10-11-1973
		CH 526256 A	15-08-1972
		CS 164834 B2	28-11-1975
		DE 1953149 A1	06-05-1970
		DK 128742 B	24-06-1974
		FR 2022369 A5	31-07-1970
		GB 1290388 A	27-09-1972
		IL 33221 A	29-06-1973
		NL 6916457 A	06-05-1970
		RO 61385 A1	15-12-1976
		US 3810988 A	14-05-1974

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0404440	A	27-12-1990	WO 9015801 A1	27-12-1990
			AT 159941 T	15-11-1997
			CA 2019349 A1	22-12-1990
			DE 69031669 D1	11-12-1997
			DE 69031669 T2	05-03-1998
			DK 404440 T3	22-12-1997
			EP 0404440 A2	27-12-1990
			ES 2109229 T3	16-01-1998
			FI 96951 B	14-06-1996
			GR 3025697 T3	31-03-1998
			IE 902245 A1	16-01-1991
			JP 2032956 C	19-03-1996
			JP 3038569 A	19-02-1991
			JP 7053722 B	07-06-1995
			US 5384318 A	24-01-1995

WO 9937630	A	29-07-1999	AU 2464499 A	09-08-1999
			CA 2318969 A1	29-07-1999
			CN 1288462 T	21-03-2001
			EP 1049682 A1	08-11-2000
			JP 2002501059 T	15-01-2002
			WO 9937630 A1	29-07-1999
			US 6239152 B1	29-05-2001

EP 0604657	A	06-07-1994	AT 188704 T	15-01-2000
			AU 653681 B2	06-10-1994
			DE 69327572 D1	17-02-2000
			DE 69327572 T2	21-06-2000
			DK 604657 T3	17-04-2000
			EP 0604657 A1	06-07-1994
			KR 185225 B1	15-05-1999
			US 5376665 A	27-12-1994
			AU 4088793 A	13-12-1993
			CA 2113561 A1	25-11-1993
			ES 2140456 T3	01-03-2000
			WO 9323409 A1	25-11-1993
			JP 2759228 B2	28-05-1998
			PT 604657 T	28-04-2000

US 4028374	A	07-06-1977	NONE	

EP 0343893	A	29-11-1989	AT 79114 T	15-08-1992
			AU 601905 B2	20-09-1990
			AU 3509889 A	30-11-1989
			CA 1328871 A1	26-04-1994
			CN 1037898 A ,B	13-12-1989
			DD 283815 A5	24-10-1990
			DE 68902358 D1	10-09-1992
			DE 68902358 T2	10-12-1992
			DK 249389 A	27-11-1989
			EP 0343893 A1	29-11-1989
			ES 2043012 T3	16-12-1993
			FI 892498 A	25-11-1989
			GR 3005844 T3	07-06-1993
			HU 51606 A2	28-05-1990
			IE 891667 L	24-11-1989
			JP 2017181 A	22-01-1990
			JP 6078331 B	05-10-1994

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06506

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0343893 A		KR 9106864 B1	09-09-1991
		MX 16158 A ,B	01-06-1993
		NO 892059 A ,B,	27-11-1989
		NZ 229234 A	26-09-1990
		PL 279613 A1	27-11-1989
		PT 90622 A ,B	30-11-1989
		SU 1681728 A3	30-09-1991
		US 4970318 A	13-11-1990
		YU 105989 A1	31-08-1990
		ZA 8903862 A	30-01-1991

WO 0119360 A	22-03-2001	AU 6863400 A	17-04-2001
		WO 0119360 A2	22-03-2001

WO 9924035 A	20-05-1999	AU 744281 B2	21-02-2002
		AU 1371999 A	31-05-1999
		BR 9814956 A	03-10-2000
		CA 2309319 A1	20-05-1999
		CN 1290165 T	04-04-2001
		EP 1037632 A1	27-09-2000
		HU 9102101 A2	28-11-2001
		JP 2001522800 T	20-11-2001
		NO 20002121 A	09-05-2000
		PL 340727 A1	26-02-2001
		TR 200001312 T2	21-09-2000
		WO 9924035 A1	20-05-1999
		ZA 9810219 A	22-06-2000
